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ABSTRACT   
Introduction: Carbapenem-resistant Acinetobacter species (Acinetobacter spp.) are increasingly 
recognised as important pathogens, whose resistance patterns present a high-risk global challenge. 
However, there is limited scientific data and a lack of a standardised approach to help the clinician 
select optimal therapy in local setting. This study aimed to provide a standardised approach for 
the management of significant Acinetobacter spp. infection based on phenotypic and genotypic 
characterisation of local isolates, as well as clinical characteristics and outcomes of patients at 
academic complex hospitals in KwaZulu-Natal. 
Objectives:  The significance of Acinetobacter spp. infections and the most effective drug 
combinations for optimal therapy were determined. Acinetobacter spp. isolates were 
phenotypically and genotypically characterised. This was followed by the development of a 
standard management guideline for local use, based on the data obtained in the different 
objectives. 
Methods: The research consisted of a retrospective and prospective observational and 
experimental laboratory component. The laboratory component included synergy testing of 
colistin, susceptibility to antimicrobial agents in use at local hospitals, polymerase chain reaction 
and sequencing for analysis of the resistant genes related to carbapenem, colistin and amikacin. 
Phenotypic, genotypic, and clinical characterisation were utilised to develop a standardised 
management approach of significant Acinetobacter spp. infection. 
Results:  Acinetobacter spp. was identified as a significant cause of sepsis and mortality among 
patients in a surgical intensive care unit (ICU). Cases of multidrug-resistant (MDR) and 
extensively drug-resistant (XDR) Acinetobacter spp. increased over seven years, together with 
the emergence of pandrug-resistant (PDR) isolates. The results of synergy testing of colistin 
combinations with amikacin, carbapemens (imipemen, meropenem), ciprofloxacin, tazocin, 
linezolid, rifampicin and vancomycin against Acinetobacter spp. was highly diverse and species-
dependent. Characterisation of Acinetobacter spp. isolates showed that oxacillinase β-lactamase 
(OXA-23)-producing MDR isolates correlated with their antibiogram. Pulsed field gel 
electrophoresis (PFGE) showed horizontal transfer between seven clusters, each containing two 
patients each, totalling 14 patients. However, the PFGE typing revealed a diverse collection of 
MDR Acinetobacter spp. clones, and that isolates from not more than two patients were related. 
This suggests, therefore, that no outbreak had occurred based on the PFGE typing interpretation. 
Further genetic investigation revealed that the aphA6 gene were associated with amikacin 
resistance and IpxA gene may be associated with colistin resistance in our local setting.  
Conclusion: The results highlighted the importance of antibiotic stewardship in the treatment 
of Acinetobacter spp. infection. Individual-specific antibiograms are recommended as the best 
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approach for treatment in KwaZulu-Natal (KZN) and synergy testing should be performed for 
individualised direct therapy. The clinical and microbiological indicators of significant infection 
are crucial when establishing the decision to treat. The study provided a valuable standardised 
approach, including a flow chart of criteria for sepsis and colonisation; a standardised algorithm 
for the management; and synergy test at academic complex hospitals, Medical Microbiology 
laboratory, National Health Laboratory Service (NHLS) in KZN.  
 
Key words:  Individual-specific antibiogram approach; standardised algorithm for 
management; significant Acinetobacter species infections; antibiotic stewardship 
programme; synergy testing; blaOXA-23;  IpxA gene; aphA6 gene. 
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OVERVIEW OF THE THESIS 
 
 The current study, with different objectives which address different aspects of the Acinetobacter 
species, was performed on a seven-year collection of clinical and laboratory data of patients 
infected and colonised with Acinetobacter species (Acinetobacter spp.) at academic complex 
hospitals in Durban, KwaZulu-Natal (KZN).  Based on the outcomes of this study, a standard 
treatment management guideline was developed for the local settings. 
This thesis is presented in a “thesis by manuscripts” format. The first section of this thesis 
(Chapter 1) consists of a brief Introduction, literature review, problem statement, research 
questions/hypothesis/aims/objectives, and general methodology. The research aspects are 
presented in chapters 2 to 6, a management guideline in chapter 7, and a synthesis of the complete 
research in chapter 8, describing the link and culminates in a conclusion, with a set of 
recommendations of future research. 
 
Chapter 2:  Multidrug-resistant Acinetobacter species: a significant cause of sepsis in an 
intensive care unit in a regional hospital, Durban 
No local literature exists on Acinetobacter spp. as a significant source of sepsis, although there 
has been a worldwide increase in carbapenem-resistant Acinetobacter infections. This 
retrospective observational analytical study investigated the prevalence of significant 
Acinetobacter spp. sepsis through clinical and microbiological data. This study elucidated the 
significant cause of sepsis with multidrug-resistant Acinetobacter species and a high mortality 
rate (60%) of patients in intensive care units. This manuscript was published in the International 
Journal of Nursing Didactics in 2015.  
 
Chapter 3:  Analysis of clinical and microbiological data on Acinetobacter species assist 
the preauthorisation of antibiotics at patient level for an effective antibiotic 
stewardship programme 
This analytical retrospective observational study was performed over seven years from 2008 to 
2014. Here, we analysed clinical and microbiological data on Acinetobacter spp. isolates in order 
to produce a flow chart to differentiate significant sepsis from colonisation for pre-authorisation 
of antibiotics. The data were collected from an electronic system and verified by clinicians and 
clinical microbiologists during clinical ward rounds. This study elucidated the criteria of 
difference between significance sepsis versus colonisation and local antibiotic resistant patterns.  
Flow charts, including criteria and relevant definitions, were provided to assist preauthorisation 
of antibiotics at patient level for an effective antibiotic stewardship programme. This manuscript 
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was published by the Journal of Infection and Public Health (Manuscript Reference number: 
JIPH-D-16-00413) in Feb 2017. http://dx.doi.org/10.1016/j.jiph.2017.01.014  
 
Chapter 4:  Colistin exhibits diverse and species-dependent synergy in combination with 
different antibiotics against Acinetobacter species 
Although drug-resistant Acinetobacter spp. is a serious problem in clinical settings, especially in 
patients with Acinetobacter polymicrobial infections, there was no optimal use of antibiotics in 
combination therapy at our local academic complex hospitals. Therefore, this analytical 
observational experimental study was conducted to determine the effectiveness of various 
antibiotic combinations, using synergy testing. This study was useful and essential to support an 
effective antibiotic stewardship programme to recommend that an empirical combination regimen 
is not suitable in this local setting. This manuscript has been published by the World Journal of 
Pharmacy and Pharmaceutical Sciences (Manuscript Reference number: WJPPS/8599/6/2017). 
2017; 6(2) 183-199 (published in Feb 2017.) 
 
Chapter 5:  Horizontal transfer of OXA-23-carbapenemase-producing  
Acinetobacter species in intensive care units at an academic complex hospital 
in Durban, KwaZulu-Natal, South Africa  
To date, there was no prior genotypic and phenotypic characterisation of MDR Acinetobacter 
species in Inkosi Albert Luthuli Central Hospital (academic complex hospitals) in KwaZulu-
Natal. This analytical experimental study determined the association of blaOXA-23 and blaOXA-58 
genes with carbapenem-hydrolysing class D β-lactamase (CHDL) production, as well as their 
relation to the spread of MDR Acinetobacter species. This molecular study showed that MDR 
Acinetobacter species carried the blaOXA-23 gene that was responsible for resistance to 
carbapenems (MIC 8 to >16 mg/L). In addition, the PFGE typing of a diverse collection of MDR 
Acinetobacter spp. clones showed that isolates from not more than two patients were related. 
Collectively, this data informs the local infection prevention and control programme which in 
turn plays a major role in supporting the management guideline and antibiotic stewardship 
programme. This manuscript has been accepted on 24th May 2017 for publication by the Southern 
African Journal of Infectious Diseases. (Manuscript Reference number: Ref.:  Ms. No. SAJID - 
2016 - 0052R2) 
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Chapter 6: Colistin resistant clinical Acinetobacter species may be mediated by the 
absence of the IpxA gene report at an academic complex hospital in Durban, 
KwaZulu-Natal, South Africa  
This study investigated the phenotypic and genotypic characteristics of Acinetobacter spp. as well 
as clinical characteristics and outcomes of the patients in an academic complex hospital. This was 
an analytical, observational experimental study, which highlighted the prevalence of colistin and 
amikacin resistant Acinetobacter species and their associated resistant genes IpxA and aphA6 
respectively. This finding contributed to the development of the urgently needed management 
guidelines and ideas for future research, including molecular surveillance. 
This manuscript was under review by the African Journal of Laboratory Medicine.  
(Manuscript Reference number: Ref. No.AJLM: 597).  
 
Chapter 7:  Standardised approach for the management of patients with significant 
Acinetobacter species infections at an academic complex hospitals in 
KwaZulu-Natal, South Africa 
Based on the outcomes of this study described in the previous five chapters, we developed a 
standardised guideline for treatment of Acinetobacter spp. infections in academic complex 
hospitals in Durban, KZN. This was an analytical, observational (combined retrospective and 
prospective study), experimental study which was submitted to Inkosi Albert Luthuli Central 
Hospital (IALCH) clinical and medical managers to be implemented via the antibiotic 
stewardship programme (ASWP) committee in 2017. 
 
Chapter 8:  Synthesis of the thesis 
This chapter thematically links all the chapters and describes the development, prospects, 
opportunities and challenges in the utilisation of a standardised approach for the management of 
patients with significant Acinetobacter spp. infections at the academic complex hospitals in KZN, 
South Africa. The study demonstrates the use of clinical, microbiological, molecular and 
epidemiological data to develop a standard laboratory and clinical approach to the management 
of MDR Acinetobacter spp. infection. Included in this approach is synergy testing on individual 
isolate and definitions of the criteria for clinical and microbiologically significant sepsis. Based 
on this work, steps for developing a standard guideline are recommended, which may be adapted 
to suit administrative structures and implementation in the KwaZulu-Natal (KZN) areas. For 
academic complex hospitals, a specific guideline for standard approach of Acinetobacter spp. 
infection needs to be implemented urgently in order to assist the preauthorisation part of the 
antibiotic stewardship programme (ASWP). The study outcomes revealed that local 
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Acinetobacter spp. was a significant cause of sepsis, with horizontal transfer of resistant genes, 
and the results of synergy testing were diversed and species dependent. Therefore, the integration 
of a standard approach to treatment and prevention is valuable and applicable.  
This study showed a potentially novel mechanism of colistin resistance, that may be due to the 
inactivation of the Lipid A domain as a result of the potential complete loss of the IpxA gene. 
This is contradictory with other reports and the results require additional molecular techniques to 
confirm the finding of the absence IpxA gene as a novel resistance mechanism.  
 
 
 
Appendix:   Ethical approval  
The series of study was approved by the Ethics Committee of 
University of KwaZulu- Natal (Ethic approved- BE 283/12). 
The consent were approved by the hospitals and Department of Health.  
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CHAPTER 1:  INTRODUCTION, LITERATURE REVIEW AND  
GENERAL METHODOLOGY 
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1.1 Introduction  
Drug-resistant Acinetobacter species (Acinetobacter spp.) present a high-risk infection control 
and preauthorisation challenge for clinicians and microbiologists worldwide (Diekema et al., 
2004; Fishbain and Peleg, 2010; Ghafur et al., 2014; Phee et al., 2015). Despite the high 
prevalence of infection, there is no local standardised approach to help the clinician to select 
optimal empirical and targeted therapy in hospital settings. 
 
Among Acinetobacter species, Acinetobacter baumannii is the most relevant common pathogen 
in the clinical context (Retailliau et al., 1979; Peleg et al., 2008; Gonzalez-Villoria and Valverde-
Garduno, 2016), since it is frequently isolated with nosocomial infections and high mortality rate 
(Lin et al., 2010; Chang et al., 2011; Leão et al., 2016). Previous reviews have addressed 
Acinetobacter spp. as a successful pathogen, investigating its biological aspects, epidemiology, 
pathogenicity factors, clinical and pathophysiological overview and global spread (Doughari et 
al., 2011; Mangoni and Zarrilli, 2011; Wong et al., 2017). These bacteria have been reported to 
be associated with bacteraemia, sepsis in intensive care units (ICUs), community acquired 
meningitis, secondary infections of wounds, and community pneumonia (Doughari et al., 2011; 
Gonzalez-Villoria and Valverde-Garduno, 2016; Samawi et al., 2016). 
 
The community acquired isolates are relatively sensitive to antibiotics and the resistant isolates 
have been reported almost exclusively in hospitals and intensive care units (Falagas and Karveli, 
2007; Perez et al., 2007; Sengstock et al., 2010). Thus, it is easy to define community-acquired 
and hospital-acquired Acinetobacter spp. isolates according to their antibiotic susceptibility 
patterns and the clinical admission history. Acinetobacter spp. isolated after 48 hours of ICU 
admission means a hospital-acquired infection. Non-resistant Acinetobacter spp. isolated from a 
patient admitted directly from the emergency room or an outpatient department means 
community-acquired isolates. 
However, it is still difficult to differentiate between a coloniser and significant Acinetobacter spp. 
sepsis isolate at the hospital level (Perez et al., 2007; Almasaudi, 2016), which is an important 
part of the antibiotic stewardship programme. Acinetobacter spp. are recognised as common 
hospital- and community-acquired pathogens and colonisers globally (Lahiri et al., 2004; Leung 
et al., 2006; Sengstock et al., 2010; Parandekar and Peerapur, 2012; Almasaudi, 2016). 
 
The early application of effective therapy is the most important step for the survival of patients 
from Acinetobacter infections. Unfortunately, due to the frequency of resistance in Acinetobacter 
infections, initiation of effective therapy is a particular problem. In addition, ineffective 
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antimicrobial treatment is more common for Acinetobacter than most other pathogens, and a 
dramatic increase in mortality, consequently (Spellberg and Bonomo, 2014; Joly‐Guillou, 2005; 
Wong et al., 2017). 
The increasing prevalence of carbapenem-resistant isolates, which are also resistant to all 
commonly used antibiotics, is of particular concern, since colistin is the only preferred agent for 
the treatment of these MDR organisms (Moffatt et al., 2010). However, its resultant renal and 
neurotoxicity makes it an unattractive alternative (Arıdoğan, 2012).  In addition, there have been 
reports of Acinetobacter isolates resistant to colistin (Moffatt et al., 2010). Colistin combination 
therapy has been suggested as the best approach even for colistin-resistant Acinetobacter spp. 
isolates. The synergy effect of combination therapy using colistin with various other agents has 
been reported (Wareham and Bean, 2006; Pankey and Ashcraft, 2009; Daoud et al., 2013; Zafar 
et al., 2015). Unfortunately, unknown factors regarding the effectiveness of synergy with colistin 
combination therapy still prevail (Ahmed et al., 2014; Zafar et al., 2015) and there is a lack of 
standard approach in the treatment and management of Acinetobacter spp. infection. Moreover, 
the clinical utility of these combinations against PDR Acinetobacter spp. remains to be 
determined (Doughari et al., 2011). The limited options in the treatment is a major concern and 
research on the use and efficacy of combination therapies (Doughari et al., 2011), as well as 
clinical outcomes, is warranted in local settings (Inkosi Albert Luthuli Central Hospital academic 
complex of KZN, South Africa). 
 
Drug-resistant Acinetobacter spp. presents a serious global infection control challenge. Previous 
studies identified the resistance-encoding genes that are responsible for MDR Acinetobacter spp. 
(Poirel et al., 2010; Antunes et al., 2014; Rolain et al., 2016). Whilst epidemiological studies have 
been conducted to investigate the spread of these bacteria (Almasaudi, 2016), Acinetobacter spp. 
isolates have not yet been characterised at the local academic hospital in Durban, South Africa.  
 
With an exponential rise in infections over the past decade, clinicians and microbiologists face 
the task of choosing optimal antimicrobial agents for treatment that is essential part of antibiotic 
stewardship programme (Diekema et al., 2004; Fishbain and Peleg, 2010). Antibiotic resistance 
is a major challenge in healthcare settings, with changes in antibiotic resistant patterns, rising 
costs and the introduction of new agents making it difficult to choose the best regimens (Van-
Belkum et al., 2016). Historically, if the optimal usage of antibiotics is not monitored and overuse 
of the antimicrobial agents occurs, their efficacy will be lost. In response to these challenges, the 
antibiotic stewardship programme (ASWP) was created, as part of the urgent essential antibiotic 
policy, in the academic complex hospital, IALCH, KwaZulu-Natal, South Africa. The first task 
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is to develop a standardised algorithm for the management of patients with significant 
Acinetobacter spp. infection.  
 
Another concern is the significant community acquired and nosocomial infections caused 
by Acinetobacter spp., which has become a serious public health concern worldwide (Doughari 
et al., 2011), including in the local hospital. The aim of the study was to offer a standard guideline 
for management of infection and perspectives on addressing this global public health problem. 
Acinetobacter spp. infections have risen exponentially over the past decade and many questions 
remain unanswered. We are unable to find any documented report of the outcomes of 
Acinetobacter spp. infections in local academic hospitals and also unable to find standardised 
guidelines locally and in other African countries.  The general guidelines were initially developed 
by unit-specific antibiograms and have been revised and expanded annually. However, the 
standardised management algorithm for Acinetobacter spp. infections will constitute the new 
guideline, based on the outcomes of the studies of this PhD research at the Medical Microbiology 
Department, National Health Laboratory Service (NHLS), and Inkosi Albert Luthuli Central 
Hospital (IALCH) academic complex hospital.  
This thesis presents a series of studies aimed at determining the epidemiological, clinical, 
phenotypic and genetic characteristics of the organism. Based on the outcomes of these studies, 
an algorithm for a standardised approach to the treatment and management of significant 
Acinetobacter spp. infection was developed.  
 
 
1.2  Literature review 
1.2.1 History of Acinetobacter species 
Acinetobacter species, of which Acinetobacter baumannii is the most common, are non- 
fermentative aerobic Gram-negative coccobacilli. Acinetobacter spp. colonise the skin, mucous 
membranes and are present in secretions of healthy people (Almasaudi, 2016). Acinetobacter 
species are one of the most common organisms in hospital environments and frequently isolated 
from the skin and urinary tracts of patients (Kim et al., 2014). The organism is found naturally in 
soil and water and as a human commensal of the skin, throat and secretions (Fournier et al., 2006). 
Although the pathogenicity of Acinetobacter was previously believed to be low  (Fournier et al., 
2006), recent data suggests that various innate and acquired resistance factors, as well as the 
ability to produce biofilm, may contribute to the recent increase in pathogenicity and presence in 
hospital environments (Kim et al., 2014; Almasaudi, 2016; Gonzalez-Villoria and Valverde-
Garduno, 2016; Samawi et al., 2016). 
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Acinetobacter was first identified in 1911 and the different genospecies were distinguished 
through DNA hybridisation, according to homology groups with more than 70% relatedness. The 
Acinetobacter calcoaceticus-baumannii complex consists of four genospecies: (Acinetobacter 
calcoaceticus, Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis). 
Acinetobacter baumannii (A. baumannii) is the most frequently associated with hospital-acquired 
infections and the highest mortality rate (Lin et al., 2010; Chang et al., 2011; Gonzalez-Villoria 
and Valverde-Garduno, 2016) and, therefore, the most important in a clinical setting (Retailliau 
et al., 1979; Peleg et al., 2008; Gonzalez-Villoria and Valverde-Garduno, 2016). 
 
1.2.1.1 Microbiology and taxonomy 
Acinetobacter species belongs to the subclasss γ-Proteobacteria in the family Moraxellaceae, a 
group of nonhaemolytic Gram-negative coccobacilli, usually diploid or in variable length chains. 
The genus Acinetobacter comprises over fifty highly diverse species of oxidase-negative, 
catalase-positive, indole-negative, and nitrate-negative bacteria (Howard et al., 2012). 
Identification of individual species by their phenotypic traits is difficult, although it may be 
facilitated by molecular methods such as 16S rDNA sequencing, DNA-DNA hybridisation 
(Howard et al., 2012), gyrB multiplex PCR and rpoB gene sequencing (Lee et al., 2014). The A. 
baumannii complex, namely Acinetobacter baumannii, Acinetobacter pittii (genospecies 3), and 
Acinetobacter nosocomialis (genospecies 13TU), are relevant in nosocomial infections (Jung and 
Park, 2015). Together with Acinetobacter calcoaceticus, which is found mostly in the natural 
environment, the group is named the A. calcoaceticus-A. baumannii complex (ACB complex) 
(Kim et al., 2014) and are closely related.   They are considered important nosocomial pathogens 
and account for most clinically significant infections (Jung and Park, 2015). Identification of 
individual species by use of current automated (e.g. Vitek 2) or manual commercial systems, 
Analytical profile index (API) strips will require further confirmatory testing may be facilitated 
by molecular methods such as gyrB multiplex PCR and rpoB gene sequencing (Lee et al., 
2014).The genus of Acinetobacter is complex and historically, there has been confusion about the 
existence of multiple species, subject to uncertainty in distinguishing the separate species. 
Community acquired infections caused by Acinetobacter spp. has been increasingly reported 
(Sengstock et al., 2010). The organism is robust, particularly in dry environments, and often 
successful in evading host immunity, factors which enhance its spread and pathogenicity (Kim et 
al., 2014). 
The history of the first isolation of the organism is unknown (Daly et al., 1962; Lessel, 1971; 
Glen et al., 1977) although it is probable that Gram-negative coccobacilli found in 1914 were 
isolates of Acinetobacter (Daly et al., 1962; Lessel, 1971; Glen et al., 1977; Howard et al., 2012). 
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Past literature until quite recently, does not distinguish between A. baumannii and A. 
calcoaceticus, and reflected a mixture of the two species (Al-Atrouni et al., 2016). The genus 
comprises over fifty species (Al-Atrouni et al., 2016), of which A. baumannii, A. calcoaceticus 
and A. lwoffii are medically relevant (Dijkshoorn and Van-Der-Toorn, 1992) and A. baumannii is 
the most virulent, according to clinical and animal model data (Dijkshoorn and Van-Der-Toorn, 
1992). A. haemolyticus, A. johnsonii, A. junii, A. nosocomialis, A. pittii, A. schindleri and A. 
ursingii are occasional pathogens (Endo et al., 2012; Chiu et al., 2015; Salzer et al., 2016) and A. 
seifertii, an emerging pathogen, may sometimes be mistaken for A. baumannii  (Nemec et al., 
2015; Kishii et al., 2016; Yang et al., 2016).  
.  
1.2.1.2 Current taxonomy 
As a result of molecular and genetic analysis, there have been numerous changes to the naming 
and classification of these organisms. According to the current classification, which seem to have 
gained wide acceptance among bacterial taxonomists, this group of bacteria as 
Gammaproteobacteria is categorised in the order Pseudomonadales and the family 
Moraxellaceae. Thus, the taxonomical classification is given as; Domain: Bacteria, Phylum: 
Proteobacteria, Class: Gammaproteobacteria, Order: Pseudomonadales, Family: Moraxellaceae, 
Genus: Acinetobacter (Nemec, 2017; http://apps.szu.cz//anemec/Classification.pdf.). The species 
A. baumannii, Acinetobacter haemolyticus and A. calcoaceticus are of clinical significance 
(Rossau et al., 1991; Bergogne-Bérézin and Towner, 1996; Jung and Park, 2015).  
 
1.2.2 Increasing impact and prevalence of Acinetobacter spp. 
The majority of Acinetobacter species are non-pathogenic but nonetheless possess mechanisms 
for antibiotic resistance, such as carbapenemases and extended-spectrum β-lactamases (ESBLs) 
(Al-Atrouni et al., 2016) and may thus serve as important environmental reservoirs for resistant 
clinically relevant isolates. They are found in wet locations such as wetlands, fish farms, 
wastewater plants and in seawater. In one study in Texas, A.baumannii-A. calcoaceticus complex 
was found as a coloniser in 17% of healthy military staff but was concluded not to be a source of 
infection since these strains did not match those in infected soldiers (Griffith et al., 2006). Highly 
pathogenic strains are therefore, seldom present in healthy humans. In the past, Acinetobacter 
spp. were not seen as clinically significant pathogens, but recently there has been a global increase 
in the prevalence of infection and drug resistant strains of these organisms (Peleg et al., 2008; 
Spellberg and Rex, 2013; Almasaudi, 2016), including both nosocomial and community acquired 
(Golanbar et al., 2011; Almasaudi, 2016). Although drug-sensitive isolates are usually 
community-acquired and drug-resistant are mostly hospital-acquired (Perez et al., 2007), it is not 
13 
 
easy to differentiate between colonisation and sepsis. Hospital surveillance data suggests that 
Acinetobacter has quickly spread throughout the world, with ICUs being most severely affected 
(Peleg et al., 2008; Spellberg and Rex, 2013; Almasaudi, 2016). The United States reported about 
45,000 cases of Acinetobacter infections annually, while global numbers range from 600,000 to 
1,400,000 cases per year (Spellberg and Rex, 2013). According to U.S. National Healthcare 
Safety Network (NHSN) data, Acinetobacter caused 1.8% of all healthcare-associated infections 
in 2009-2010 (Sievert et al., 2013). 
 
The majority of infection is acquired in healthcare facilities, but it is also reported to cause severe 
community-acquired pneumonia in alcoholics (Anstey et al., 2002). This pathogen was also found 
to cause infections associated with war-related injuries in the Iraq/Kuwait/Afghanistan regions 
(Johnson et al., 2007; Scott et al., 2007) and in survivors of the Asian tsunami in 2004 (Garzoni 
et al., 2005). Mortality associated with Gram-negative bacteremia was significantly higher in 
patients with multidrug-resistant Acinetobacter spp., compared with other Gram-negative bacilli, 
which ranged from 19% to 54% (Gaynes and Edwards, 2005; Robenshtok et al., 2006; Kim et 
al., 2016). The changing epidemiology, the increasing incidence and the significant mortality 
rates has moved Acinetobacter spp. into the clinical spotlight (Russo et al., 2010; Almasaudi, 
2016). It is now recognised that Acinetobacter spp. play a significant role in the colonisation, 
community-acquired infections and nosocomial infections (Parandekar and Peerapur, 2012).  
 
Global surveys show that Acinetobacter is a frequent cause of hospital acquired infection (Leung 
et al., 2006; Sengstock et al., 2010; Wong et al., 2017). There are reports of serious infections in 
immunocompromised hosts and especially in ICUs (Perez et al., 2007; Almasaudi, 2016). These 
include ventilator-associated pneumonia, bacteraemia, urinary tract infections, burn wound 
infections, endocarditis, secondary meningitis, and septicaemia, mostly involving patients with 
impaired host defenses, especially in ICUs (Fournier et al., 2006; Patwardhan et al., 2008; 
Almasaudi, 2016). In one study, Acinetobacter spp. accounted for 2% to 10% of Gram-negative 
infections in Europe (Fournier et al., 2006). 
 
According to the Centers for Diseases Control and Prevention (CDC) and European Centre for 
Disease Control and Prevention (ECDC), MDR microorganisms are resistant to at least one agent 
in three or more antimicrobial categories (Magiorakos et al., 2012) or MDR Acinetobacter spp. 
are those isolates that showed resistance to carbapenems. Drug resistant isolates have a significant 
effect on optimal antibiotic use in patients with serious infections (Fishbain and Peleg, 2010; 
Ghafur et al., 2014; Phee et al., 2015) and the previous surveillance studies have reported 
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increased resistance to carbapenems, considered to be the primary treatment against these bacteria 
(Arıdoğan, 2012; Sievert et al., 2013; Maraki et al., 2016; Zilberberg et al., 2016). 
 
In KZN, the pathogen has emerged as a particularly important organism in late-onset ventilator 
associated pneumonia, possibly related to an increased invasiveness of ICU procedures (Reddy 
et al., 2015). The study in Morocco reported that the frequency and rates of MDR Acinetobacter 
spp. infections was statistically higher in ICUs (p <0.05), with recommendation of infection 
prevention and control only (Uwingabiye et al., 2016). ICUs also harbour similar patterns of drug 
resistant Acinetobacter and reviews indicate that novel agents are needed to address resistance 
(Doughari et al., 2011; Gonzalez-Villoria and Valverde-Garduno, 2016). Despite the high 
prevalence of infection, there is a lack of a standardised approach for optimal therapy in the 
African countries and Saudi Arabia (Almasaudi, 2016). 
 
1.2.3 Antibiotic resistance patterns of Acinetobacter spp. 
Acinetobacter species (Acinetobacter spp.)  have acquired resistance to most treatment options, 
including aminoglycosides (amikacin), quinolones (ciprofloxacin) and broad-spectrum β-lactams  
(Piperacillin-tazobactam and carbapenems). Most isolates are resistant to cephalosporins and 
carbapenem resistance has also emerged (Kim et al., 2010; Jung and Park, 2015). The pathogen 
poses a danger in hospitals due to carbapenem, amikacin and colistin resistance, as seen by 
outbreak incidents occurring in various countries (Dijkshoorn et al., 2007; Almasaudi, 2016).  
An emerging challenge both internationally and in South Africa is the prevalence of drug resistant 
Acinetobacter, including multidrug-resistant (MDR), extensively drug-resistant (XDR) and 
pandrug- resistant (PDR) Acinetobacter species that cause serious problems in clinical settings 
globally (Fishbain and Peleg, 2010; Ghafur et al., 2014; Phee et al., 2015). According to the 
Centers for Disease Control and Prevention (CDC) and European Centers for Disease Control and 
Prevention (ECDC), MDR microorganisms are resistant to at least one agent in three or more 
antimicrobial categories (Magiorakos et al., 2012) or MDR Acinetobacter spp. are those isolates 
that showed resistance to carbapenems. XDR Acinetobacter spp. demonstrate resistance to all 
tested agents except tigecycline, rifampicin and polymyxin B, while PDR isolates are resistant to 
all agents (Falagas and Karageorgopoulos, 2008; Tan et al., 2011; Magiorakos et al., 2012).  
The increasing prevalence of MDR Acinetobacter spp. is a serious concern in the management of 
infections worldwide. This organism has the capacity to acquire putative genetic factors, such as 
plasmids and pathogenicity islands, which facilitate high-level multidrug and metal resistance 
(Shakibaie et al., 1998). The global rise in MDR. (Peleg et al., 2008; Sahu et al., 2012), XDR and 
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PDR Acinetobacter spp.  (Falagas and Karageorgopoulos, 2008, Çelik et al., 2014) is therefore, a 
major challenge to current treatment options.  
 
1.2.4 Mechanisms of antibiotic resistance  
The mechanisms of antimicrobial resistance in Acinetobacter spp. are generally classified into 
four broad categories: changes in outer membrane proteins (OMPs), efflux pumps, changes in 
penicillin binding proteins (PBPs) and antimicrobial-inactivating enzymes (Kamolvit et al., 
2015).   
 
1.2.4.1 Changes in outer membrane proteins (OMPs) 
OMPs, or porins, have been implicated in Acinetobacter drug resistance but the mechanisms are 
poorly understood. Membrane changes likely work in concert with β-lactamases to produce β-
lactam resistance (Manchanda et al., 2010). Carbapenem resistance has been linked to protein 
loss through porin channels and it has been suggested that mutations and reduced porin expression 
may also play a role. The loss of CarO, a 29-kDa protein is linked to imipenem and meropenem 
resistance; the carO gene disruption by distinct insertion elements leads to loss of the CarO porin 
in imipenem-resistant Acinetobacter species.  
Detected clinical outbreaks of carbapenem-resistant Acinetobacter species due to porin loss that 
included reduced expression of a number of OMPs such as 47, 44, and 37 kDa OMPs in 
Acinetobacter species isolates (Bonomo and Szabo, 2006). Heat-modifiable protein HMP-AB, a 
33-36-kDa and 43 kDa proteins are also identified OMPs involved in β-lactam resistance (Jain 
and Danziger, 2004). 
 
1.2.4.2 Efflux pumps 
Efflux pumps consist of a pump in the cytoplasmic membrane and an exit portal, linked by a 
lipoprotein. In the Acinetobacter genus, the adeB gene, which encodes a resistance-nodulation-
cell division (RND), protein type pump, is associated with resistance to aminoglycosides, 
quinolones, tetracyclines, chloramphenicol, erythromycin, trimethoprim and ethidium bromide. 
(Nowak et al., 2015).  
 
A wide variety of multidrug efflux pumps are present in multidrug-resistant Acinetobacter. The 
substrate profile of the AbeM pump includes fluoroquinolones (Perez et al., 2007). The (RND) 
familytype pump AdeABC is the most studied so far and it has a substrate profile that includes β-
lactams (including carbapenems) and other class of antimicrobials. (Perez et al., 2007). Its 
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structure consists of AdeA forming the inner cytoplasmic membrane protein, AdeB creates the 
linking component and AdeC forms the porin (Nowak et al., 2015). 
The regulation of AdeABC is controlled by a regulator (adeR) and sensor (AdeS), where point 
mutations may lead to overexpression of AdeABC, and therefore higher efflux (Peleg et al., 2008). 
In combination with OXA, this amplification results in high-level resistance to carbapenems 
(Perez et al., 2007; Nowak et al., 2015). 
 
1.2.4.3 Changes in Penicillin binding proteins (PBPs) 
Seven different PBPs (1a, 1c, 2, 3, 4, 4b and 5) have been found in Acinetobacter species. Porin 
deficiency results in decreased uptake of carbapenems, while modification of the PBPs results in 
decreased affinity. Isolates from Spain have revealed mutations leading to reduced expression of 
PBP-2 (Perez et al., 2007).  
 
1.2.4.4 Antimicrobial-inactivating enzymes 
The most common mechanism is facilitated by β-lactamases. β-lactamases are divided into 4 
molecular groups: consisting of Ambler class A, class B (metallo enzymes), Class C (β-
lactamases), and class D (oxacillinases) (Jain and Danziger, 2004). 
These enzymes, at least partially, hydrolyse carbapenems along with other β-lactams (Jain and 
Danziger, 2004). Ambler class β-lactamases are mentioned in section; 1.2.5.1. 
 
1.2.5 Mechanisms of resistance to selected antibiotics 
The selected appropriate antibiotics that commonly use for Acinetobacter spp. are β- lactams 
(ceftazidime, piperacillin-tazobactam, and carabapenems), aminoglycosides (amikacin) and 
colistin (CLSI 2014). 
 
1.2.5.1 Resistance to β- lactams 
Acinetobacter spp. display resistance to β-lactams through hydrolysis of β-lactams by β-
lactamases, (Dijkshoorn et al., 2005; Peleg et al., 2008; Stoeva et al., 2008) changes in penicillin-
binding proteins (PBPs), changes in the structure and number of porin proteins leading to 
decreased permeability, and efflux pumps that decrease the concentration of antibiotic in the 
cytoplasm (Perez et al., 2007). The Ambler scheme divides β-lactamases into four major classes 
(A to D). The basis of this classification scheme rests upon protein homology (amino acid 
similarity), and not phenotypic characteristics. In the Ambler classification scheme, β-lactamases 
of classes A, C, and D are serine β-lactamases. Carbapenemases, oxacillinases (OXA) or metallo-
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β-lactamases (MBLs) are of major concern because of their ability for rapid dissemination 
(Abdalhamid et al., 2014). 
 
(i) Class A β-lactamases  
Narrow-spectrum β-lactamases, such as TEM β-lactamases (class A) most commonly 
encountered β-lactamase in Gram-negative bacteria, is able to hydrolyze penicillin and first 
generation cephalosporins β-lactamase. Acinetobacter spp. isolates harboring PER-1, an ESBL, 
demonstrate high-level resistance to penicillins and extended-spectrum cephalosporins, but 
fortunately, PER-1 β-lactamase does not confer resistance to carbapenems in Acinetobacter spp. 
PER-1 is very prevalent among Acinetobacter spp. isolates. (Perez et al., 2007). Both Extended-
spectrum β-lactamases (ESBLs) and Narrow-spectrum β-lactamases (NSBLs) such as TEM-1 and 
TEM-2, from the Ambler class A group have been identified in Acinetobacter (Jain and Danziger, 
2004). 
 
(ii) Class B β-lactamases.  
A recent phenomenon in β-lactam resistance is the increase in metallo-β-lactamases (MBLs) in 
Acinetobacter spp. (Walsh et al., 2005). Metallo-β-lactamases (MBLs) are Ambler class B, or β-
lactamases that can hydrolyse carbapenems and all β-lactam antibiotics, excluding aztreonam. 
Unlike class A and D carbapenemases, class B β-lactamases have a metal ion in the active site, 
usually zinc, which plays a role in catalysis (Walsh et al., 2005(Perez et al., 2007).). Mishra et al. 
(2012) and Altun et al. (2013) determined that Acinetobacter were the most common MBL-
producing isolates and reported a higher incidence of MBL-production than Pseudomonas 
aeruginosa (El-Kazzaz and El-khier, 2015; Potron et al., 2015).  
The two major metallo-β-lactamases that have been reported in Acinetobacter species are “Verona 
integron-encoded metallo-β-lactamases” (VIM) and ‘‘Imipenem hydrolysing β -lactamase” 
(IMP). The IMP or VIM family has been described in various areas in the world such as in Japan, 
Italy, Hong Kong, and Korea. These enzymes are encoded by genetic elements located on 
chromosomes or on plasmids and are known to hydrolyse all β-lactam antibiotics except 
aztreonam. Enzymatic degradation by β-lactamases is the most frequent mechanism of β-lactam 
resistance in Acinetobacter species.  The highly mobile nature of plasmids poses a risk of 
transmission among other microorganisms (Urban et al., 2003).  
 
(iii) Class C β-lactamases.  
Acinetobacter spp. have a chromosomally encoded class C β-lactamase in the bla genes. Class C 
cephalosporinases hydrolyse penicillins and cephalosporins, both narrow-spectrum and extended-
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spectrum, but do not hydrolyse cefepime or carbapenems. Therefore, many Acinetobacter spp. 
isolates are resistant to ceftazidime (Perez et al., 2007).  
Metallo-enzymes that hydrolyse carbapenems and other β-lactams except monobactams. These 
are not inhibited by clavulanic acid. AmpC-type cephalosporinase, or Acinetobacter-derived 
cephalosporinases (ADCs) are produced by Acinetobacter species but do not hinder the efficacy 
of cephalosporins with regular rates of expression (Manchanda et al., 2010). However, over 
expression of ADC caused by the upstream insertion sequence (IS) element known as ISAba1 
that codes for class C cephalosporinases, results in resistance. ADCs hydrolyse penicillin and 
extended spectrum cephalosporins but have no effect on cefepime and carbapenems (Manchanda 
et al., 2010).   
 
(iv) Class D β-lactamases.  
Class D β-lactamases, also known as OXA-type enzymes or oxacillinases, are represented by 
more than 350 genetically diverse enzymes that are widely disseminated in Gram-negative 
bacteria (Antunes et al., 2014). Although they exhibit weak hydrolysis of carbapenems, the genes 
encoding OXA associated with insertion sequences that provide strong promoters, leading to 
overexpression and carbapenem resistance (Turton et al., 2006). Class D OXA β-lactamases are 
robust penicillinases i.e. oxacillinases. Some, like OXA ESBLs, can hydrolyse extended-
spectrum cephalosporins (Aubert et al., 2001; Walther-Rasmussen and Hoiby, 2006). The most 
worrying in this class are the OXA β-lactamases that can inactivate carbapenems, the first of 
which was discovered in 1985 before carbapenems were introduced. The plasmid-encoded 
enzyme, OXA-58 has since been discovered. OXA-58 has been described both as chromosomal 
and as a plasmid-mediated carbapenemase in A.baumannii (Brown and Amyes, 2006). β-lactam 
resistance occurs mainly through carbapenem-hydrolysing class D β-lactamases (CHDLs) 
(Joseph et al., 2010), also known as OXA-type enzymes or oxacillinases (Shakibaie et al., 1998; 
Kim et al., 2010). Previously, Class D carbapenemase enzymes are classified into four subgroups 
according to their amino acid sequence identity: OXA-23 (plasmid-encoded), OXA-24 
(chromosomally encoded), OXA-51 (chromosomally encoded) and OXA-58 (plasmid-encoded) 
(Peleg et al., 2008; Kock et al., 2013). Based on their amino acid sequence identity, CHDLs have 
been subdivided into several subgroups. There are five subclasses of OXA associated with A. 
baumannii reported in  literature; the intrinsic chromosomal OXA-51-like, of which there are over 
70 variants, and the acquired OXA-23-like, OXA-24 (OXA-40-like), OXA-58-like, and OXA-
143-like (Poirel et al., 2010). Acquired OXA are found both chromosomally and on plasmids and 
can be detected by multiplex PCR (Woodford et al., 2006; Higgins et al., 2010). OXA-143-like 
subgroups are of major clinical importance due to their wide dissemination in bacterial pathogens.  
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Acquired OXA are found both chromosomally and on plasmids and can be detected by multiplex 
PCR (Woodford et al., 2006; Higgins et al., 2010). In addition, the OXA-235-like, OXA-236-
like, and OXA-237-like, first representatives of a novel subclass of CHDLs, were described in A. 
baumannii strains in 2013 that could not be detected by previous PCR methods (Higgins et al., 
2013). The majority of these carbapenemases have been identified in various Acinetobacter 
isolates, predominantly in Acinetobacter baumannii (Dijkshoorn and Van-Der-Toorn, 1992; 
Manchanda et al., 2010; Kishii et al., 2016; Yang et al., 2016). These were described in regions 
such as Scotland, Spain, France, Japan, Singapore, China, Brazil, Cuba, and Kuwait (Manchanda 
et al., 2010). 
 
Carbapenem-hydrolysing class D enzymes occur globally (Falagas and Karageorgopoulos, 2008; 
Sahu et al., 2012). Koh et al. in 2007, reported that 91% of Acinetobacter spp. isolates in 
Singapore were carbapenemase producers and possessed the blaOXA-23 gene (Koh et al., 2007). 
The high prevalence of OXA-23-like can be linked to plasmids and transposons, although the 
gene can also be found on a chromosome (Parandekar and Peerapur, 2012). In 2012, Liakopoulos 
et al., reported a 95% prevalence of OXA-23-like in Greece between 2010 and 2011. A 2013 
study conducted at Pretoria Academic Hospital (South Africa) revealed a prevalence of OXA-51-
like (83%) and OXA-23-like (59%) (Kock et al., 2013).  
OXA-23 carbapenemase was detected in 1985 before the introduction of carbapenems. Since 
then, the initially termed ARI-1 (Acinetobacter resistant to imipenem), which is a plasmid-
encoded enzyme, has been reported in England, Brazil, Polynesia, Singapore, Korea, and China 
(Manchanda et al., 2010).  
Carbapenem-hydrolysing class D β-lactamases (CHDLs) are most problematic clinically, as they 
produce resistance to the antibiotics of last resort, carbapenems, thus severely limiting therapeutic 
options.  
 
1.2.5.2 Resistance to aminoglycosides 
Resistance is facilitated primarily by aminoglycoside-modifying enzymes (AMEs), including 
aminoglycoside phosphotransferases, aminoglycoside acetyltransferases, and aminoglycoside 
nucleotidyltransferases (Perez et al., 2007; Jung and Park, 2015).  
Genes coding for AME within class 1 integrons are frequently present in multidrug-resistant 
Acinetobacter species isolates.  
The AAC (3) enzymes found in Gram-negative bacteria are divided into nine classes. The AAC 
(3)-I, present in many Gram-negative isolates including Enterobacteriaceae, is made up of five 
enzymes linked to gentamicin, sisomicin, and fortimicin (astromicin) resistance (Ramirez and 
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Tolmasky, 2010).  Resistance to parenteral aminoglycosides, conferred by 16S rRNA methylases, 
have been reported in Japan, Korea and the United States (Perez et al., 2007; Jung and Park, 
2015). The genes are present on transposons in plasmids, making them at risk of horizontal 
transfer (Doi and Arakawa, 2007; Jung and Park, 2015). The AME that was discovered in Japan 
plays a role in amikacin resistance (Perez et al., 2007; Jung and Park, 2015). 
Other mechanisms of resistance include alterations in the target ribosomal protein, impaired 
transport of aminoglycosides into the cell, and efflux pump-mediated removal of aminoglycosides 
(Jung and Park, 2015).  
A wide array of AME have been observed in Acinetobacter spp. (Perez et al., 2007). The 
predominant AME, an AAC (3) class enzyme occurred in nearly 50% of the isolates resistant to 
aminoglycosides while some of the AAC (A4)-harbouring Acinetobacter spp. remained 
susceptible to amikacin (Akers et al., 2010). The AME, encoded by aacA6, which has been 
reported from Japan, plays a crucial role in amikacin resistance (Doi et al., 2004). Amikacin 
resistance in Acinetobacter spp. is facilitated by APH (3’)-VI, encoded by the aphA6 gene 
(Nemec et al., 2004; Aliakbarzade et al., 2014). In addition, the aacA4 gene, which encodes AAC 
(6’)-Ib, confers resistance to amikacin, netilmicin, and tobramycin (Aliakbarzade et al., 2014), 
while aadB is associated with resistance to kanamycin, gentamicin and tobramycin (Aliakbarzade 
et al., 2014). 
 
1.2.5.3 Resistance to polymyxins  
The peptides, polymyxin B and polymyxin E (also known as colistin or intravenous colistimethate 
sodium) have seen increased use as final resort therapy in MDR Acinetobacter spp. (Perez et al., 
2007). Colistin displays bactericidal activity through its interaction with the lipid A components 
of lipopolysaccharide (LPS), thus disrupting the outer membrane of Gram-negative bacteria 
(Olaitan et al., 2014). In Acinetobacter spp, colistin-resistance is mediated by complete loss of 
LPS production via mutations within the genes (lpxA, lpxC and lpxD) of the lipid A biosynthesis 
pathway or by modification of lipid A components of LPS via mutations in the pmrA and pmrB 
genes of the two-component regulatory system and pmrC that encodes a lipid A 
phosphoethanolamine transferase (Adams et al., 2009; Park et al., 2015). It was demonstrated in 
two different isolates of Acinetobacter spp. that colistin resistance may occur from a susceptible 
sample through lipid A biosynthesis mutants. The isolates which do not possess LPS demonstrate 
high levels of resistance to colistin (Arıdoğan, 2012). Acinetobacter isolates that are resistant to 
colistin have been reported (Adams et al., 2009; Moffatt et al., 2010). The clinical significance 
of colistin-heteroresistant isolates following colistin treatment has been highlighted in a case 
report (Hernan et al., 2009).  
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Isolates producing OXA-23 and OXA-58 carbapenemases exhibited a high percentage of colistin 
heteroresistance (Rodriguez et al., 2010). The wide usage of colistin against carbapenem-resistant 
Acinetobacter spp. led to the development of resistance (Pogue et al., 2015).  
 
 
1.2.6 Antibiotic resistance drives outcomes 
Acinetobacter spp. possess extensive drug resistance mechanisms, with a resistance island of 45 
genes in its genome (Adams et al., 2009; Blackwell et al., 2016), with an additional ability to 
acquire resistance genes from other bacteria (Adams et al., 2009; Blackwell et al., 2016), and 
develop resistance to a particular agent during therapy (Cheng et al., 2015). 
The clinical challenge therefore, lies in providing effective antibiotic therapy and overcoming the 
pathogen’s massive potential for drug resistance (Adams et al., 2009; Blackwell et al., 2016). 
Carbapenem resistance in particular, poses a threat to effective treatment options, with 
Acinetobacter isolates showing an interplay of a number of resistance mechanisms. Among these, 
oxacillinase (OXA) production and the absence of PBP2 are the most common, while reduced 
entry of carbapenems caused by downregulation of porin also occurs  (Fernandez-Cuenca et al., 
2003). Oxacillinases OXA-23-like, OXA-24-like or -40-like, OXA-51-like, OXA-58-like, and 
OXA-143-like have been linked to most cases of carbapenem resistance worldwide (Higgins et 
al., 2010; Ben et al., 2011; Principe et al., 2014; Kamolvit et al., 2015; Labarca et al., 2016). 
OXA-23 is a plasmid- or transposon encoded -lactamase, while OXA-51 is a chromosome-based 
enzyme and is intrinsic to Acinetobacter. OXA-24/40 can be chromosomal or plasmid based, and 
OXA-58 is plasmid encoded. These class D -lactamases are not very robust carbapenemases, but 
the presence of an insertion sequence (IS) element, such as ISAbaI and ISAba9, increases 
expression of the carbapenemase significantly, resulting in clinical carbapenem resistance 
(Higgins et al., 2010; Nigro and Hall, 2015;  Warner et al., 2016). 
Another element in resistance is the class β-lactamases, or metallo-lactamases (MBLs) (Perez et 
al., 2007), with the finding that the enzymes IMP, VIM, SIM and NDM are present in 
Acinetobacter (Perez et al., 2007; Dortet et al., 2014). In addition, identification of the composite 
transposon Tn125 suggests that Acinetobacter was the source of blaNDM genes which later spread 
to Enterobacteriaceae (Bonnin et al., 2012; Bonnin et al., 2014; Krahn et al., 2016). 
 
Acinetobacter is disproportionately responsible for an increase in patient mortality, resulting from 
treatment failure with antimicrobial drugs. Due to the high rates of resistance, early effective 
treatment is difficult, thus compromising clinical outcomes (Blot et al., 2003; Maragakis and Perl, 
2008; Spellberg and Bonomo, 2014; Zilberberg et al., 2016). 
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XDR strains, namely those demonstrating resistance to all available agents except for those that 
are more toxic or less effective copered to first-line therapy, is common in Acinetobacter species 
(Infectious Diseases Society of America, 2012). Carbapenem resistance is usually the mark of 
XDR Acinetobacter, which leaves polymixins, tigecycline and sometimes aminoglycosides as 
treatment options (Chopra et al., 2013; Chopra et al., 2014; Freire et al., 2016). According to 
National Healthcare Safety Network (NHSN) and Eurofins, over half of A. baumannii in ICUs in 
the United States show carbapenem resistance, which is the highest rate of all pathogens surveyed 
(Sievert et al., 2013; Zilberberg et al., 2016). Data from other countries show even higher rates 
of resistance and a sharp increase in recent decades, with global figures rising from 4% in 2000 
to 60% in 2008 (Kallen et al., 2010) and in some settings the proportion of XDR strains is close 
to 90% (Sievert et al., 2013; Guo and Xiang. 2016). 
 
Ineffective initial therapy was likely the reason for differences in outcome for XDR, carbapenem 
resistant strains, and not differences in virulence, since treatment with tigecycline or colistin 
within 48 hours reduced the mortality rates in these patients from 88% to 38% (Lee et al., 2014). 
Similar outcomes were observed in ICUs in the U.S., where mortality was doubled in cases of 
ineffective initial therapy (Zilberberg et al., 2016).  
 
 
1.2.7 Drug susceptibility testing 
The standardised method for drug susceptibility testing of Acinetobacter spp. includes the disk 
diffusion test (Kirby-Bauer), the automatic identification and susceptibility system (VITEK 2 
system (BioMérieux) and MicroScan Walk-Away® (Becton Dickinson Diagnostic Systems, 
Sparks, MD). Minimum inhibitory concentrations (MICs) are widely performed using the 
Epsilometer test (‘E-test’) (BioMérieux).  
 
1.2.7.1 The Kirby-Bauer disk diffusion test  
Agar disk-diffusion test was implemented in 1940 (Heatley, 1944) as per the Clinical Laboratory 
Standards Institute (CLSI) and is the official method routinely used in many clinical microbiology 
laboratories for antimicrobial susceptibility testing. The procedure involves the growth of the 
organism on Mueller-Hinton agar in the presence of various antimicrobial impregnated filter 
paper disks. The presence or absence of growth around the disks is an indirect measure of the 
ability of the specific compound to inhibit the organism (Hudzicki, 2009). The antibiogram 
provides qualitative results by interpreting as susceptible (S), intermediate (I) or resistant (R) 
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(Reller et al., 2009). [Examples: imipenem (10 µg), ≥ 22 (S), 19-21 (I), ≤18 mm (R); meropenem 
(10 µg), ≥ 18 (S), 15-17 (I), ≤14 mm (R)] for Acinetobacter species (CLSI 2014).  
As a useful phenotype of the microbial strain tested, it can guide clinicians in the appropriate 
selection of initial empiric treatments and antibiotics used for individual patients (Caron, 2012; 
Balouiri et al., 2016). However, since the bacterial growth inhibition does not equate to bacterial 
death, this method cannot distinguish bactericidal and bacteriostatic effects. 
Moreover, the agar disk-diffusion method is not appropriate to determine the minimum inhibitory 
concentration (MIC), as it is impossible to quantify the amount of the antimicrobial agent diffused 
into the agar medium. An approximate MIC can be calculated for some microorganisms and 
antibiotics by comparing the inhibition zones with stored algorithms (Nijs et al., 2009). The disk-
diffusion assay provides many advantages over other methods such as simplicity, low cost, the 
ability to test enormous numbers of microorganisms and antimicrobial agents, and ease of 
interpretation of results. In addition, several studies have demonstrated the great interest in 
patients who suffer from bacterial infection of an antibiotherapy based on the antibiogram of the 
causative agent (Kreger et al., 1980). This fact is due to the good correlation between in vitro data 
and in vivo evolution (Caron, 2012; Balouiri et al., 2016).  
 
1.2.7.2 The VITEK 2 system (BioMérieux)    
 This system uses a fluorescence-based technology and is an automated instrument that is capable 
of rapid, simultaneous identification and antimicrobial sensitivity testing of microorganisms 
(Funke et al., 1998), in accordance with the guidelines established by the CLSI (CLSI 2014). A 
transmittance optical system allows interpretation of test reactions using different wavelengths 
during incubation.  Each test reaction is read every 15 mins to measure either turbidity or colour 
products of substrate metabolism. Both VITEK 2 ID-GNB (an identification system) and VITEK 
2 AST-No. 12 (a susceptibility testing system) card systems gave rapid, reliable, and highly 
reproducible results (Ling et al., 2001). Several advantages of the VITEK 2 system were 
mentioned; first, it is a closed system that can avoid unwanted cross-contamination or 
environmental contamination. Second, it has a reliable recheck system if a specimen card is 
misplaced on the specimen cartridge. Third, the VITEK 2 system is able to handle dozens of 
specimens automatically at the same time. It is also easy for laboratory staff to prepare and load 
bacterial specimens. The decreased turnaround and hand-on times greatly improve the efficiencies 
of routine clinical laboratories. In conclusion, both the VITEK 2 ID-GNB (an identification 
system) and VITEK 2 AST-No. 12 (a susceptibility testing system) card systems gave rapid, 
reliable, and highly reproducible results (Ling et al., 2001). 
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1.2.7.3 The E-test  
The E-test is based on diffusion of a preformed antibiotic gradient from a plastic strip. It is 
technically simple and similar to the disk diffusion method, but it can provide MICs. The 
versatility and ease of use of the E-test means that it is an attractive alternative to conventional 
dilution tests.  Problems in performing in vitro colistin susceptibility testing of Acinetobacter spp. 
have been encountered: the disk diffusion method has been found to be inaccurate and not 
reproducible for Acinetobacter spp. (Gales et al., 2001; Arroyo et al., 2005). Agar dilution and 
broth microdilution (BMD), currently the recommended susceptibility test methods for this 
organism, are cumbersome and impractical (Gales et al., 2001; Arroyo et al., 2005). The E-test 
(bioMerieux), being quick, cost effective and helps in decreasing the laborious work, has been 
reported to be a simple and accurate alternative method for determining the antimicrobial 
susceptibilities of various microorganisms. A study suggested that the E-test could be a reliable 
and suitable alternative to the reference method for the detection of colistin resistance in 
Acinetobacter spp. clinical isolates by clinical laboratories (Arroyo et al., 2005). 
 
1.2.7.4 Conventional dilution tests  
These are the earliest methods of antimicrobial susceptibility testing and include the broth 
macrodilution or tube dilution method.  
 
1.2.7.4.1 Broth dilution method 
Broth micro- or macro-dilution is one of the most basic antimicrobial susceptibility testing 
methods (Balouiri et al., 2016). The procedure involves preparing two-fold dilutions of the 
antimicrobial agent (e.g. 1, 2, 4, 8, 16 and 32 µg/mL) in a liquid growth medium dispensed in 
tubes containing a minimum volume of 2 mL (macrodilution) or with smaller volumes using 96-
well microtitration plate (microdilution) (Washington and Woods, 1995). Then, each tube or well 
is inoculated with a microbial inoculum prepared in the same medium after dilution of 
standardised microbial suspension adjusted to 0.5 McFarland scale. After mixing well, the 
inoculated tubes or the 96-well microtitration plate are incubated (mostly without agitation) under 
suitable conditions depending upon the test microorganism. The MIC is the lowest concentration 
of antimicrobial agent that completely inhibits growth of the organism in tubes or microdilution 
wells as detected by the unaided eye (CLSI 2012) (Washington and Woods, 1995; Jorgensen and 
Ferraro, 1998). 
Unlike microdilution method, the main disadvantages of the macrodilution method are the 
tediousness, manual undertaking, risk of errors in the preparation of antimicrobial solutions for 
each test, and the comparatively large amount of reagents and space required (Reller et al., 2009). 
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Thus, the reproducibility and the economy of reagents and space that occurs due to the 
miniaturisation of the test are the major advantages of the microdilution method. Nevertheless, 
the final result is significantly influenced by approach, which must be carefully controlled if 
reproducible results (intralaboratory and interlaboratory) are to be attained (CLSI 2012). For the 
determination of MIC endpoint, viewing devices can facilitate reading microdilution tests and 
recording results with high ability to discern growth in the wells. Moreover, several colorimetric 
methods based on the use of dye reagents have been developed (Al-Bakri and Afifi, 2007). The 
Alamar blue dye (resazurin), an effective growth indicator, can also be used for this purpose 
(Bouhdid et al., 2009; Ouedrhiri et al., 2015). 
It is well known that the inoculum size, the type of growth medium, the incubation time and the 
inoculum preparation method can influence MIC values (CLIS 1998). Therefore, broth dilution 
has been standardised by CLSI for testing bacteria that grow aerobically (CLSI 2012). The 
EUCAST broth dilution method is principally similar to that of CLSI with modifications usually 
concerning some of the test parameters such as inoculum preparation, inoculum size, and the MIC 
reading method which is visual in CLSI assay and spectrophotometric in EUCAST guidelines 
(CLSI 1998; Balouiri et al., 2016). 
 
The determination of minimum bactericidal concentration (MBC) also known as the minimum 
lethal concentration (MLC), is the most common estimation of bactericidal activity. The MBC is 
defined as the lowest concentration of antimicrobial agent needed to kill 99.9% of the final 
inoculum after incubation for 24 hr under a standardised set of conditions described in document 
M26-A (CLSI 1998; Balouiri et al., 2016), in which the MBC can be determined after broth 
macrodilution or microdilution by sub-culturing a sample from wells or tubes, yielding a negative 
microbial growth after incubation on the surface of non-selective agar plates to determine the 
number of surviving cells (CFU/mL) after 24 h of incubation. The bactericidal endpoint (MBC) 
has been subjectively defined as the lowest concentration, at which 99.9% of the final inoculum 
is killed (CLSI 1998; Balouiri et al., 2016). 
 
1.2.8 Impact of molecular methods on infection control 
Suitable molecular typing methods are essential for epidemiological investigations and infection 
control studies. The increasing rates of resistance of Acinetobacter spp. to the available 
antimicrobial drugs means that outbreaks should be identified and controlled early. Knowledge is 
lacking about the diversity within the species and the emergence of epidemic clones (Nemec et 
al., 2008). Pulsed-field gel electrophoresis (PFGE) is considered the “gold standard” of 
epidemiological typing among the various genotypic methods for Acinetobacter spp. (Smith et 
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al., 1993; Hamouda et al., 2010). Among traditional and molecular typing methods, antibiotic 
resistance typing has been used for the epidemiological investigation of outbreaks caused by 
Acinetobacter species. Multiplex PCR used to identify antibiotic resistance genes encoding the 
MDR phenotypes in clinical isolates of Acinetobacter spp. demonstrated that MDR Acinetobacter 
spp. isolates harboured the same resistance genes (Ghajavand et al., 2015). Infection prevention 
and control measures form a crucial part of the management of MDR Acinetobacter spp. 
(Almasaudi, 2016; Uwingabiye et al., 2016; Samawi et al., 2016).  
 
 
1.2.9 Role of synergy testing for combination therapy against Acinetobacter spp.  
The high frequency of resistance to standard treatment in Acinetobacter spp., as well as the 
emergence of MDR strains, has changed the options for optimal antibiotic therapy in serious 
infections (Fishbain and Peleg, 2010; Ghafur et al., 2014; Phee et al., 2015). Despite toxicity 
risks, colistin is commonly used in the face of limited options (Peleg et al., 2008; Vidaillac et al., 
2012). Combination therapy with colistin is preferred over monotherapy, due to the drug’s toxic 
effects and the development of colistin resistance (Leu et al., 2014).   
 
1.2.9.1 Combination therapy  
The emergence of MDR, XDR and PDR Acinetobacter spp. is a serious problem globally, and 
these resistant isolates have a significant effect on the optimal use of antibiotics in patients with 
serious infections (Fishbain and Peleg, 2010; Ghafur et al., 2014; Phee et al., 2015). With limited 
therapeutic options, colistin is an alternative antimicrobial agent, despite concerns about renal 
toxicity and neurotoxicity, especially in chronic conditions of hospitalised patients who are prone 
to developing renal failure (Peleg et al., 2008; Vidaillac et al., 2012). In addition, patients with 
Acinetobacter spp. bacteremia who are receiving early and appropriate antimicrobial therapy are 
expected to show favourable clinical outcomes. However, the presence of any underlying 
pathology and polymicrobial sepsis negatively affect such outcomes (Kim et al., 2012). 
 
The emergence of resistance during colistin monotherapy, as well as the potential toxic effects, 
has led to its increased use in combination with other drugs, instead of merely increasing the dose 
in monotherapy (Leu et al., 2014). Therefore, therapy using various synergistic combinations of 
antimicrobials (including carbapenems, colistin, rifampicin, and ampicillin-sulbactam) has been 
suggested as the best approach, and empirical combination of therapies have become common 
practice (Bonapace et al., 2000; Petrosillo et al., 2014).  
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The administration of antibiotic combinations has been proposed for three main reasons: (i) to 
broaden the spectrum of activity (ii) to minimise the development of antibiotic resistance and (iii) 
to achieve antibiotic synergy. The latter may be important if an antibiotic with marginal activity 
is used against the infecting bacterium.  
In vitro activity and kill-kinetics of a vancomycin-colistin combination were shown to have a 
synergistic action against five number of multidrug-resistant Acinetobacter baumannii (MDRAB) 
isolates [defined as resistant to at least three different antimicrobial classes 
(aminoglycosides/quinolones/β-lactams) but susceptible to colistin] (Falagas et al., 2006), and A. 
baumannii ATCC19606, was used as a drug-susceptible type isolate in United Kingdom. (Gordon 
et al., 2010). Vancomycin, a glycopeptide and an inhibitor of bacterial peptidoglycan synthesis, 
lacks activity against Gram-negative bacteria due to its large size and hydrophobicity. The cell-
permeabilising properties of colistin could however, be exploited to improve the penetration of 
glycopeptides through the Acinetobacter spp. outer membrane, toward their targets in the cell 
wall (Gordon et al., 2010). This mechanism of synergy for colistin and vancomycin against MDR 
Acinetobacter species may be useful for polymicrobial infection with Gram-positive and 
MDR/XDR Acinetobacter spp. mixed infection. However, the clinical utility of these 
combinations against drug-resistant Acinetobacter remains to be determined (Doughari et al., 
2011). Previous studies reporting on synergy tests of colistin with different combinations of 
antimicrobials showed contradictory and contrasting outcomes, and further synergy research 
needs to be conducted to obtain more conclusive results (Falagas et al., 2006; Wareham and Bean 
2006; Pankey and Ashcraft. 2009; Vidaillac et al., 2012; Petrosillo et al., 2014; Temocin et al., 
2015; Zafar et al., 2015).  
 
1.2.9.2 Different methods of synergy testing  
In vitro synergy tests are used in XDR and PDR Acinetobacter spp. infections to evaluate 
synergism between available combination agents (Sopirala et al., 2010). The desired 
characteristics of a test are simplicity, accuracy and reproducibility. Although time- kill and 
checkerboard tests are commonly used, they are time consuming and labour intensive. The E-test 
is simpler but has not been studied for this purpose previously (White et al., 1996). E-test was 
easier to perform, less time-consuming, less expensive and more accurate (Sopirala et al., 2010). 
Nevertheless, some literature suggests that accuracy is not pathogen but method dependent 
(Sopirala et al., 2010).  The interesting new rapid synergy testing method, a novel two-
dimensional antibiotic gradient technique named XactTM, for meropenem/colistin synergy testing 
for multidrug-resistant Acinetobacter baumannii strains has been recommended in routine 
microbiology (Van-Belkum et al., 2015). This new test was comparable, shown to be 
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diagnostically useful, easy to implement and less labour intensive than the classical method (Van 
Belkum et al., 2015).  Therefore, synergy testing should be done using the new method and 
compared with E-test method in future. 
 
Time–kill and checkerboard titration methods 
The time-kill curve, which determines lethal effect, and the checkerboard titration method, which 
provides bacteriostatic and bactericidal results, are two basic techniques for the quantitative 
assessment of synergism (Young, 1978; Greenwood, 1979; Moellering, 1979; Hallander, 1982). 
In a modification of the checkerboard method proposed by Berenbaum (1978), two drugs were 
mixed in fractions of their MICs for each bacterial isolate and serially diluted (Berenbaum, 1978). 
MICs and fractional inhibitory concentrations (FICs) were determined after overnight incubation, 
by examining for turbidity.  
 
1.2.9.2.1 Time-kill test  
Time-kill test is the most appropriate method for determining the bactericidal effect. It is a strong 
tool for obtaining information about the dynamic interaction between the antimicrobial agent and 
the microbial strain. The time-kill test reveals a time-dependent or a concentration-dependent 
antimicrobial effect (CLSI 1998). For bacteria, this test has been well standardised and described 
in M26-A document of CLSI (CLSI 1998). It is performed in broth culture medium using three 
tubes containing a bacterial suspension of 5×105 CFU/mL. The first and the second tubes contain 
the molecule or the extract tested usually at final concentrations of 0.25×MIC and 1×MIC, and 
the third one is considered as the growth control. The incubation is done under suitable conditions 
for varied time intervals (0, 4, 6, 8, 10, 12 and 24 h) (CLSI 1998; Konaté et al., 2012). Then, the 
percentage of dead cells is calculated relatively to the growth control by determining the number 
of living cells (CFU/mL) of each tube using the agar plate count method. Generally, the 
bactericidal effect is obtained with a lethality percentage of 90% for 6 h, which is equivalent to 
99.9% of lethality for 24 h (Konaté et al., 2012). In addition, this method can be used to determine 
synergism or antagonism between drugs (two or more) in combinations (White et al., 1996; CLSI 
1998). 
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1.2.9.2.2 Checkerboard method  
The checkerboard, or checkerboard titration, method is the most frequently used evaluation 
method. The technique derives its name from the square array of tubes, agar plates or microtiter 
wells used to hold the different antibiotic concentrations against which the offending pathogen is 
being tested. Twofold dilutions of each antibiotic, both alone and together, are used (Marymont 
et al., 1983). Any antibiotics which are stored at 2° to 8°C until used. The stock solutions and 
serial twofold dilutions of each drug at least double the MIC were prepared according to the 
recommendations method immediately prior to testing (Bajaksouzian et al., 1997).  
A total of 50 µL of Mueller-Hinton broth was distributed into each well of the microdilution 
plates. The first antibiotic of the combination is serially diluted along the ordinate, while the 
second drug was diluted along the abscissa. An inoculum equal to a 0.5 McFarland turbidity 
standard was prepared from each isolate in Mueller-Hinton broth (BBL). Each microtiter well 
was inoculated with 100 µL of a bacterial inoculum of 5 x105 CFU/ml, and the plates were 
incubated at 35°C for 48 h under aerobic conditions. The resulting checkerboard contains each 
combination of two antibiotics, with tubes that contain the highest concentration of each antibiotic 
at opposite corners. According to the standard guidelines for broth microdilution, the MIC was 
defined as the lowest concentration of antibiotic that completely inhibited the growth of the 
organism as detected with the naked eye. Synergy is more likely to be expressed when the ratio 
of the concentration of each antibiotic to the MIC of that antibiotic was same for all components 
of the mixture. The fractional inhibitory concentration index (ƩFICs) were calculated as follows: 
ƩFIC=FIC A + FIC B, where FIC A is the MIC of drug A in the combination/MIC of drug A 
alone, and FIC B is the MIC of drug B in the combination/MIC of drug B alone. The combination 
is considered synergistic when the ƩFIC is ≤ 0.5, indifferent when the ƩFIC is ≥ 0.5 to ≤ 2, and 
antagonistic when the ƩFIC is ≥ 2 (Orhan et al., 2005). 
 
1.2.9.2.3 Synergy test by colistin-incorporated plate and E-test  
Synergy testing can also be performed by the E-test method, whereby one drug is incorporated 
into the agar at a fixed concentration, seeded with the inoculum, after which the second drug is 
applied on an E-test (Berenbaum, 1978; Gordon et al., 2010). The MIC of the second drug is 
compared in the presence and absence of the first drug. Different drug combinations can be tested 
in this manner. Hence, the performance of the E-test for synergy testing in comparison to the 
checkerboard (CB) dilution method, widely used to assess synergy between antibiotics, have been  
systematically analysed (White et al., 1996; Sopirala et al., 2010). 
While both the E-test  (Plates containing colestimethate) and CB correlated well with time-kill 
analysis in demonstrating synergy for two-drug combinations, there was better correlation of the 
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E-test with time-kill results (Sopirala et al., 2010). All the antibiotic combinations that showed 
synergy in the time-kill analysis in all tested isolates also showed synergy in E-test as documented 
in the previous study (Sopirala et al., 2010). On the other hand, most of the isolates showed 
additivity (no synergy) in the CB test. E-test was also easier to perform, less time-consuming, less 
expensive and more accurate (Sopirala et al., 2010). 
 
1.2.9.2.4 Synergy Testing using the two strips E-test method (fixed ratio method) 
This method involves the use of Mueller-Hinton (MH) agar inoculated with bacterial suspensions 
at an optical density of 0.5 McFarland units. Minimum inhibitory concentration (MICs) of two 
drugs are determined and also determined on the combination setup on the MH agar plate by 
placing strips/scales in each gradient’s position. Briefly, this involves the addition of E-test strips 
containing antibiotics to the bacterial lawn in a sequential manner.  Plates are incubated with the 
first E-test strip for 1 h at (20°to 25°C) room temperature, and then removed. This is followed by 
the addition of the second E-test strip immediately over the imprint of the first E-test strip. After 
incubation for 18 h at 35°C, MICs are determined by placing strips/scales in each gradient’s 
position.  
 
 
1.2.10 Clinical impact of Acinetobacter spp. 
Community and nosocomial acquired infections caused by Acinetobacter spp. have become a 
serious public health concern in many countries, including South Africa. Acinetobacter spp. were 
reported as the most common organisms isolated from bronchoalveolar  lavage specimens in 
ventilator-associated pneumonia (VAP)-defined patients in a South African pediatric ICU, 
followed by Klebsiella pneumoniae, Staphylococcus aureus and Pseudomonas aeruginosa 
(Morrow et al., 2009).  
 
The emergence of MDR Acinetobacter spp. in South African neonatal and pediatric units has 
been associated with greater than 50% mortality and significant morbidity (Jeena et al., 2001). 
These results are similar to a study in Brazil, a developing country with challenges similar to those 
of South Africa (Abramczyk et al., 2003). In addition, a marked increase in the number of ICU 
infections due to MDR Acinetobacter spp. has been reported in South Africa (Ahmed et al., 2012). 
The first study on the characteristics and outcome of pediatrics intensive care unit (PICU) patients 
with positive Acinetobacter spp. blood culture (distinguishing between colonisation and 
pathogen) had been published in 2015 (Reddy, 2015).  
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1.2.11 Antibiotic stewardship programme (ASWPs) 
According to a consensus statement from the Infectious Diseases Society of America (IDSA), the 
Society for Healthcare Epidemiology of America (SHEA), and the Pediatric Infectious Diseases 
Society (PIDS), antibiotic stewardship is defined as “coordinated interventions designed to 
improve and measure the appropriate use of [antibiotic] agents by promoting the selection of the 
optimal [antibiotic] drug regimen including dosing, duration of therapy, and route of 
administration” (Fishman et al.,2012 ). The benefits of antibiotic stewardship include improved 
patient outcomes, reduced adverse events improvement in rates of antibiotic susceptibilities to 
targeted antibiotics, and optimisation of resource utilisation across the continuum of care. IDSA 
and SHEA strongly suggest that antibiotic stewardship programs (ASPs) are led by infectious 
disease physicians with additional stewardship training (Barlam et al., 2016).  
The 2016 guidelines from the Infectious Diseases Society of America/Society for Healthcare 
Epidemiology of America (IDSA/SHEA) recommend preauthorisation and prospective review of 
antibiotics as a measure to improve the efficacy of ASWP (Barlam et al., 2016).  
Preauthorisation requires providers to obtain approval before prescribing these antibiotics, while 
prospective audits allow antibiotic stewards and clinicians to assess and optimise treatment after 
the antibiotic has been prescribed. The strategies may be used alone or in combination, with the 
aim of reducing antibiotic misuse and preventing the emergence of resistant strains. Hospitals 
should use one or both of these methods based on their local resources and expertise (Barlam et 
al., 2016). Rapid synergy testing supports the improvement of aims of ASWPs and has been 
published in 2015 (Van-Belkum et al., 2015). 
 
 
1.2.12 Problem statement 
MDR, XDR and PDR Acinetobacter spp. isolates are on the rise worldwide (Begum et al., 2013; 
Ogutlu et al., 2014) and pose a great challenge for physicians and clinical microbiologists 
regarding Antibiotic Stewardship Programs (ASWPs), both globally and locally. Successful 
ASWPs are crucial in making sure that available treatment options are preserved (Manchanda et 
al., 2010; Barlam et al., 2016). The emergence and spread of drug-resistant (MDR, XDR, PDR) 
Acinetobacter spp. are alarming, since the organism is responsible for many healthcare-associated 
infections (Manchanda et al., 2010; Gonzalez-Villoria and Valverde-Garduno, 2016; Samawi et 
al., 2016). Moreover, the resistance patterns of Acinetobacter spp. present a high-risk global 
infection control challenge (Coelho et al., 2006; Cheon et al., 2016). Despite the prevalence of 
infection, there is limited scientific data and a lack of a standardised management guideline to 
assist ASWPs and help the clinician select optimal therapy in local hospital settings.  
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ASWPs in hospitals aim to optimise antimicrobial prescribing so that individual patient care is 
improved, antimicrobial resistance is decreased and hospital costs are reduced (MacDougall and 
Polk, 2005). Guidelines from the Infectious Diseases Society of America/Society for Healthcare 
Epidemiology of America (IDSA/SHEA) (2016) recommends preauthorisation and prospective 
review of antibiotics as a measure to improve the efficacy of ASWP (Barlam et al., 2016). 
Preauthorisation means that providers need approval before prescribing antibiotics, while 
prospective audit allows antibiotic stewards to communicate with clinicians after the antibiotic 
has been used in order to optimise treatment. These strategies may be used alone or in combination 
to prevent antibiotic misuse and resistance. Hospitals should use one or both of these methods 
based on their local resources and expertise (Barlam et al., 2016). However, it is difficult to 
differentiate between isolates that cause sepsis versus colonisation when establishing the decision 
to treat, which is a major part of ASWPs (Swe Swe-Han and Pillay, 2015).  
Although Acinetobacter was previously, and even now in some units, ignored when isolated from 
clinical samples, there are now over 1000 references to ‘infections and resistant Acinetobacter’ 
in the international literature. In addition, the type of infections caused by Acinetobacter has 
changed over the past 30 years (Joly-Guillou, 2005; Mathai et al., 2012; Begum et al., 2013; 
Ogutlu et al., 2014). The literature has explored Acinetobacter spp. as a successful pathogen; its 
biological aspects; epidemiology and pathogenicity factors; global spread and surveillance and 
multilateral system and related outbreak investigation (Naas et al., 2005; Higgins et al., 2010; 
Antunes et al., 2014; Kim et al., 2015). The literature shows that standard treatment and clinical 
decisions are difficult in Acinetobacter spp. infection due to its ability to develop resistance with 
unusual resistance patterns, and lack of standard guidelines to determine significant infection 
(Ogutlu et al., 2014; Cheon et al., 2016). In order to plan health care policies, a standardised 
management approach and intervention measures need to be implemented to reduce 
Acinetobacter spp. sepsis in resource-poor settings. It is necessary to have evidence of the 
prevalence, proportion of sepsis and colonisation groups; drug resistance patterns; effectiveness 
of synergy of colistin with other drug combinations; and characterisation of Acinetobacter spp. 
isolates in local hospitals to initiate the health care policies (Ntusi et al., 2012). 
 
In the KZN province of South Africa, there is a paucity of such data and no guidelines to 
differentiate the Acinetobacter spp. isolates that cause infection versus colonisation.  Data on the 
prevalence of resistance patterns of Acinetobacter spp. and their significance with regards to 
sepsis and colonisation is limited in South Africa.  
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The increasing prevalence of carbapenem-resistant Acinetobacter spp. isolates that are also 
resistant to all commonly available antibiotics is of particular concern. Colistin is the only drug 
of choice for the treatment of MDR Acinetobacter spp. (Moffatt et al., 2010). However, its 
resultant renal toxicity and neurotoxicity makes it an unattractive alternative (Arıdoğan, 2012).  
In addition, Acinetobacter isolates that are resistant to colistin have also been observed (Moffatt 
et al., 2010). Therefore, therapy using combinations of antimicrobials (including carbapenems, 
colistin, rifampicin, and ampicillin-sulbactam) has been suggested as the best approach. The 
clinical utility of these combinations against PDR Acinetobacter spp. remains to be determined 
(Doughari et al., 2011). The limited available options are major concern and further work on the 
use and efficacy of combination therapies, as well as on clinical outcomes, is warranted (Doughari 
et al., 2011). The synergistic effects of colistin in combination with various other agents has been 
reported, but there is a lack of a standard approach in the treatment and management of infection 
(Almasaudi, 2016; Gonzalez-Villoria and Valverde-Garduno, 2016).  
 
Drug-resistant Acinetobacter spp. presents a serious global infection control challenge (Fishbain 
and Peleg, 2010; Ghafur et al., 2014; Phee et al., 2015; Almasaudi, 2016). Previous studies have 
examined its spread and identified genes encoding drug resistance. However, characterisation of 
Acinetobacter spp. clinical isolates in the local academic hospital in Durban (South Africa) has 
not been previously reported.  
 
With an exponential rise in infections over the past decade, clinicians and microbiologists face 
the task of choosing optimal antimicrobial agents for treatment regarding ASWPs. Antibiotic 
resistance is a major challenge to the healthcare system and it is difficult to provide optimal 
treatment options due to changes in resistance patterns, increased costs and the availability of new 
agents (Diekema et al., 2004; Fishbain and Peleg, 2010; Ghafur  et al., 2014; Phee et al., 2015). 
Historically, it has been shown that if an optimal antibiotics usage guideline is not developed, this 
can lead to overuse of antimicrobial agents and the loss of their efficacy (Ventola, 2015). 
In order to address the above, this study investigated the clinical significance of Acinetobacter 
spp. infections; criteria for colonisation versus significant sepsis based on clinical and 
microbiological data, determined the most effective combinations of drugs and characterised 
Acinetobacter spp. isolates phenotypically and genotypically. A standard approach for the 
treatment and management of Acinetobacter spp. infections for community-centred academic 
complex hospitals was developed for implementation in the local setting.  This was an analytical, 
observational, experimental study performed at the Microbiology laboratory, NHLS academic 
complex hospital IALCH, in Durban (South Africa). This research provides a valuable 
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standardised approach to assist the clinician to select optimal therapy in the form of a standardised 
algorithm for the management of patients with significant Acinetobacter spp. infections, including 
a synergy test protocol at this unit.   
 
 
1.2.13 Research questions, hypotheses, aims and objectives  
Acinetobacter spp. isolates are recognised as common hospital- and community-acquired 
pathogens and colonisers (Kim et al; 2014; Wong et al., 2017). A significant number of 
Acinetobacter spp. nosocomial isolates, including MDR isolates, have been identified in the 
academic complex hospitals of KZN, South Africa. The synergistic effect of colistin combined 
with various agents has been reported (Falagas et al., 2006; Wareham and Bean. 2006; Pankey 
and Ashcraft, 2009; Vidaillac et al., 2012; Petrosillo et al., 2014; Temocin et al., 2015; Zafar et 
al., 2015; Bae et al., 2016), but there is a lack of a standard approach in the treatment and 
management of infection.  
This thesis describes a standardised approach for the management of patients with significant 
Acinetobacter spp. infections in KZN. The following research questions were addressed: 
 What is the prevalence and resistance pattern of Acinetobacter spp., both as colonisers and 
significant pathogen causing significant sepsis, in KZN academic complex hospitals?  
 What are the criteria to differentiate between significance for sepsis versus colonisation of 
Acinetobacter spp.? 
 Which is the most effective drug combinations against these organisms? 
 What is the phenotypic and genotypic correlation of resistanct Acinetobacter species?  
 For the purpose of epidemiology and infection control, what are the genes related to 
carbapenem, amikacin and colistin resistant Acinetobacter spp. in the local academic complex 
hospital. 
 Are there carbapenemase encoded genes (blaOXA-23) spread in the ICUs in the local hospital? 
 What are the clinical outcomes of different treatment modalities currently used in the 
treatment of Acinetobacter spp. at academic complex hospitals in KZN? 
This thesis presents a series of studies aimed at determining epidemiological and clinical 
characteristics and outcomes, and includes both genetic and phenotypic characterisation of the 
organism. Based on the outcomes, an algorithm for a standardised approach to the treatment and 
management of significant Acinetobacter spp. infection was developed and will be implemented 
at academic complex hospitals, Durban, KZN. 
In line with the research questions proposed, the hypotheses, aims and objectives of this study are 
addressed below. 
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1.2.14 Hypotheses of the study 
1. Acinetobacter spp. infections are significantly associated with severe sepsis in patients.  
2. Criteria for sepsis and colonisation differ, based on the clinical and microbiological   
analysis of each patient.  
3. The presence of mutations in drug targets or acquired mechanism will correlate with high-
level drug resistance.  
4. Specific effective combination drug combinations can be used appropriately as standard 
guidelines. 
 
 
1.2.15 Aims of the study 
1. To determine the significance of Acinetobacter spp. infection in patients hospitalised at 
the IALCH academic complex hospitals, KZN. 
2. To characterise Acinetobacter spp. isolated from patients. 
3. To determine the most effective combinations of drugs against Acinetobacter spp. 
4. To develop a standardised approach for the treatment and management of significant 
Acinetobacter spp. infection in KZN, in respect of antibiotic stewardship programme. 
  
1.2.15.1 Objectives for each aim 
Aim 1 
 To determine the prevalence of Acinetobacter spp. associated with and without sepsis from 
2008 to 2012 retrospectively. 
 To determine the prevalence of Acinetobacter spp. associated with and without sepsis in 2013 
and 2014 prospectively. 
 To determine the significance of infections including clinical outcomes. 
Aim 2 
 To determine drug susceptibility profiles of Acinetobacter spp. in patients from 2008 to 2013. 
 To determine MICs of colistin, amikacin and meropenem against Acinetobacter spp. isolated 
from patients. 
 To perform mutation analysis on genes encoding drug targets in isolates resistant to colistin, 
aminoglycosides and meropenem, and to determine the spread of the isolates in ICUs and 
related units (suspected outbreak).  
Aim 3 
 To determine the drug combination that is most effective against Acinetobacter species. 
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Aim 4 
 To determine, prospectively, the clinical outcome of Acinetobacter-infected patients after 
treatment with appropriate antibiotics, such as colistin, meropenem, ciprofloxacin, tazocin 
(piperacillin-tazobactam), amikacin and combination therapy (colistin and each of the drugs). 
 To develop a standardised treatment algorithm for the management of patients with 
significant Acinetobacter species infections. 
 
 
1.3 General methodology 
1.3.1 Study setting 
Durban is the largest city in the province of KZN, South Africa. It has a population of almost 10.3 
million (https://census2011.adrianfrith.com/place/5), making the combined municipality, one of 
the biggest African cities on the Indian Ocean coast. The city is served by a regional, tertiary 
hospital (King Edward VIII Hospital) and a central referral hospital (Inkosi Albert Luthuli Central 
Hospital). King Edward VIII Hospital is the second largest hospital in the Southern hemisphere, 
providing regional and tertiary services to the whole of KZN and Eastern Cape provinces. King 
Edward VIII is a 922 bed hospital. Inkosi Albert Luthuli Central Hospital (IALCH) commissions 
the outstanding beds and has a total of 892 beds. The hospital accommodates referrals from all 
KZN regional hospitals, as well as from the Eastern Cape. Both hospitals are under academic 
complex teaching hospitals for the University of KwaZulu-Natal’s Nelson R. Mandela School of 
Medicine. They are attached to a Nursing College and house the following specialties: 
orthopedics, ICUs / critical care, pediatrics, cardiology, oncology, hematology, plastic surgery, 
vascular surgery, burns, and other specialist facilities.  
 
1.3.2 Study design  
This thesis used a combination of methods, including analytical, observational (retrospective and 
prospective) and laboratory experimental studies. The overall study approach includes molecular 
epidemiology, clinical and experimental components. 
The specific study design involved determining the prevalence of Acinetobacter spp. infections 
and their drug susceptibility profiles in KZN academic complex hospitals, by a retrospective and 
prospective clinical and microbiological data information review by using the criteria of 
colonisation and significant pathogens for the period of 2008 to 2014. The stored of representative 
isolates obtained as part of routine standard of care were characterised by MIC determinations 
and mutation analysis. The MICs of selected drugs (i.e., colistin, amikacin, and carbapenem) were 
conducted using the Vitek 2 automatic identification and sensitivity method (CLSI 2012) and 
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confirmed by the E-test.  PCR and amplicon sequencing was performed to analyse mutations in 
the genes encoding drug targets in resistant isolates associated with severe sepsis.  
E-test was used to evaluate the effectiveness of the different combination of drugs against the 
significant sepsis-related Acinetobacter species. Clinical outcomes of infected patients after 
treatment with appropriate drugs (colistin, meropenem, ciprofloxacin, tazocin [piperacillin-
tazobactam], amikacin or a combination of colistin with each drug) were documented 
prospectively and statistically analysed. An algorithm of a standardised approach for the treatment 
and management of significant Acinetobacter spp.-infection was developed. 
 
1.3.3 Study population 
All in-patients identified with Acinetobacter spp. isolates were included in the study from the 
academic complex hospitals, following study sites: 
 Patients from the ICU at King Edward VIII Hospital in 2008;  
 Patients from high-risk areas (ICUs, renal unit, oncology unit, etc.) at IALCH from 2008 to 
2014. 
 
1.3.4 Sampling strategy  
Significant Acinetobacter species sepsis was determined by positive blood culture and isolation 
from multiple sites repeatedly or multiple sites singly, with clinical significance. 
Diagnosis of Acinetobacter pneumonia with sepsis was based on endotracheal aspirate results, 
and clinical manifestations and identification of new infiltrates on chest x-rays. Bacteremia was 
determined by at least one positive blood culture. 
The following data were collected retrospectively from 2008 to 2012 and prospectively for 2013 
and 2014: total number of Acinetobacter spp. isolated, total number of patients with Acinetobacter 
spp., type of specimens, antibiogram, antibiotic usage in the unit and outcome.  
Laboratory data was collected from the completed laboratory worksheets. The selected marker 
antibiotics against Acinetobacter spp. included: aminoglycosides (amikacin), β-lactams 
(piperacillin-tazobactam), fluoroquinolones (ciprofloxacin), carbapenems (meropenem) and 
colistin. Colistin drug susceptibility testing against selected Acinetobacter spp. was initiated in 
2011. 
 
1.3.5 Statistical planning (variables / confounders) 
Simple statistical analysis was performed on information captured from the laboratory database 
and correlated with the clinical data. The prevalence of Acinetobacter spp. associated with and 
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without sepsis was calculated for the period of 2008 to 2014. Only one representative isolate from 
each specimen per patient, both with or without sepsis, was included in the analysis.  
The prevalence rate of significant Acinetobacter spp.-infection was calculated using the formula: 
𝑧 =
𝑥
𝑦
 𝑋 100 
x = Total number of patients with significant Acinetobacter spp. infection 
y = Total number of patients with Acinetobacter spp. isolated 
z = Percentage 
Clinical outcome of treatment with various drugs or drug combinations was recorded. Recorded 
data was analysed by the investigator and statistician. The data was collected, captured and 
thereafter analysed using the Statistical Package for Social Sciences (SPSS version 19). The 
results were summarised using descriptive statistics, such as frequencies and percentages. Pearson 
chi-square-test or Fisher’s exact test was used for the association between underlying conditions 
and response to antibiotics. Logistic regression tested for factors associated with clinical survival 
status.  
 
1.3.6 Sample size for laboratory synergy test and molecular characterisation 
One hundred and seven isolates were selected based on their antibiograms and the relevant clinical 
criteria decided upon during clinical wards rounds.  Patients’ data were collected and recorded 
prospectively. Sixty isolates of Acinetobacter spp. from 107 patients were selected based on the 
clinical and microbiological significance criteria (sepsis patients who need combination therapy; 
significant specimens; pure growth or significant growth; ICU patients and chronically ill 
patients). Sixty isolates were stored at -70°C, prior to molecular characterisation and synergy tests 
assessment. Synergy test and molecular characterisation were determined based on the 
antibiogram (antibiotic resistance patterns) and clinical data (clinical units, underlying risk and 
type of specimens). 
Sixty isolates were used for synergy testing, using seven combinations of antimicrobial agents 
(The isolates were selected based on the patients with significant sepsis and local infections). 
Twenty-four (excluding 3 controls) isolates were selected for blaOXA-23 and blaOXA-58 (The isolates 
were cultured from the patients admitted to ICUs and non-ICUs within the weeks in which 
significantly increased number of isolates with same antibiogram without MICs were observed). 
Twenty-four isolates (excluding 3 controls) for pulsed field gel electrophoresis (PFGE) were 
selected based on clinical criteria, same antibiogram, same ICUs and specimen collection dates 
within one week.); 
Twenty-four isolates including six colistin resistant isolates for IpxA;  
Ten isolates including six amikacin resistant isolates for aphA6 and aacA4; 
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Mutation analysis by genomic sequencing was performed on genes associated with resistance as 
below; 
Eighteen carbapenems resistant MDR Acinetobacter spp. (OXA-23 band detected isolates) were 
sequenced for blaOXA-23. Six amikacin resistant isolates were sequenced for aphA6.  
Six colistin resistance isolates were sequenced for IpxA. 
 
 
1.3.7  Inclusion / exclusion criteria: 
Inclusion criteria:  
All adult patients (HIV infected and uninfected) with and without sepsis identified with 
Acinetobacter spp. infection and: 
 admitted to ICU at KEH in 2008  
 admitted to high risk wards (ICUs, renal unit, oncology unit etc.) at IALCH from  
2009 to 2014. 
 
Exclusion criteria 
 Patients not infected with Acinetobacter spp. 
 Patients from other non- high risk wards (out patients’ clinic, occupational health clinics). 
 
 
1.3. 8 Ethics consideration of the project 
Ethics approval for the study was obtained from Biomedical Research Ethics Committee (BREC) 
at the University of KwaZulu-Natal. Reference No: BE 283/12 in 18 July 2013, and recertified 
annually. 
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Abstract   34 
Introduction: Acinetobacter species (Acinetobacter spp.) are common hospital environmental 35 
bacteria that have gained importance during the past few decades as important nosocomial 36 
pathogens in critically ill patients. This problem has been compounded by the worldwide increase 37 
in carbapenem-resistant Acinetobacter infections. In South Africa also, multidrug-resistant, 38 
including carbapenem resistant Acinetobacter spp. causing significant sepsis has recently 39 
increased. Acinetobacter baumannii remains an important and difficult-to-treat pathogen whose 40 
resistance patterns result in significant challenges for the clinician. The study was conducted to 41 
determine the prevalence of multidrug-resistant (MDR) Acinetobacter spp., and to differentiate 42 
between significant infection and colonisation by correlation with clinical data. 43 
Method: All patients identified with Acinetobacter spp. isolates after 48 hrs in the intensive care 44 
unit (ICU) were included in the study over a year period. Data was recorded prospectively 45 
including any underlying chronic disease, type of specimens, antibiogram, antibiotic usage in the 46 
unit and outcome during daily ward rounds. Analyses were done retrospectively. 47 
Results: During the study period, there were 187 isolates from different specimens of 86 patients. 48 
Significant sepsis was identified in 30/86 (35%), colonisation in 51/86 (59%) and bacteraemia in 49 
5/86 (6%) patients with Acinetobacter spp., respectively. Lack of appropriate treatment resulted 50 
in the death of 18/86 (21%) patients. Acinetobacter spp. was isolated mainly from endotracheal 51 
aspirates 67/187 (36%), and the others were from the various types of specimens. Isolates were 52 
multidrug-resistant including carbapenem. 53 
Conclusion: MDR- Acinetobacter spp. was identified as a significant cause of sepsis and a high 54 
mortality rate (P <0.001) among the patients in surgical ICU. Our findings highlight the impact 55 
of antibiotic stewardship in the treatment of patients in whom Acinetobacter spp. is isolated and 56 
the urgent need for the development of standardised guidelines for management of patients with 57 
Acinetobacter spp. sepsis. 58 
 59 
Key words:  Multidrug-resistant; Acinetobacter species; colonisation; sepsis; intensive care 60 
                      unit 61 
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Introduction 69 
The prevalence of Acinetobacter species (Acinetobacter spp.) infection in hospitals is increasing 70 
worldwide [1] with a concomitant significant increase in mortality associated with bacteraemia 71 
(19 to 54%) compared to other bacterial infections [2, 3]. It is now well recognised that in addition 72 
to colonisation, Acinetobacter spp. play a significant role in community as well as hospital 73 
acquired infections [4]. Although it is difficult to differentiate between colonisation and sepsis, 74 
community acquired Acinetobacter pathogens are relatively sensitive to antibiotics and the 75 
resistant isolates are almost exclusively present in hospitals and high risk areas [5]. 76 
 77 
Acinetobacter spp. had been reported as the cause of serious infectious diseases such as ventilator 78 
associated pneumonia, bacteraemia, urinary tract infections, burn wound infections, endocarditis, 79 
secondary meningitis, and septicaemia, involving mostly patients with impaired host defences, 80 
especially in intensive care units (ICUs) [6, 7].  Acinetobacter spp. have emerged as particularly 81 
important organisms causing late-onset ventilator associated pneumonia which may have been 82 
related to the increasingly invasive diagnostic and therapeutic procedures used in hospital ICUs 83 
in recent years [8]. 84 
 85 
Acinetobacter spp. have acquired resistance to almost all currently available antimicrobial agents, 86 
including the aminoglycosides, quinolones, and broad-spectrum β-lactams. The spectrum of 87 
antibiotic resistance of these organisms, together with their survival capabilities, makes them a 88 
threat in hospital environments, as documented by recurring outbreaks both in highly developed 89 
countries and elsewhere [9]. Most strains are resistant to cephalosporins, while resistance to 90 
carbapenems is being reported increasingly [9]. 91 
 92 
There has been a worldwide increase in infections caused by multidrug-resistant Acinetobacter 93 
baumanni (MDRAB) [1]. In South Africa also, an increase in carbapenem resistant Acinetobacter 94 
spp. has been recently reported [10, 11]. 95 
 96 
The challenges of treating multidrug-resistant bacteria continue to be at the forefront of the 97 
clinician’s practice in caring for hospitalised patients. Acinetobacter baumannii has proven to be 98 
an increasingly important and challenging species in health care–associated infections. The drug-99 
resistant nature of the pathogen, its unusual and unpredictable susceptibility patterns and poor 100 
clinical understanding of significant sepsis, make empirical and therapeutic decisions even more 101 
difficult [12]. 102 
 103 
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During our routine standard of care, we have observed that a significant proportion of nosocomial 104 
isolates include MDR Acinetobacter spp. in the ICU at a regional hospital in Durban. The clinical 105 
significance of this has yet to be elucidated. In this retrospective study, we determined the 106 
proportion of MDR Acinetobacter spp. in an adult surgical ICU, differentiated significant 107 
infection from colonisation and clinical outcomes of treatment. Outcomes of both significant 108 
infection and colonisation were recorded. Our findings highlight the impact of antibiotic 109 
stewardship in the treatment of patients in whom Acinetobacter spp. are isolated in order to 110 
develop guidelines for treatment and management of Acinetobacter spp. infection. 111 
 112 
 113 
Methods 114 
Study setting: 115 
The regional academic hospital accommodates 950 beds and includes multi-discipline speciality 116 
wards. There is one ICU (13 bed ward) for the management of mainly surgical adult patients. 117 
 118 
Study design and patient population: 119 
In this analytical, descriptive cross-sectional study, all patients identified with Acinetobacter spp. 120 
after 48 hrs in ICU was included over a year study period. 121 
 122 
Ethical consideration: 123 
The study was approved by the Biomedical Research Ethics Committee, University of KwaZulu-124 
Natal (Ref: BE 283/12). 125 
 126 
Data collection: 127 
The data collection included the total number of Acinetobacter spp. isolated, total number of 128 
patients with Acinetobacter spp., specimen type, antibiogram, antibiotic usage in the unit and 129 
clinical outcomes of the patients from whom Acinetobacter spp. was isolated. The data was 130 
prospectively recorded during routine daily ward rounds during the one year study period. The 131 
clinical and laboratory data were analysed retrospectively. 132 
 133 
Case definitions: 134 
Diagnosis of Acinetobacter pneumonia was based on the results of endotracheal aspirates together 135 
with clinical manifestations and identification of new infiltrates on CXR. 136 
 137 
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Acinetobacter bacteremia was diagnosed on at least one positive blood culture. Significant 138 
Acinetobacter spp. sepsis was based on positive blood culture and repeated isolation from 139 
multiple sites. 140 
 141 
Colonisation was defined as Acinetobacter spp. isolated from a single specimen of a clinically 142 
stable patient on whom a sepsis screen was performed. 143 
 144 
Data analysis: 145 
Frequency distributions were calculated for the number of Acinetobacter spp. isolated from the 146 
specimen types, antibiograms and stratification of patients with clinical symptoms or 147 
colonisation. Chi-squared test was used to calculate statistical significance, which was set at  148 
P ≤0.05. 149 
 150 
 151 
Results 152 
During the study period, isolates of Acinetobacter spp. were cultured from 187 different 153 
specimens of 86 patients. The most predominant specimen type was endotracheal aspirates 154 
67/187(36%) followed by blood 24/187 (13%), CVP tips, peritoneal fluid, arterial line tip, pus 155 
and catheter urine. Abdominal drains, tissue, pleural fluid and others were less commonly 156 
sampled 3/187 (2% and less) (Figure 1).  157 
 158 
Colonisation was observed in the majority 51/86 (59%) of the 86 patients. Significant clinical 159 
sepsis was observed in 30/86 (35%) of patients, whilst 5/86 (6%) were diagnosed with bacteremia 160 
(Figure 2).  161 
 162 
The majority of isolates were multidrug-resistant, including resistance to carbapenems (Figure 3). 163 
Amikacin sensitive Acinetobacter spp. was isolated from 39/86 (45%) of the 86 patients. The 164 
other patients were infected with isolates sensitive to meropenem 10/86 [12%], ciprofloxacin 9/86 165 
[10%], TZP (piperacillin and tazobactam) 4/86 [5%], and ceftazidime 4/86 [5%]. 166 
The majority of patients; 68/86 (79%) recovered and were discharged in a stable condition, whilst 167 
18/86 (21%) died. Acinetobacter was significantly associated with sepsis in 30 patients. Of these, 168 
18/30 (60%) died and 12/30 (40%) recovered (P <0.001) (Table 1). 169 
 170 
 171 
 172 
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Discussion 173 
Acinetobacter spp. are aerobic Gram-negative coccobacilli that are commonly found in hospital 174 
environments and easily colonise skin and mucous membranes. In the past, Acinetobacter spp. 175 
were considered to be of little clinical significance, but the appearance of drug resistant 176 
Acinetobacter infections have increased worldwide frequently [13]. 177 
 178 
This study showed that Acinetobacter spp. were more commonly colonisers, especially from 179 
endotracheal aspirates of patients in ICU. Although it is difficult to differentiate between 180 
colonisation and sepsis with Acinetobacter spp., the former increases the risk of the latter. 181 
Therefore, appropriate infection control and good oral hygiene practices are of paramount 182 
importance during the collection of ETA and management of patients. 183 
 184 
Although the proportion of colonisation was higher, clinical sepsis was identified in a large 185 
proportion of patients (35%) with multiple sites being culture positive. The majority of isolates 186 
in this study was MDR, including resistance to carbapenem. Acinetobacter spp. were regarded as 187 
colonisers in general and therefore, not directly targeted for therapy in surgical ICUs and other 188 
clinical units. The patients in ICU during that study period were treated for hospital acquired 189 
infections with tazocin (piperacillin-tazobactam) and followed by carbapenem empirically 190 
according to the local antimicrobial therapy protocols. Despite an exponential rise in 191 
Acinetobacter baumannii infections over the past decade, the treatment regimen remains 192 
controversial and many questions remain unanswered on the issue of appropriate therapy [14]. 193 
 194 
Difference between case patients and control subjects in most previous studies did not show 195 
statistical significance; however, higher mortality was observed consistently among the case 196 
patients [12]. Although, the data in the local hospital did not reach statistical significance in 197 
previously, it is evident during daily ward rounds for the management of the patients that 198 
Acinetobacter baumannii is also important as other common pathogens during study period. To 199 
implement the optimal usage of antimicrobial agents using the local antibiogram is the challenge 200 
for clinicians. The prescription of colistin combination therapy (both empirical and directed) for 201 
the Acinetobacter spp. has not yet been used often but hopefully, future studies would demonstrate 202 
the synergy effect of combination therapy. 203 
 204 
The in-hospital mortality attributable to Acinetobacter spp. sepsis reported in other studies ranged 205 
from 8% to 23%, while in the intensive care unit, it was found to be 10% to 43% [12]. Until now, 206 
clinical outcomes of patients with Acinetobacter spp. infections were not documented in our local 207 
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setting. Our study documented for the first time significant mortality rates (60%) associated with 208 
patients diagnosed with sepsis compared to those who were colonised (P<0.001) (Table 1). 209 
 210 
The twelve (40%) patients who recovered from sepsis were treated with tazocin, which is used to 211 
treat the common known pathogens empirically. Tazocin is chosen for both empirical and direct 212 
therapy of common pathogens as second line therapy in the current treatment guideline in the 213 
study hospital.  214 
 215 
Community and nosocomial infections caused by Acinetobacter spp. have become a serious 216 
public health concern in many countries [15, 16]. In this study at a regional hospital in KwaZulu-217 
Natal (KZN) province in South Africa, we have shown that MDR Acinetobacter spp. contributes 218 
significantly to nosocomial isolates causing sepsis. This problem is compounded by the lack of 219 
information on clinical significance and a recommended policy guideline for Acinetobacter spp. 220 
infection. 221 
In conclusion, MDR Acinetobacter spp. is a significant cause of sepsis in surgical ICUs. This 222 
highlights the impact of antibiotic stewardship in the treatment of patients in whom Acinetobacter 223 
spp. is isolated and the urgent need for the development of standardised guidelines for the 224 
management of patients with Acinetobacter spp. sepsis. 225 
 226 
There is a lack of surveillance studies on antibiotic-resistance patterns and their associated genes 227 
of Acinetobacter spp. in local clinical settings. Further research should include the determination 228 
of genetic relatedness of circulating Acinetobacter spp. to study transmission dynamics. In 229 
addition, the comparisons of phenotypic and molecular antibiotic resistance patterns should be 230 
studied. This would serve to identify the possible sources of these strains and to introduce 231 
intervention strategies to interrupt the transmission chains. 232 
 233 
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  307 
Figure 1. The number of Acinetobacter species isolated from different specimen types in 308 
86 patients from the surgical ICU between January to December 2008. The 309 
commonest specimen was ETA.  310 
Key:  ETA (Endotracheal aspirate); CVP (Central venous pressure tip);  311 
PD (Peritoneal fluid); A tip (arterial line tip); C-urine (catheterised urine);  312 
abd drain (specimen from abdominal drain); t/s (Tissue); pl fluid (pleural fluid); 313 
unk (unknown specimen)  314 
 315 
 316 
 317 
 318 
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 319 
Figure 2. Stratification of patients with significant clinical symptoms or colonisation.  320 
                  Patients with bacteremia comprised 6% and significant clinical sepsis, 35%.  321 
   The majority of patients (59%) were colonised. 322 
 323 
 324 
 325 
Figure 3.  Antibiogram of Acinetobacter species isolated from sepsis patients (total= 86)  326 
 surgical-ICU in 2008 327 
      AK (Amikacin); TZP (Tazocin: piperacillin + tazobactam); CAZ (Ceftazidime);  328 
     CIP (Ciprofloxacin); MERO (Meroenem) 329 
 330 
 331 
35%
59%
6%
patients with significant
sepsis  30 (30/86=35%)
patients with colonisation
51(51/86=59%)
patients with bacteraemia
5(5/86=6%)
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Table 1: Clinical outcomes of patients following treatment in surgical ICU during 332 
study period  333 
 334 
Number of patients 
Outcome              Sepsis             colonised           Total                  P  
Recovered               12                     56                     68 
Deceased                 18                       0                     18                  <0.001 
Total                        30                     56                     86 
 335 
 336 
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Abstract   36 
Background: Drug-resistant Acinetobacter species (Acinetobacter spp.) poses serious treatment 37 
challenges and is on the rise worldwide. The Infectious Diseases Society of America/Society for 38 
Healthcare Epidemiology of America recommends preauthorisation of antibiotics to ensure 39 
successful antibiotic stewardship programs (ASWPs). This study investigates and analyses the 40 
microbiological and clinical characteristics of Acinetobacter spp. with differentiating criteria for 41 
sepsis versus colonisation, in order to support preauthorisation and assist ASWPs at the patient 42 
level. 43 
Methods: A retrospective observational study was performed from 2008 to 2014. The clinical 44 
and microbiological characteristics of Acinetobacter spp. were correlated to assess pathogenic 45 
status and antibiotic resistance patterns. A flow chart was produced to differentiate between sepsis 46 
and colonisation amongst patient groups. 47 
Results: Acinetobacter spp.  were cultured in 2656 cases, with a prevalence of 0.9% to 2.4% 48 
during seven years study periods. There was a statistically significant difference between the 49 
sepsis and colonisation groups (P: 0.02). Sepsis accounted for 37% to 51% of Acinetobacter spp. 50 
isolates and colonisation for 49% to 63% (P <0.01). Multidrug-resistant (MDR), extensively 51 
drug-resistant (XDR) and pandrug-resistant (PDR) Acinetobacter spp. were detected in 53% to 52 
60%, 1% to 19% and 1% respectively, of cultures in the sepsis group, and 75%, 8-23% and 1% 53 
respectively, in the colonised group. There was a high percentage of polymicrobial infection in 54 
the sepsis group and pure growth was not always significant for sepsis. 55 
Conclusion: Cases of MDR and XDR Acinetobacter spp. increased over the seven year study, 56 
while PDR strains emerged. For a successful ASWP, both clinical and microbiological 57 
information should be interpreted when establishing preauthorisation/decision to treat. 58 
 59 
Key words: MDR-XDR-PDR Acinetobacter species; prevalence; sepsis, colonised group; 60 
preauthorisation; antibiotic stewardship programme 61 
 62 
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Introduction   71 
Antibiotic stewardship programs (ASWPs) in hospitals seek to optimise antimicrobial prescribing 72 
in order to improve individual patient care, slow the spread of antimicrobial resistance and reduce 73 
hospital costs [1]. The 2016 guidelines from the Infectious Diseases Society of America/Society 74 
for Healthcare Epidemiology of America (IDSA/SHEA) recommend preauthorisation and 75 
prospective review of antibiotics as a measure to improve the efficacy of ASWPs [2].  76 
Preauthorisation requires providers to obtain approval before prescribing these antibiotics, while 77 
prospective audit allows antibiotic stewards and clinicians to assess and optimise treatment after 78 
the antibiotic has been prescribed. The strategies may be used alone or in combination, with the 79 
aim of reducing antibiotic misuse and preventing the emergence of resistant strains. Hospitals 80 
should use one or both of these methods based on their local resources and expertise [2].  81 
Multi-, extensive- and pandrug- resistant (MDR, XDR, PDR) Acinetobacter spp.  [3-6] isolates 82 
are on the rise worldwide [7, 8] and present infection control and treatment challenges for 83 
clinicians and clinical microbiologists. ASWP have become a crucial tool in preserving the 84 
efficacy of antimicrobial agents [1, 6]. 85 
Acinetobacter spp. are ubiquitous in the natural environment [9] and are occasionally found as 86 
skin and throat commensal, and in the secretions of healthy people [10]. Although Acinetobacter 87 
was previously ignored when isolated from clinical samples, there are now over 1000 references 88 
to “infections and resistant Acinetobacter” in the international scientific literature [11]. In 89 
addition, the types of infection caused by Acinetobacter has changed over the past 30 years [7, 90 
11-13].  91 
The emergence and spread of Acinetobacter spp. resistant to most of the available antimicrobial 92 
agents poses problems for future management, since the pathogen plays a role in nosocomial 93 
infections [6]. Acinetobacter isolates from the community are usually sensitive to antibiotics, 94 
while drug- resistant isolates are mainly found in hospitals and high risk areas. Therefore, it is 95 
fairly easy to differentiate between community and hospital acquired isolates based on 96 
hospitalisation history and antibiogram. However, it is more difficult to differentiate innocuous 97 
colonisers from strains that cause sepsis when establishing decision to treat [14]. 98 
Evidence regarding Acinetobacter spp. prevalence and the proportion of sepsis versus 99 
colonisation, as well as drug resistance patterns, is essential when planning policies and 100 
interventions to reduce ICU-associated Acinetobacter spp.  sepsis in resource-poor settings [15]. 101 
In the KwaZulu-Natal (KZN) province of South Africa, there is a paucity of such data and no 102 
guidelines to differentiate the Acinetobacter spp. that cause infection versus colonisation. This 103 
study was conducted to guide the decision to treat based on the analysis of microbiological and 104 
clinical aspects of Acinetobacter spp. isolates, in order to assist ASWP at patient level. 105 
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We investigated the prevalence and proportion of Acinetobacter spp. infections that caused sepsis 106 
and colonisation using both clinical and microbiological criteria, including demographic data of 107 
patients cultured with Acinetobacter spp.; accuracy of correlation between clinical diagnosis and 108 
microbiological significance; pure and mixed growth of Acinetobacter spp. in the sepsis group 109 
and colonised group, and drug resistance patterns of Acinetobacter species. These aspects were 110 
studied retrospectively from 2008 to 2014 in patients at Inkosi Albert Luthuli Central Hospital 111 
(IALCH), a specialised referral facility in Durban, KZN. 112 
 113 
 114 
Methods  115 
An analytic, retrospective observational study was performed on clinical and laboratory patient 116 
data from January 2008 to December 2014, at the IALCH academic complex hospital, 117 
Microbiology department, National Health Laboratory Service (NHLS) in Durban, South Africa. 118 
This research was approved by the Biomedical Research Ethics Committee of University of 119 
KwaZulu-Natal (Ethics approval: BE283/12). 120 
 121 
The antibiograms were studied to identify MDR, XDR and PDR- Acinetobacter species. The 122 
clinical and laboratory data from patient groups of sepsis and colonisation were correlated, 123 
including the identification of pure and mixed growth and an assessment of pathogenic status. A 124 
flow chart was produced to differentiate the two groups according to the abovementioned criteria 125 
(Figure 1). 126 
 127 
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 128 
 129 
Figure 1. Flow chart of clinical and microbiological criteria of sepsis and  130 
  colonisation 131 
 132 
 133 
 134 
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There was no infectious diseases specialist at IALCH nor a hospital antibiotic policy for 135 
Acinetobacter spp. in place during the study period. Colistin drug susceptibility testing was 136 
initiated in 2011. 137 
 138 
Definitions 139 
Clinical diagnosis: 140 
Microbiology specimens were sent to the laboratory marked by the clinician with an indication 141 
of either clinical sepsis or localised infection. 142 
Sepsis is based on the indicators of systemic inflammatory response syndrome (SIRS) [16, 17]. 143 
Clinically localised infection is based on clinical examination. 144 
 145 
Pure growth: 146 
The isolation of only Acinetobacter spp. on culture media was regarded as pure growth, isolated 147 
with no other bacteria. 148 
 149 
Mixed growth: 150 
The isolation of Acinetobacter spp. mixed with other bacteria on culture media was regarded as 151 
mixed growth. 152 
 153 
Microbiological significance:  154 
Acinetobacter spp. isolated from any biological site combined with a compatible clinical picture 155 
warranting antibiotic treatment. 156 
 157 
Criteria for microbiological significance:  158 
Pure growth Acinetobacter spp. cultured from a blood culture bottle, sterile specimen, or repeated 159 
specimens from the same or multiple sites in patients not responsive to empirical treatment and 160 
broad-spectrum antibiotics;  161 
Or   162 
Mixed growth Acinetobacter spp. cultured from repeated specimens from the same site in patients 163 
with clinical symptoms. 164 
 165 
Microbiological criteria for colonisation: 166 
Acinetobacter spp. isolated from the blood culture from the first specimen sent and with repeat 167 
specimens showing growth of other organisms or no growth;  168 
Or 169 
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Acinetobacter spp. isolated from endotracheal aspirate (ETA) from the first specimen sent and 170 
with repeat specimens showing growth of other organisms or Acinetobacter spp. no growth; 171 
Or 172 
 Mixed growth Acinetobacter spp. cultured in any one site of a septic screen; and patient 173 
responded to empirical or current broad spectrum antibiotics that resistant to Acinetobacter 174 
species. 175 
 176 
Clinical significance:  177 
Acinetobacter spp. cultured from specimens from a clinically relevant site. 178 
 179 
Sepsis group:  180 
Microbiologically significant Acinetobacter spp. infection together with clinically significant 181 
Acinetobacter spp. infection. 182 
 183 
Criteria for inclusion in the sepsis group: 184 
Acinetobacter spp. from sterile specimens in clinically unstable patients;  185 
or  186 
Acinetobacter spp. mixed with other bacteria from non-sterile specimens in a patient with 187 
clinically significant sepsis who did not respond to empirical or current broad spectrum antibiotics 188 
that resistant to Acinetobacter species. 189 
 190 
Criteria for inclusion in the colonised group: 191 
Acinetobacter spp. mixed with other bacteria from non-sterile specimens in a clinically stable 192 
patient; or 193 
Acinetobacter spp. from sterile specimens in a clinically stable patient.  194 
 195 
MDR, XDR, PDR [3-6] 196 
Criteria for defining MDR, XDR and PDR in Acinetobacter species [5]: 197 
MDR: Non-susceptible to ≥ 1 agent in ≥ 3 antimicrobial categories. 198 
XDR: Non-susceptible to ≥ 1 agent in all but ≤ 2 categories. 199 
PDR: Non-susceptible to all antimicrobial agents listed. 200 
The isolates were divided into three groups based on their resistance pattern to six different classes 201 
of antimicrobials i.e. aminoglycosides (amikacin), β-lactams with inhibitors (piperacillin–202 
tazobactam), cephalosporin (ceftazidime), fluoroquinolones (ciprofloxacin), carbapenem 203 
(imipenem, meropenem) and colistin. 204 
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Group 1: Resistant to all six groups of antimicrobials; defined as PDR. 205 
Group 2: Resistant to five groups of antimicrobials except colistin; defined as XDR. 206 
Group 3: Resistant to carbapenem or any three groups of antimicrobials; defined as MDR. 207 
 208 
Data extraction 209 
The data included the total number of specimens received in each year, number of patients with 210 
Acinetobacter spp., type of specimen, hospital ward, clinical history, demographic data and 211 
antibiogram. To determine significant infections, Acinetobacter spp. were cultured from aerobic 212 
blood culture and other relevant specimens of sepsis patients; pure growth of isolate from sterile 213 
site or non-sterile sites; and repeated isolated Acinetobacter spp. from multiple sites with 214 
clinically sepsis. 215 
 216 
Data analysis 217 
Acinetobacter spp. growth combined with relevant clinical signs and symptoms was considered 218 
to be one episode of infection. Acinetobacter spp. isolated within 48 hours of ICU admission was 219 
a hospital-acquired infection. Non-resistant Acinetobacter spp. isolated from a patient admitted 220 
directly from the emergency room or an outpatient department was community-acquired. 221 
Only one representative infection per patient within a seven day period was considered in the 222 
analysis. Prevalence was the total number of patients with Acinetobacter spp. out of the total 223 
number of patients’ specimens sent each year.  224 
The sepsis and colonised groups were determined according to clinical and microbiological data 225 
analysis. The proportion of sepsis to colonised groups was calculated. The accuracy of the 226 
interpretation of microbiology results on the correlation of clinical history was analysed from 227 
2011 to 2014.  228 
 229 
Statistical analysis 230 
The data were analysed using the Statistical Package for Social Sciences (SPSS version 19) and 231 
summarised with descriptive statistics. The relationship between underlying conditions and 232 
treatment response was analysed using the Pearson chi-square test (P value was calculated for 233 
large sample size) and Fisher’s exact test (a statistical significance test, if sample size was <1000). 234 
Factors associated with patient survival were tested using logistic regression. 235 
 236 
 237 
 238 
 239 
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Results  240 
Analysis of the microbiological and clinical aspects of Acinetobacter spp. isolates 241 
The prevalence of Acinetobacter spp. ranged from 0.9% to 2.4% during the study period (2008-242 
2014). The prevalence of Acinetobacter spp. in colonised group and sepsis group ranged from 243 
0.5% to 1.5% and 0.4% to 1.1% respectively during the study period (2008-2014) [Figure 2].  244 
 245 
Figure 2. Prevalence of Acinetobacter spp. at IALCH from 2008 to 2014  246 
  Key:   Data is presented as % of patients. 247 
  The number of specimens received were 17511, 17266, 18073, 20557, 23200, 24561, 248 
  24253 in 2008, 2009, 2010, 2011, 2012, 2013, 2014 respectively.  249 
 250 
 251 
The numbers of patients per year with Acinetobacter spp. at IALCH ranged from 155 to 453 252 
within the seven-year study period, being statistically significant for the increase from 2008 to 253 
2012 and the decrease from 2013 to 2014 (P: 0.001). The proportion of significant sepsis ranged 254 
from 37% to 51%, and of colonisation from 49% to 63% [Figure 2].  255 
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 256 
Figure 3. Proportion [%] of Acinetobacter spp. sepsis and colonisation at IALCH from 257 
2008 to 2014.  258 
Key:  Data is presented as % of patients. 259 
The proportion of of Acinetobacter spp. sepsis and colonisation were ranged from 260 
37% to 51% and 49% to 63% during study period (2008-2014). 261 
 262 
 263 
Demographic characteristics  264 
The presence of Acinetobacter spp. was statistically insignificant for gender in the sepsis and 265 
colonised groups (P >0.05) [Figure.4]. There was a greater risk of infection for patients less than 266 
one year old in the sepsis group, and for patients aged 13 to 60 years old patients in the highly 267 
colonised group. The proportion of sepsis and colonisation cases was not significantly different 268 
in ICU and non-ICU units in the years 2010, 2011, 2013 and 2014, but more sepsis occurred in 269 
ICU units in the years 2008 and 2009. 270 
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 271 
Figure 4.  Flow chart.  Demographic data of patients cultured with  272 
                          Acinetobacter spp. from 2008 – 2014. 273 
Key:  Data is presented as n (%) of patients.  274 
* a greater risk of infection in patients less than one year old in the sepsis group; 275 
** highly colonised group in 13 to 60 year old; 276 
ICU: Intensive care unit, ETA: Endotracheal aspirate, CSF: Cerebrospinal Fluid.  277 
 278 
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Sites and source of infection 279 
Respiratory tract specimens from endotracheal aspirate (ETA) were common sites for 280 
Acinetobacter spp. in both the sepsis and colonised groups. Acinetobacter spp. were isolated most 281 
commonly from blood (46%) followed by ETA (27% and 38% in the sepsis and colonised groups 282 
respectively). Cerebrospinal fluid (CSF) was the only specimen from which Acinetobacter spp. 283 
were isolated from patients in the sepsis group who had neurological-related infections (8%) 284 
[Figure.4]. 285 
 286 
Clinical history of sepsis and local infection versus microbiological significance of infection 287 
and colonisation  288 
A significant number of clinically diagnosed sepsis cases 397/684 (58%) was caused by 289 
Acinetobacter spp. infection whereas the remaining cases 287/684 (42%) were merely colonised 290 
with Acinetobacter species. Among the clinically localised infections, 337/829 (41%) were 291 
caused by Acinetobacter spp. and 492/829 (59%) were colonised with Acinetobacter spp. [Figure. 292 
5]. 293 
 294 
 295 
Figure 5. Clinical History versus Microbiological Results of Acinetobacter spp. during a 296 
four year period (2011-2014 (n: 1513).  297 
Key:  Data is presented as % of patients.  298 
        397 (58) # were microbiological and clinically significant sepsis;  299 
       337(41) # were microbiological and clinically significant local infections; 300 
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# the appropriate antibiotics needed to be prescribed for the Acinetobacter spp.; 301 
287(42) ## were microbiological colonisation in clinically significant sepsis 302 
group; 303 
492(59) ## were microbiological colonisation in clinically significant local 304 
infections; 305 
## a prescription was not needed for the Acinetobacter species;  306 
        S, Sepsis group; C, Colonised group.  307 
 308 
Accuracy of the interpretation of microbiology results in correlation with clinical history  309 
According to the correlation between the clinical and microbiological results, both infection with 310 
Acinetobacter spp. and colonisation percentages in the sepsis and colonisation groups were 311 
statistically significant [<0.05 (P: 0.02)] [Figure.5]. Therefore, it is important to correlate the 312 
clinical and microbiological analysis when interpreting sepsis or colonisation caused by 313 
Acinetobacter spp. isolates in individual infection. 314 
 315 
Pure and mixed growth of Acinetobacter spp. in sepsis and colonised groups of patients  316 
Pure growth of Acinetobacter spp. in the sepsis group was statistically significant in 2013 [P<0.05 317 
(0.001)], but not in 2012 and 2014 [P >0.05 (P 0.835 in 2012; P 0.267 in 2014)]. The specimens 318 
from patients with clinical sepsis showed pure growth in 72 (36%), 117 (59%) and 97 (51%) of 319 
specimens in 2012, 2013 and 2014 respectively. Pure growth of Acinetobacter spp. was also 320 
obtained from specimens with local infection; namely 55 (22%), 55 (23%), and 94 (43%) in 2012, 321 
1013 and 2014 respectively. Similarly, mixed cultured Acinetobacter spp. and other bacteria were 322 
found from specimens of both clinical sepsis and colonised groups; namely 130 (64%), 80 (48%), 323 
95 (49%) in the sepsis group and 190 (78%), 181 (77%) and 125 (57%) in the colonised group 324 
for 2012, 2013 and 2014 respectively [Figure.6].  325 
 326 
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 327 
Figure 6.  Pure and Mixed Growth of Acinetobacter spp. in sepsis and colonised group  328 
  (2012-2014).  329 
Key:  Data is presented as (%). C: colonised patients group; S: sepsis patients group  330 
with Acinetobacter spp. significant infection; pure growth: Acinetobacter spp. 331 
cultured only; Mixed growth: cultured Acinetobacter spp. cultured along with 332 
other bacteria 333 
 334 
Antibiotic resistance patterns 335 
During the study period, the drug resistance patterns of Acinetobacter spp. in the sepsis group for 336 
MDR, XDR and PDR was 53 to 60%, 1% to 19%; 1% respectively, and 22% to 75%, 8% to 23%; 337 
1% respectively in the colonised group. Amikacin sensitivity was high (59% to 90%) and 99% of 338 
Acinetobacter spp. remained sensitive to colistin throughout the seven years [Figure. 7].  339 
 340 
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 341 
Figure 7. Antibiotic resistant pattern % with MDR, XDR, PDR, and resistant to colistin   342 
      and amikacin from 2008-2014.   343 
Key:  Data is presented as (%). 344 
MDR, multi-drug resistant; XDR, extensively-drug resistant; PDR, pandrug- 345 
resistant, CST, colistin; AK, amikacin; S, Sepsis group; C, Colonised group  346 
 347 
The percentage of community acquired Acinetobacter spp. strains sensitive to all appropriate 348 
antibiotics was 10% to 70% in the colonised group and 7% to 36% in the sepsis group [Figure 8].  349 
 350 
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 351 
Figure 8. The Percentage of community acquired sensitive Acinetobacter spp.*  352 
  during study period (from 2008 to 2014) 353 
Key:  Data is presented as n (%).  354 
* Community acquired Acinetobacter spp. are sensitive to all appropriate 355 
antibiotics (CAZ, TZP, AK, CIP, IMP, MEM, CST).  356 
CAZ, Ceftazidime; TZP, Piperacillin-tazobactam; AK, Amikacin;  357 
CIP, Ciprofloxacin; IMP, Imipenem; MEM, Meropenem; CST, Colistin.  358 
 359 
 360 
 361 
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 362 
 363 
Figure 9. Preauthorisation decision assist the ASWP 364 
Key: ICU: Intensive care unit; ETA: Endotracheal aspirate; CSF: Cerebrospinal 365 
fluid; PDF: Peritoneal dialysis fluid; GPB: Gram positive bacteria;  366 
GNB: Gram- negative bacteria; HAP: Hospital acquired pneumonia; 367 
HA-VAP: Hospital acquired ventilator associated pneumonia;  368 
IPC: Infection prevention control.  369 
 370 
 371 
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Discussion 372 
Management of MDR, XDR and PDR Acinetobacter spp. infections currently poses serious 373 
clinical and epidemiological challenges [6]. The problem of antimicrobial resistance is both an 374 
international concern and a local issue that occurs in individual hospitals and communities [18, 375 
19]. Thus, it will take a widespread effort at the individual and institutional level to impact on 376 
antimicrobial usage. The clinical and microbiological indicators of significant infections are 377 
crucial in establishing preauthorisation and prospective review of antibiotics in order to assist the 378 
ASWP at the patient level. 379 
In this study, Acinetobacter spp. were found to be frequent cause of significant sepsis in both ICU 380 
and non-ICU wards. There was a high risk of infection in non-ICU units, with the hospital 381 
receiving patients, specifically those with chronic illnesses, across KZN. The results show a 382 
recorded prevalence of Acinetobacter spp. at 0.9% in 2008. At that time it was not recognised as 383 
a pathogen in this local hospital. The increased prevalence in 2009 (2.2%) and 2010 (2.4%) led 384 
to the recognition of Acinetobacter spp. as a potential pathogen and the implementation of strict 385 
infection prevention control for patients with positive Acinetobacter spp. isolated. In 2014, the 386 
prevalence was reduced to 1.6% due to reinforced infection prevention practices. . This rate is 387 
lower than that reported in global surveillance reports (19.2%: highest in Asia; 3.7%: lowest 388 
reported in North America) [7, 11-13, 15]. 389 
Although Acinetobacter spp. was cultured proportionally more in the colonised group versus the 390 
sepsis group, the organism was persistently isolated as a potential pathogen in the sepsis group 391 
(P: 0.001) during every year of this local study, in ICUs and non-ICUs. Previous studies reported 392 
that Acinetobacter infection rates vary among countries [7, 12, 13].  393 
This study results showed the highest percentage of Acinetobacter spp. in blood culture specimens 394 
(41% to 50%), followed by ETA (17% to 48%) and CSF (1% to 18%) from 2011 to 2014 in the 395 
sepsis group. ETA specimens constituted the largest proportion of samples in both the sepsis and 396 
colonised groups. This result was similar to other studies [7, 13] that found most isolates from the 397 
respiratory tract [7]. The respiratory tract was the most common site affected, especially in the 398 
neonatal sepsis group of patients, and similar results were reported by Reddy et al in 2015 [20]. 399 
Patients with ETA specimens from both the sepsis and colonised groups experienced a 400 
significantly higher rate (P <0.5) of Acinetobacter spp. lung infection than those with other sites 401 
of infection. Known risk factors for Acinetobacter spp. colonisation and infection include 402 
prolonged hospital or ICU stay, previous admission to another unit, immunosuppression, 403 
debilitation, and the previous use of third-generation cephalosporins [5, 21].  404 
This study also revealed that the percentage of polymicrobial infections was high in the sepsis 405 
group (48% to 64%). Literature suggests that most ICU patients infected with these organisms 406 
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also have the highest rate of polymicrobial bacteremia (25.2%), which is associated with 407 
Pseudomona aeruginosa, coagulase-negative Staphylococci and Escherichia coli bacteria, 408 
representing 13.7% to 15.5% of total bacteremic episodes [7]. The high polymicrobial bacteremic 409 
rate of Acinetobacter spp. may reflect the potential polymicrobial sources of infection [22, 23]. 410 
Pure growth of Acinetobacter spp. in the sepsis group was statistically significant (P <0.05) in 411 
2013, but not in 2012 and 2014 (P >0.05). These results show that although mixed growth of 412 
Acinetobacter spp. may result in colonisation, it also may be a pathogen among the mixed bacteria 413 
in sepsis group. Similarly, pure growth of Acinetobacter spp. was not always interpreted as a 414 
significant pathogen for sepsis, indicating the importance of checking other factors, such as the 415 
microbiological and clinical indicators, before deciding on the course of treatment. Correlation of 416 
the clinical and microbiological data showed a statistically significant difference between the 417 
pathogen and colonisation (P <0.05), indicating that interpretation of both clinical and 418 
microbiology data is essential before prescribing treatment for Acinetobacter spp. infections or 419 
sepsis in order to reduce over and under medicating (Figure 9). 420 
The high prevalence of MDR Acinetobacter spp. and the rates of resistance to polymyxins were 421 
of concern. Colistin has generally been considered as the last bastion against such infections, 422 
within the context of a lack of new antimicrobial agents against developing PDR [12]. In IALCH, 423 
tigecycline is not used routinely to treat Acinetobacter spp. infections or sepsis, and consequently, 424 
drug susceptibility testing of this antibiotic was not performed until 2012.  425 
Kim et al., reported that PDR was responsible for more than 60% of Acinetobacter spp. isolates 426 
causing hospital-acquired pneumonia in Asian countries [24, 25].  427 
This local study showed that a large proportion of sepsis group patients had infections with MDR, 428 
XDR and PDR Acinetobacter species. Although similar resistance patterns of MDR, XDR and 429 
PDR were found in both sepsis and colonised groups over the seven years, amikacin sensitivity 430 
was high but the majority of Acinetobacter spp. isolates (99%) were sensitive to colistin. In the 431 
local hospitals, amikacin inhaler/nebulisation is commonly prescribed for pneumonia cases.  432 
Imipenem, meropenem, and piperacillin/tazobactam were the most potent antibiotics, although 433 
resistance for these drugs emerged, highlighting the need to use broad-spectrum antibiotics with 434 
caution. Hospitals, being the main site for the development of antimicrobial-resistant organisms, 435 
are responsible for the stewardship of the available antimicrobial agents. This local study 436 
indicated that Acinetobacter spp. isolates acquired by colonised patients from the community 437 
were sensitive to the appropriate antibiotics. The Percentage of community acquired sensitive 438 
Acinetobacter spp were reange from 10% to 70% in the colonised groups and 7% to 36% in the 439 
sepsis group of patients during study period (2008-2014). 440 
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Acinetobacter spp. are part of the natural flora of the human skin and environmental areas and is 441 
linked to the high temperature and humidity in Durban, KZN. Moreover, significant community 442 
and nosocomial infections caused by Acinetobacter spp. have become a serious public health 443 
concern in many countries, including South Africa. The emergence of MDR Acinetobacter spp. 444 
in South African neonatal and pediatric units has been associated with greater than 50% mortality 445 
and significant morbidity [26] and a marked increase in the number of ICU infections due to MDR 446 
Acinetobacter spp. has been reported [27]. These results are similar to a study in Brazil, a 447 
developing country with some challenges common to those of South Africa [28]. 448 
The first study on the characteristics and outcome of pediatrics intensive care unit (PICU) patients 449 
with positive Acinetobacter spp. culture, which distinguished between sepsis and colonisation 450 
based only on clinical factors, was published in 2015 [20]. The current study is the first in South 451 
Africa to describe the characteristics of different age groups of ICU and non-ICU patients with 452 
positive Acinetobacter spp. culture, and attempt to distinguish between colonisation and infection 453 
through analysis of microbiological and clinical indications. 454 
 455 
This study revealed a high prevalence of Acinetobacter spp. infections or sepsis, specifically 456 
MDR Acinetobacter spp., in both ICU and non-ICU settings. The particular concern was XDR 457 
and PDR Acinetobacter spp. which emerged in both the significant sepsis and colonised patient 458 
groups. Recognising vulnerable patient groups who are at a higher risk of morbidity and making 459 
appropriate antibiotic choices is critical in managing patients with Acinetobacter spp. infection. 460 
To the best of our knowledge, no such data has been reported from Durban, KZN, South Africa.  461 
This study analyses several relevant factors that could be associated with Acinetobacter infections 462 
using ICU and non-ICU data over seven years. It differentiates Acinetobacter infections and 463 
colonisations according to the source of infection, types of specimens, quantity of organisms and 464 
microbiology results, and identifies factors, that may reduce adverse outcomes. The results will 465 
aid clinicians in using early and appropriate antibiotic regimens, particularly in patients at risk of 466 
more virulent MDR infection, as well as in those with late onset ventilator associated pneumonia 467 
(VAP) who are at the highest risk for mortality. 468 
Clinical and microbiological indicators of sepsis patients should be analysed by collaboration 469 
between clinical microbiologists, clinicians, and infectious disease specialists. This information 470 
is crucial when establishing decision to treat in order to assist the preauthorisation and prospective 471 
review of antibiotics as part of ASWP at the patient level (Figures 1 and 9). 472 
Since this was a retrospective analysis based on laboratory and clinical data of a large sample of 473 
patients, it was not possible to obtain a more detailed analysis of antibiotic usage and clinical 474 
outcomes. Further prospective studies should be done to confirm the findings, specifically the 475 
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effect of an intervention, using combination versus monotherapy as well as outcomes in the 476 
context of multidrug- resistance. The increasing emergence of drug-resistant Acinetobacter spp. 477 
means that continuous surveillance is needed to determine the prevalence and epidemiology of 478 
resistant Acinetobacter species. 479 
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Abstract    36 
Background: Drug resistant- Acinetobacter species (Acinetobacter spp.) is a serious problem in 37 
clinical settings worldwide and has a significant effect on the optimal use of antibiotics, especially 38 
in patients with polymicrobial infections. This study was conducted to determine the effectiveness 39 
of various antibiotics with colistin combinations against multidrug-resistant Acinetobacter spp. 40 
using synergy testing. 41 
Methods: Acinetobacter spp. were analysed for antibiotic susceptibility and synergistic efficacy 42 
of colistin in combination with other seven antimicrobial agents. These included carbapenems, 43 
amikacin, piperacillin-tazobactam, ciprofloxacin, vancomycin, linezolid and rifampicin. In vitro 44 
synergy tests were performed using a colistin-incorporated plate with the Epsilometer test (E-test) 45 
strip method.  46 
Results: Of the sixty isolates tested, 90% were susceptible to colistin and amikacin, 25% to 47 
carbapenems and ciprofloxacin, and 20% to piperacillin-tazobactam. The combination of colistin 48 
and rifampicin showed synergistic effects against 28% of tested isolates, while colistin 49 
combinations with carbapenems, piperacillin-tazobactam, ciprofloxacin and vancomycin each 50 
showed synergistic effects in range 2-3% of tested isolates. Seventeen isolates (28%) showed 51 
antagonistic effects against colistin in combination with rifampicin. 52 
Conclusion: Synergy testing of colistin combinations yielded highly diverse and species 53 
dependent results. Our findings suggest that such combinations should not be used for empirical 54 
treatment of Acinetobacter spp. infections in Durban, synergy testing should rather be performed 55 
for individualised direct therapy. Optimal treatment and the role of combination therapy should 56 
be addressed in future research. 57 
 58 
Key words:   Extensively drug resistance (XDR); combination therapy; synergy test;  59 
individualised direct therapy 60 
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Introduction   71 
The emergence of multidrug-resistant (MDR), extensively-drug resistant (XDR) and pandrug- 72 
resistant (PDR) Acinetobacter species (Acinetobacter spp.) is a serious problem in clinical 73 
settings worldwide, including South Africa.1,2,3 According to the Centers for Diseases Control and 74 
Prevention (CDC) and European Centre for Disease Control and Prevention (ECDC), MDR 75 
microorganisms are resistant to at least one agent in three or more antimicrobial categories or 76 
MDR Acinetobacter spp. are those isolates that showed resistance to carbapenems.4  In this study, 77 
MDR Acinetobacter spp. are those isolates that showed resistance to carbapenems or any three 78 
groups of antimicrobials. Acinetobacter spp. resistant to five groups of antimicrobials excluding 79 
colistin are defined as XDR isolates, while those resistant to all six groups of antimicrobials are 80 
defined as PDR isolates.4 81 
Drug resistant isolates have a significant effect on optimal antibiotic use in patients with serious 82 
infections1,2,3  and recent surveillance studies have reported increased resistance to carbapenems, 83 
considered to be the primary treatment against these bacteria.5 With limited therapeutic options 84 
for MDR Acinetobacter spp. infection, colistin has been accepted as an alternative agent and is 85 
often prescribed in spite of toxicity concerns.6,7 However, the emergence of resistance during 86 
single therapy, as well as the potential toxicity, have led to the use of colistin in combination with 87 
other drugs instead of merely increasing the dose in monotherapy.8 Increasing resistance rates 88 
seen in Acinetobacter spp. isolates have resulted in the administration of combination therapies, 89 
often prescribed empirically, as an alternative choice.9, 10  90 
The rationale for using colistin combination treatment is its synergistic effect against resistant 91 
isolates, prevention of further resistance and reduced risk of dose dependent side effects.11 It is 92 
also used to treat polymicrobial infections and severe infections with high mortality rates.12 93 
In our local hospital, the common challenge is to choose the optimal combination therapy for 94 
polymicrobial infections, such as MDR, XDR Acinetobacter spp. with other Gram- positive and 95 
negative bacteria. Among the various combinations, meropenem showed the best synergy results 96 
and no antagonistic effect.13,14 However, imipenem achieved a superior results to meropenem in 97 
another study.15 Additional research showed that colistin/meropenem combination has a better 98 
synergistic effect in colistin-susceptible Gram- negative bacteria than colistin/imipenem.15 Other 99 
various antibiotic combinations have a better synergistic effect with different tests in various 100 
studies.12,16 There are several reports on the synergistic effects of colistin,17,18  all with 101 
contradictory results.19,20 102 
Rifampicin in combination with colistin has shown effective synergy in multiple studies involving 103 
colistin-resistant isolates, although this combination has not yet been implemented clinically.16, 21 104 
A conflicting report showed no synergy with colistin in combination with imipenem, rifampicin 105 
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or azithromycin.17 In addition, antagonism was detected in a colistin/sulbactam combination.12 106 
Because these drug combination studies are relatively new and demonstrate contrasting outcomes, 107 
further research is needed for conclusive results.7 To determine their efficacy, in this study, we 108 
examined the synergy effect of colistin and other drug combinations commonly used in local 109 
hospitals, including colistin/carbapenem (imipenem or meropenem), colistin/rifampicin, 110 
colistin/piperacillin–tazobactam, colistin/aminoglycoside, colistin/ciprofloxacin, 111 
colistin/vancomycin and colistin/linezolid, each against sixty Acinetobacter spp. isolates from 112 
patients in the high risk units of Inkosi Albert Luthuli Central Hospital (IALCH), Durban, KZN, 113 
South Africa. Our investigations may be used to plan future guidelines for an effective standard 114 
management policy in the high-risk wards of IALCH and potentially in other hospitals worldwide. 115 
 116 
 117 
Methods  118 
The study was performed from January 2014 to January 2015 at the Medical Microbiology 119 
laboratory, National Health Laboratory Service, Inkosi Albert Luthuli Central Hospital Academic 120 
complex, Durban, KwaZulu-Natal, South Africa. The research was approved (Ref: BE283/12) by 121 
the Biomedical Research Ethics Committee of the University of KwaZulu-Natal. 122 
 123 
Sixty isolates of Acinetobacter spp. from 107 patients were selected based on the clinical and 124 
microbiological significance criteria.22 All sixty isolates were subjected to antimicrobial 125 
sensitivity testing by the Kirby-Bauer disc diffusion method and the Vitek 2 (bioMérieux, France) 126 
automated method. The antimicrobials tested were ceftazidime (30 μg), ciprofloxacin (5 μg), 127 
amikacin (30 μg), piperacillin-tazobactam (100/10 μg), imipenem (10 μg) and meropenem (10 128 
μg).  129 
Based on their resistance patterns to different classes of antimicrobials, i.e. aminoglycosides 130 
(amikacin), β-lactams with inhibitors (piperacillin–tazobactam), cephalosporin (ceftazidime), 131 
fluoroquinolones (ciprofloxacin), carbapenems (imipenem, meropenem), and colistin, the isolates 132 
were divided into three groups. Group 1 isolates were resistant to all six groups of antimicrobials, 133 
defined as pandrug-resistant (PDR). Group 2 isolates were resistant to five groups of 134 
antimicrobials, except colistin, defined as extensively drug resistant (XDR). Group 3 isolates were 135 
resistant to carbapenem or any three groups of antimicrobials, defined as multidrug- resistant 136 
(MDR) based on the locally used different classes of antimicrobial agents. 137 
 138 
 139 
 140 
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Detection of Minimum inhibitory concentration (MIC) by drug susceptibility testing  141 
Susceptibility results were obtained using the Vitek 2 (bioMérieux France) bacterial identification 142 
as per the manufacturer’s instructions. The identification was repeated for confirmation before 143 
performing the synergy test.  The Epsilometer test (E-test) (bioMérieux France) was used to test 144 
the (MIC) for each of the 60 representative isolates exposed to colistin in combination with 145 
different antimicrobials. MIC results were interpreted according to the Clinical and Laboratory 146 
Standards Institute (CLSI) breakpoint criteria for Acinetobacter spp.23  Since there are no such 147 
criteria for vancomycin, linezolid and rifampicin, the susceptibility breakpoints for these 148 
antibiotics were based on the MIC interpretive standards of CLSI for Gram-positive bacteria.24 A 149 
control isolates (ATCC 19606) was included.  150 
 151 
Synergy testing  152 
The synergy test was performed using the E-test method24, 25, on colistin with seven different 153 
combinations such as amikacin, piperacillin-tazobactam, ciprofloxacin, carbapenems (imipenem, 154 
meropenem). Gram- positive appropriate drugs (vancomycin, linezolid) were also included 155 
against the 60 clinical Acinetobacter spp. isolates to test for synergistic effect. Synergy testing of 156 
colistin with vancomycin and linezolid are essential for both the polymicrobial infection and for 157 
synergy effect against MDR and XDR Acinetobacter spp. sepsis.  158 
We excluded ceftazidime for colistin combination synergy testing due to it not being commonly 159 
used. 160 
 161 
Media preparation  162 
Two sets of Iso-Sensitest agar (CMO471 OXOID LTD, ENGLAND) plates were prepared, 163 
namely, drug-free media without colistin and plates with a fixed concentration of colistin at  164 
0.5 µg/mL.24 165 
 166 
Synergy testing by an E-test method. 167 
Synergy testing was performed using the E-test® method.24, 25 Plates were inoculated with a 168 
bacterial suspension of optical density equivalent to the 0.5 McFarland standard. Thereafter, E-169 
test strips (bioMérieux) were applied to the plate containing colistin and the colistin-free plate 170 
that were prepared in-house at the NHLS laboratory. Plates were incubated aerobically at 37°C 171 
for 24 hrs. The MIC values were recorded for each drug in the presence and absence of colistin. 172 
The synergy tests were performed twice for each isolate against seven combination of agents. The 173 
procedure was repeated twice or more to ensure reproducible results. The average of 2 to 3 MICs 174 
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for each isolate was calculated. The MICs values of single agents were correlated with those of 175 
results from the Vitek 2 automated method. 176 
  177 
 178 
Interpretation I 26    179 
Definitions,   180 
MICA = MIC of drug A alone 181 
MICB = MIC of drug B alone 182 
MICAB = MIC of drug A in the presence of drug B 183 
 184 
Synergy  185 
Synergy defined as MIC of combination is ≥ 2 dilutions less than MIC of the most active drug 186 
alone. 187 
E.g. MICA = 8, MICB = 16 (i.e. A= most active);  188 
MICAB = 2. MIC of A is reduced from 8 to 2 in combination with B i.e. by 2 dilutions 189 
 190 
Antagonism  191 
Antagonism defined as MIC of combination is ≥ 2 dilutions higher than MIC of the most active 192 
drug alone. 193 
E.g. MICA = 4, MICB = 16 (i.e. A= most active);  194 
MICAB = 16. MIC of A is increased from 4 to 16 in combination with B i.e. by 2 dilutions 195 
 196 
Indifference/Additive       197 
MIC of combination is within +/- 1 dilution compared to the most active drug alone. 198 
E.g. MICA= 1, MICB = 2 (i.e. A= most active); MIC of A or B in combination = 1 199 
Combination of A with B shows no change in MIC of A, the most active drug (Indifference) 200 
Data analysis 201 
Excel data analysis was performed using the functions of Sort, Filter, Pivot Table and Formulas.  202 
 203 
 204 
Results 205 
Among the sixty Acinetobacter spp. isolates obtained from patient specimens during the study 206 
period (Table 1), the susceptibility rate was highest against colistin and amikacin, followed by 207 
ceftazidime, carbapenems (imipenem and meropenem), ciprofloxacin, piperacillin/tazobactam 208 
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and rifampicin (Figure 1). No isolates were susceptible to vancomycin and linezolid, which are 209 
appropriate antibiotics for Gram- positive bacteria (Figure 1). 210 
The MIC values were estimated for the 60 isolates, which were representative of differing levels 211 
of drug resistance. Acinetobacter spp. showed a high degree of sensitivity to amikacin and colistin 212 
at 90% (Figure 1). 213 
Forty-five isolates (75%) were found to be MDR, six isolates (10%) were XDR and six isolates 214 
(10%) were resistant to colistin but sensitive to other agents. There were no PDR isolates in our 215 
sample (Figure 1). Our interpretation of the synergy effects in the isolates by using the 216 
interpretation I criteria of synergistic, additive/ineffective (indifferent) and antagonistic is 217 
presented in Table 2 and Table 3, along with data on the percentages of interactions. Minimum 218 
inhibitory concentration (MIC) values showed synergistic effects in twenty-three different 219 
isolates (Table 2). The combination of colistin and rifampicin showed a synergistic effect in 17 220 
(28%) of the 60 bacterial isolates tested. Colistin with piperacillin-tazobactam and colistin with 221 
ciprofloxacin showed synergy in 2 (3%) isolates, while colistin with carbapenem and colistin with 222 
vancomycin showed synergy in 1 (2%) isolates. None of the E-tested isolates showed synergistic 223 
effects for colistin with amikacin and colistin with linezolid. Combination tests revealed an 224 
antagonism effect and also an indifference/additive effect in the majority of isolates tested for 225 
colistin with seven combinations (Table 3). The study demonstrated no synergy effects in a 226 
number of isolates, although the MIC values of the combined drugs was lower than the MIC 227 
values of each individual drug.  228 
 229 
 230 
Discussion  231 
Acinetobacter spp., being one of the most important causes of nosocomial infection, poses a 232 
global public health problem3 and a serious threat to hospitalised patients.3 Drug-resistant 233 
Acinetobacter spp. infections are increasingly becoming a challenge to health care 5, 9, since 234 
isolates have limited treatment options due to their resistance to a wide range of agents.  235 
In this study the proportion of carbapenem resistant Acinetobacter spp., classified as MDR, was 236 
75% out of sixty isolates and the proportion of XDR was 10%. Although 10% of isolates was 237 
resistant to colistin, these isolates were sensitive to other agents. No PDR isolates were found in 238 
tested isolates during study time (Figure1). 239 
Acinetobacter is a leading cause of nosocomial infections1, 20; which are severe and life-240 
threatening. In addition, the organism is difficult to manage because antibiotic resistance often 241 
emerges during treatment 9  and results in severe adverse outcomes.  242 
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However, antimicrobial susceptibility testing of Acinetobacter spp. demonstrates equally high 243 
susceptibility rates for polymyxin B (95% to 99%) and colistin (98% to 100%) in other studies.27, 244 
28 This is comparable to our own data in this study, where maximum sensitivity to appropriate 245 
commonly used antimicrobial agents, such as amikacin and colistin was 90% and some isolates 246 
were found to be sensitive to several other drugs (Figure 1). Therefore, this study suggests that 247 
direct therapy, rather than empirical therapy, is still a good approach for Acinetobacter spp. 248 
infections.  249 
Although the isolates in this study had a low degree of sensitivity to imipenem and ciprofloxacin 250 
at 25% and to penicillins with inhibitors (piperacillin-tazobactam) at 20 %, we still use these drugs 251 
as an appropriate choice for direct therapy. Therefore, monotherapy may be preferred if the 252 
bacterial isolates are susceptible to one of the tested agents18 except colistin and amikacin that can 253 
be used as nebuliser monotherapy. However, due to its poor diffusion into lung epithelial lining 254 
fluid, the use of colistin as a single agent may have limited effects in Acinetobacter spp. 255 
pneumonia.29  256 
This study showed that the Acinetobacter spp. isolates were mostly grown from blood culture 257 
followed by endotracheal aspirate (Table 1).  Hence, the synergy test of colistin with vancomycin 258 
and linezolid combination were performed against MDR, XDR- Acinetobacter species from 259 
polymicrobial pneumonia cases. The synergy results revealed no synergy effect with a colistin-260 
linezolid combination, and a species dependent synergy effect with a vancomycin-colistin 261 
combination. The pneumonia cases with polymicrobial culture, benefit from combination therapy, 262 
especially the combination of linezolid-colistin cannot be used as this study showed an 263 
antagonistic effect (Table 3). 264 
Literature has reported that the intensive use of antimicrobials inevitably leads to the appearance 265 
of isolates resistant to these drugs, with increasing resistance for carbapenems which are still the 266 
main treatment option.5 No new antibiotics have been available the treatment of XDR Gram-267 
negative pathogens including Acinetobacter spp. for at least a decade.30 For MDR Acinetobacter 268 
spp. infection, the practise is to prescribe either colistin, amikacin with carbapenem, or amikacin 269 
with piperacillin-tazobactam.6 Amikacin appears to retain activity against many A. baumannii 270 
isolates. As with all antimicrobial agents and multidrug-resistant pathogens, resistance is 271 
increasing, and susceptibility testing is required to determine activity. Aminoglycosides are not 272 
often used as single agents for treatment, and the toxicity profiles often hinder their use for longer 273 
treatment courses. Historically, aminoglycosides have been used mostly in combination therapy, 274 
and monotherapy appears to be inferior to other agents and there are concerns regarding the 275 
development of resistance, also enhanced by the pressure of increased amikacin use.31, 32 276 
However, the efficacy of inhaled antibiotics, including aminoglycosides, outside the cystic 277 
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fibrosis population is of increasing interest.1, 33,34 Therefore, the usage of amikacin with guided 278 
right dose, frequency, duration and susceptibility is crucial.  279 
This current study supports this approach according to susceptibility results in the local setting, 280 
since the pathogen demonstrated sensitivity to colistin with amikacin in 90% of isolates, and lower 281 
sensitivity to cabapenems in 25% of the isolates.  Carbapenems are still considered the primary 282 
treatment if the bacteria is sensitive.  283 
Previous studies suggested that colistin should be combined with another antibiotic for adequate 284 
pharmacological effect. Those in vitro studies combined carbapenem and a polymyxin for 285 
carbapenem-resistant Acinetobacter spp. isolates17, 18, 35, an approach that results in higher levels 286 
of synergy.   287 
Pongpech et al., (2010) examined 30 MDR Acinetobacter spp. isolates all resistant to imipenem 288 
and meropenem and found 100% synergistic activity between imipenem and colistin, which may 289 
be related to the ability of colistin to weaken the cell wall or membrane. 5, 31 It is likely that this 290 
combination would play a major role in the treatment of Acinetobacter spp. infection. According 291 
to Pankey and Ashcraft (2009), meropenem and polymyxin B provided in vitro synergy against 292 
genetically unique meropenem-resistant Acinetobacter species.18 In our setting, another option is 293 
to combine colistin with other drugs (such as amikacin, carbapenems, ciprofloxacin, piperacillin-294 
tazobatam, vancomycin, linezolid and rifampicin) in order to achieve lower dose-related toxicity 295 
and also for polymicrobial infection with MDR-XDR-Acinetobacter spp. sepsis. However, the 296 
effectiveness of synergy results was diverse in this study. The estimated MIC for 60 representative 297 
isolates of differing levels of drug resistance suggests that drug-resistant Acinetobacter spp. is an 298 
increasingly challenging pathogen.  299 
In another study, no synergy was detected with the combinations of colistin-carbapenems or 300 
rifampicin, while decreases in carbapenem and rifampicin MIC values were detected 17, which 301 
were consistent with the current study. Most prior research did not detect an antagonism effect 302 
with other combinations. However, one recent study reported antagonism in a sulbactam-colistin 303 
combination in 6.66% of isolates.12 The current study found an antagonism effect with colistin 304 
combinations in some isolates and an indifference/additive effect in most isolates. Colistin can be 305 
used against multidrug-resistant and colistin-sensitive Acinetobacter infections, although the 306 
synergistic effect is specific for individual isolates and efficacy of treatment varies among 307 
species.36 308 
The in vitro effects of antibiotics vary depending on the test methodology and at the moment there 309 
is no standardised method for in vitro synergy testing of resistant isolates (Sopirala et al., 2010).37 310 
The limitation of the current is that only one method was used to test synergy.  311 
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However, the colistin-incorporated plate and E-test strip method has been used in previous 312 
research to demonstrate synergy38,39, 40 and may be more reliable that the sequential E-test strip 313 
method.13, 38 When using combination therapy, synergy testing with the direct individualised 314 
isolates and employing pre-existing antibiotics is a plausible alternative approach for the 315 
treatment of infections due to multidrug-resistant isolates (Tangden, 2014).41 The available 316 
literature on combination therapy for Gram-negative sepsis is diverse and contradictory.  317 
One recommendation based on retrospective analysis is to use combinations of agents, including 318 
a carbapenem if the MIC for carbapenem is <4 mg/L (Tangden, 2014).41However, this study 319 
showed a synergy effect of combination of colistin and carbapenems, regardless of the MICs. 320 
This study indicated that synergy was apparent when isolates were susceptible or resistant to the 321 
combination drugs. Surprisingly, synergy was not affected by the MIC value of each drug against 322 
the specific isolate if either of the isolates had high or low MIC values.  323 
 324 
In conclusion, the need for effective, first-line treatment options necessitates synergistic 325 
combinations of drugs that are a suitable alternative to amikacin, carbapenems, or colistin. 326 
Additionally, these combinations may be used for mixed polymicrobial infections. The results of 327 
synergy testing of colistin in combination therapy against Acinetobacter spp. are highly diverse. 328 
However, among these combinations, the synergistic effect of colistin with rifampicin was most 329 
promising. The potential of rifampicin to act synergistically with colistin against resistant isolates 330 
may prove advantageous when selecting antimicrobial therapy in settings with high rates of drug 331 
resistant Acinetobacter spp. pneumonia especially in those patients initiated on anti-tuberculosis 332 
(TB) treatment. Because of the TB endemic in South Africa, patients who had been on anti-TB 333 
medication with PDR-Acinetobacter sepsis cases, the synergy effect on colistin and rifampicin 334 
should be tested.  335 
 336 
Previous in vitro studies suggest that if combination therapy is the treatment of choice, proven 337 
combinations may be used, since synergistic activity may depend on bacterial isolates and 338 
susceptibility testing methods. The study also discovered the antagonistic effects of colistin and 339 
rifampicin combination. Therefore, it is important to note that combinations should be evaluated 340 
using synergy tests as a guide to treatment. This study suggest that colistin in combination with 341 
another agent should not be prescribed as empirical therapy of standard of care. Rather, synergy 342 
testing must routinely be performed for Acinetobacter spp. isolated from each patient for 343 
individualised therapy and hence, a standard operational procedure (SOP) for synergy testing 344 
should be implemented. 345 
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Nevertheless, some literature suggests that accuracy is not pathogen but method dependent 346 
(Sopirala et al., 2010).37  The interesting new rapid synergy testing method, a novel two-347 
dimensional antibiotic gradient technique named XactTM, for meropenem/colistin synergy testing 348 
for multidrug-resistant Acinetobacter baumannii strains has been recommended in routine 349 
microbiology (Van-Belkum et al., 2015).42 This new test was comparable, shown to be 350 
diagnostically useful, easy to implement and less labour intensive than the classical method (Van 351 
Belkum et al., 2015).42  Therefore, synergy testing should be done using the new method and 352 
compared with E-test method in future. Further research is needed in the form of comprehensive 353 
studies with clinical evidence. Synergy mechanisms need to be explored in order to facilitate 354 
understanding of our results and predict the effects of other antibiotic combinations. 355 
 356 
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 547 
Figure 1. Antibiotic susceptibility of Acinetobacter spp. isolates. 548 
 549 
      Ceftazidime 16(27),               Piperacillin/tazobactam 12(20) 550 
Amikacin 54(90),                  Ciprofloxacin 15(25) 551 
*Carbapenem (Imp, Mem) 15(25),           **Colistin 54 (90) 552 
Vancomycin (0)               Linezolid (0) 553 
Rifampicin 6(10) 554 
 555 
Data presented as n (%) of Acinetobacter spp. isolates 556 
* Carbapenem resistant Acinetobacter spp. isolates, MDR (multidrug- resistance), were 45 out of 557 
60 isolates; 45 (75%) 558 
** Colistin resistant Acinetobacter spp. isolates were 6 out of 60 isolates; 6 (10%). 559 
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116 
 
Table 1:  Distribution of 60 Acinetobacter spp. clinical isolates according to wards and 568 
specimen type 569 
 570 
  Specimen type   
Wards  Blood  
culture 
CSF Tracheal 
aspirate 
Pus PDF Tip Tissue Urine Total 
ICU  10 2 8 3 3 1 - 2 29 
Burns/Plastic unit 1 - - 1 - - 1 - 3 
Neurosurgery - 3 2 - - 1 - - 6 
PDU - - - - 2 - - - 2 
BMT 2 - - - - - - - 2 
HCU 3 1 1 - - - 1 - 6 
Vascular unit 1 - - 1 2 - - - 4 
Labour unit 6 - - 1 - 1 - - 8 
Total 23 6 11 6 7 3 2 2 60 
 571 
Keys: Data presented as (n) of Acinetobacter spp. clinical isolates. 572 
ICUs: Intensive care surgery; Intensive care medical unit; Intensive care trauma;  573 
Intensive care neonatal and pediatric unit; 574 
PDU:  Peritoneal dialysis unit;   575 
BMT: Bone marrow transplant unit;  576 
HCU: High care unit;   577 
PDF: Peritoneal dialysis fluid;  578 
CSF: Cerebrospinal fluid 579 
 580 
 581 
 582 
 583 
 584 
 585 
 586 
 587 
 588 
 589 
 590 
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Table 2: Minimum inhibitory concentration (MIC) values for colistin, other  591 
combined drugs and colistin combined with each drug for  592 
Acinetobacter spp.   isolates in which a synergistic effecta was demonstrated 593 
isolates no. MIC (µg/mL) Interpretation I Analysis 
 
CST RIF CST+RIF less 2 dilution/ actual dilution 
2 12 4 1 1  
6 6 1 0.18 0.25 
7 0.125 3 0.023 0.31 
15 0.38 3 0.012 0.095 
18 0.125 3 0.008 0.031 
26 0.125 2 0.023 0.031 
37 0.25 2 0.008 0.062 
42 0.125 4 0.002 0.031 
45 0.125 2 0.032 0.031 
46 8 3 0.5 0.75 
47 3 4 0.5 0.75 
49 0.25 2 0.003 0.062 
52 0.125 6 0.008 0.031 
56 0.125 3 0.03 0.031 
57 0.125 8 0.008 0.031 
58 0.094 1.5 0.023 0.023 
59 0.125 32 0.006 0.031 
 
CST Carb(IMP/MEM)  CST+Carb  
6 6 0.94 0.094 0.23 
 
CST TZP CST+TZP 
 
1 32 1 0.023 0.25  
34 0.38 0.094 0.016 0.023 
 
CST  CIP CST+CIP 
 
2 12 0.5 0.125 0.125 
49 0.25 0.47 0.016 0.062 
 
CST VAN CST+VAN 
 
20 0.25 256 0.02 0.062 
Key: a, Synergistic effect means; MIC of combination is ≥ 2 dilutions lower than MIC of 594 
the most active drug alone.  595 
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CST, Colistin; RIF, Rifampicin; TZP, piperacillin +tazobactam; Cip, Ciprofloxacin;  596 
Carb, Carbapenem (IMP, imipenem and MER, meropenem); VAN, vancomycin;  597 
 598 
 599 
Table 3: Synergy test results for colistin–combined with other antibiotics against  600 
   Acinetobacter spp. isolates.   601 
 
No. of isolates (%) 
  
Combination Synergistica effect Additive/Indifferentb effect Antagonisticc 
 effect 
CST+ RIF 17 (28) 26 (43) 17 (28) 
CST+ TZP 2 (3) 10 (17) 48 (80) 
CST+CIP 2 (3) 11 (19) 47 (78) 
CST+ Carb* 1 (2) 17 (28) 48 (80) 
CST+ VAN 1 (2) 6 (10) 53 (88) 
CST+ LZ 0 0 60 (100) 
CST+ AK 0 14 (23) 46 (77) 
 602 
Key: Data presented as n (%) of bacterial isolates 603 
a Synergistic effect means MIC of combination is ≥ 2 dilutions lower than MIC of the 604 
most active drug alone. 605 
b Additive/Indifferent effect means MIC of combination is within +/- 1 dilution compared 606 
to the most active drug alone. 607 
c Antagonistic effect means MIC of combination is ≥ 2 dilutions higher than MIC of the 608 
most active drug alone. 609 
CST, colistin; RIF, Rifampicin; TZP, piperacillin +tazobactam; CIP, ciprofloxacin;  610 
Carb, Carbapenem (IMP, Imipenem and MEM, meropenem); VAN, vancomycin;  611 
LZ, Linezolid; AK, Amikacin.  612 
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Abstract   36 
Introduction: Carbapenemase production in multidrug-resistant Acinetobacter species is an 37 
important mechanism of carbapenem resistance. This study investigated the presence of the 38 
carbapenem-hydrolysing class D β–lactamase- encoding genes, blaOXA-23 and blaOXA-58, and their 39 
association with the spread of MDR Acinetobacter species in intensive care units at an academic 40 
hospital. 41 
Method: Forty-four MDR Acinetobacter species from sixty stored isolates were confirmed using 42 
VITEK®2. The minimum inhibitory concentrations (MICs) of imipenem and meropenem were 43 
determined using VITEK®2 and Epsilometer tests. The blaOXA-23 and blaOXA-58 genes were 44 
detected by polymerase chain reaction (PCR) in twenty-four selected isolates. The blaOXA-23 45 
amplicons were sequenced and compared to the GenBank database. Genotypic relatedness of 46 
isolates was determined by pulsed field gel electrophoresis (PFGE). Clinical and laboratory data 47 
were analysed. 48 
Results: Among the twenty-four isolates, eighteen were carbapenem resistant and six were 49 
carbapenem sensitive. The blaOXA-23 gene, but not blaOXA-58, was detected in the eighteen resistant 50 
strains. The blaOXA-23 amplicons showed 100% identity with the GenBank database of blaOXA-23. 51 
The MICs of carbapenems against Acinetobacter species carrying the blaOXA-23 gene were 8 to 52 
>16 µg/mL. Genetic relatedness was evident among isolates of seven pairs from fourteen patients. 53 
Of these patients, twelve were in the same ICU and two were adjacent to another ICU during the 54 
same hospitalisation period. 55 
Conclusion: The selected MDR Acinetobacter species carried the blaOXA-23 gene responsible for 56 
resistance to carbapenems (MICs 8 to >16 mg/L), while molecular and clinical data analysis 57 
suggested horizontal transmission in ICUs. In addition, the PFGE typing of a diverse collection 58 
of MDR Acinetobacter species clones showed that isolates were related from no more than two 59 
patients, suggesting that no outbreak had occurred. Continuous molecular surveillance for 60 
resistance genes is recommended. 61 
 62 
Key words:  blaOXA-23 genes; carbapenem-hydrolysing class D β -lactamases (CHDLs); 63 
horizontal transmission; molecular surveillance 64 
 65 
 66 
 67 
 68 
 69 
 70 
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Background 71 
Multidrug-resistant (MDR) Acinetobacter species (Acinetobacter spp.), are both community 72 
acquired and nosocomial opportunistic infection and have been responsible for outbreaks around 73 
the globe, especially in intensive care units ICUs settings.1-5 The past twenty years has seen an 74 
increase in the prevalence of the pathogen 6- 8 with MDR outbreaks reported in the United States.9- 75 
11 A significant reservoir is the large number of chronically ill patients 5 from whom colonisation 76 
of recently hospitalised patients may take place.6, 7  77 
There has been an increase of Acinetobacter spp. resistance to cephalosporins and carbapenems 78 
over the years,12-14 leaving clinicians with limited therapeutic options.12-14  Resistance to 79 
carbapenems, which display high efficacy and low toxicity, is of global concern.12- 14 Surveillance 80 
reports from China determined that carbapenem resistance in Acinetobacter spp. doubled from 81 
30% in 2006 to 63% in 2013.12-14 South African studies revealed Acinetobacter spp. resistance 82 
towards carbapenems and cephalosporins,15,16 specifically imipenem (86%), meropenem (86 %) 83 
cefepime (90%) and ceftazidime (89%).16 84 
The major mechanism of resistance to β-lactams in Acinetobacter spp. is carbapenem-hydrolysing 85 
class D β-lactamases (CHDLs), also known as OXA-type enzymes or oxacillinases.16  Previous 86 
studies classified the  class D carbapenemases into four subgroups: associated with  OXA-87 
23, OXA-58 as plasmid-encoded and OXA-24, OXA-40, OXA-51 as chromosomally 88 
encoded.17,18  There are five subclasses of OXA associated with Acinetobacter spp.; the intrinsic 89 
chromosomal OXA-51-like, of which there are over 70 variants, and the acquired OXA-23-like, 90 
OXA-24 (OXA-40-like), OXA-58-like, and OXA-143-like.19 In addition, the OXA-235, OXA-91 
236, and OXA-237, the first representatives of a novel subclass of CHDLs, were described in A. 92 
baumannii strains in 2013.20 Enzymes belonging to the OXA-23, OXA-24/ 40, OXA-48, OXA-93 
51, OXA-58, and OXA-143 subgroups are of major clinical importance due to their wide 94 
dissemination in bacterial pathogens.21-23 The genes encoding these enzymes are widespread 20 95 
and have been found on both chromosome and plasmids, allowing for spread across Acinetobacter 96 
species.20, 24 The prevalence of OXA-23 can be attributed to the acquisition of genetic elements, 97 
such as plasmids and transposons, as the OXA-23 gene is located on a plasmid or chromosome.16 98 
In a 2012 study, Liakopoulos et al. reported the  prevalence of OXA-23 in Greece from 2010 to 99 
2011 to be 95%,25 while Koh et al. reported that 91% of Acinetobacter spp. isolates from 100 
Singapore produced carbapenemase and carried the blaOXA-23 gene.26  Previous studies conducted 101 
at Pretoria Academic Hospital revealed the high prevalence of OXA-51 at (83%, 99%) and of 102 
OXA-23 at (59%, 77%) in 2013 and 2015 respectively.16, 18  Isolates of carbapenem resistant 103 
Acinetobacter spp. are often extensively drug-resistant (XDR), since they are susceptible to one 104 
or two agents only.27 Additionally, the recent  rise not only in XDR but also pandrug-resistant 105 
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(PDR) Acinetobacter spp.22 is of global concern. Due to the problem of resistance and 106 
antimicrobial availability, the Infectious Diseases Society of America determined that 107 
Acinetobacter spp. is a particularly concerning pathogen.28 Moreover, the Centers for Diseases 108 
Control and Prevention has highlighted the importance of MDR Acinetobacter spp. transmission 109 
in nosocomial and community acquired infections.5 In our setting, the latter half of 2008 110 
discovered the emergence of Acinetobacter spp. clinical strains with resistance to multiple classes 111 
of antimicrobials, including carbapenems, piperacillin-tazobactam, ceftazidime and 112 
fluoroquinolones. Hence, treatment options were restricted to salvage agents like colistin and 113 
amikacin.  114 
In this study, we investigated a representative sample of Acinetobacter spp. from Inkosi Albert 115 
Luthuli Hospital (IALCH) from 2013 to 2014. We determined the presence of two carbapenem 116 
resistance genes using PCR, sequencing and correlated the MIC of the carbapenems with the 117 
genes. We also investigated the clinical data of patients, including ward of admission, site of 118 
specimen, prescribed antibiotics and outcome. Nosocomial spread of the strains was investigated 119 
through pulsed field gel electrophoresis (PFGE). 120 
 121 
 122 
Methods 123 
Study setting 124 
The study was conducted at the Department of Medical Microbiology, University of KwaZulu-125 
Natal (UKZN)/National Health Laboratory Service (NHLS). Ethics approval was obtained from 126 
the Biomedical Research Ethics Committee, UKZN (Reference No BE 283/12). 127 
The stored Acinetobacter spp. (n=60) isolates had previously been isolated from the patients 128 
hospitalised at IALCH from January 2013 to January 2014.  Of the sixty, forty-four MDR 129 
Acinetobacter spp. were confirmed by using VITEK 2 (BioMérieux, France). The MICs of 130 
imipenem and meropenem were determined using the VITEK 2 and Epsilometer tests (E-test) 131 
(BioMérieux, France).  132 
 133 
Using the antibiogram, four XDR and fourteen MDR isolates with the same sensitivity patterns 134 
were selected for molecular investigation.  PCR, sequencing and PFGE typing were used to 135 
investigate carbapenem-hydrolysing class D β –lactamase production, the presence of the blaOXA-136 
23 and blaOXA-58 genes, as well as the association between drug resistance and presence of the 137 
genes.  138 
The A. baumannii ATCC 19606 strain was used as quality control for antimicrobial susceptibility 139 
tests and molecular methods. The blaOXA-23 and blaOXA-58 carrying Acinetobacter spp. isolates 140 
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obtained from the National Institute for Communicable Diseases (NICD) served as controls for 141 
PCR, sequencing and PFGE. 142 
 143 
Drug susceptibility tests and MIC  144 
The stored isolates were confirmed as MDR Acinetobacter spp. before PCR. Identification and 145 
antibiotic susceptibility testing (AST) of MDR Acinetobacter spp., including MICs, was 146 
performed using the VITEK® 2 GN Card automatic method (BioMérieux, France) and the 147 
Epsilometer test (E-test®) (BioMérieux, France) as per the guidelines from the Clinical and 148 
Laboratory Standards Institute (CLSI), 2013.29  149 
 150 
Carbapenem-resistant Acinetobacter spp. was resistant to both imipenem and meropenem with 151 
MICs of 8 µg/mL, whereas carbapenem-susceptible Acinetobacter spp. possessed a MIC of <1 152 
µg/mL and carbapenem-intermediate Acinetobacter spp. a MIC of 1-2 (<4) µg/mL.29 153 
 154 
Detection of blaOXA-23 and blaOXA-58 155 
Eighteen MDR Acinetobacter spp. belonging to the same antibiogram groups were selected for 156 
amplification by PCR to detect the carbapenem resistance genes blaOXA-23 and blaOXA-58. 157 
Resistance mediating genes were assessed for the presence of polymorphisms with the Big Dye 158 
Terminator v3.1 Cycle Sequencing kit (Life Technologies, ThermoFisher Scientific, South 159 
Africa) 160 
 161 
DNA extraction of Acinetobacter spp. isolates 30, 31 162 
Genomic DNA, from each of twenty-seven isolates, comprising eighteen clinical MDR strains, 163 
three controls and six sensitive clinical isolates, was extracted from an overnight culture using a 164 
loopful of colonies suspended in 500 µL of 1x TE buffer (Tris EDTA) (Capital Laboratory 165 
Supplies, Durban, South Africa). Cell lysis and protein digestion were performed using a 166 
combination of 10% Sodium Dodecyl Sulfate and 10 mg/mL proteinase K (Capital Laboratory 167 
Supplies, Durban, South Africa). Proteins were precipitated with 10% Cetyltrimethyl ammonium 168 
bromide (CTAB)/4% NaCl and polysaccharides were extracted by the addition of 24:1 169 
chloroform-isoamyl alcohol (Capital Laboratory Supplies, Durban, South Africa). The DNA was 170 
precipitated with isopropanol, washed with 70% cold ethanol (Capital Laboratory Supplies, 171 
Durban, South Africa) and dissolved in an appropriate volume of 1xTE buffer. The DNA was 172 
electrophoresed in a 1% agarose gel (Capital Laboratory Supplies, Durban, South Africa) to 173 
determine quality and quantity. The extracted genomic DNA was stored at -20°C (Defy Ltd, 174 
Multimode, SA) until further analysis. 175 
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Amplication of the blaOXA-23 and blaOXA-58 genes  176 
The blaOXA-23 and blaOXA-58 gene regions were amplified using primers (Roche Diagnostics, 177 
Randburg, South Africa) specific to the up and downstream regions of the gene sequences (Table 178 
1). The PCR master mix consisted of 5 µL template DNA, 10x PCR buffer, 0.2 µM of each primer, 179 
2.5 mM dNTPs, 1 U Taq DNA Polymerase (Thermofisher Scientific, United States), 1.5 µM 180 
MgCl and nuclease free water, with a total volume of 25 µL. The initial denaturation steps were 181 
performed for 5 min at 95°C, followed by 40 cycles of 20 s at 95°C, 1 min at 55°C and 30 s at 182 
72°C. This was followed by a final extension step of 5min at 72°C. Both positive and negative 183 
controls were used during the PCR amplification process. PCR products were electrophoresed on 184 
a 1.5% agarose gel (Capital Laboratory Supplies, Durban, South Africa) with markers of known 185 
molecular weights (ThermoFisher Scientific, Waltham, Massachusetts) and visualised under UV 186 
light. 187 
 188 
Table 1: Primer sequences and the corresponding annealing temperatures 189 
Primers 
  
Sequence (5’ to 3’) Annealing 
temperature (°C) 
Reference 
blaOXA-23 
Forward 
TCTGGTTGTACGGTTCAGC 53 [32] 
blaOXA-23 
Reverse 
AGTCTTTCCAAAAATTTTG 53 [32] 
blaOXA-58 
Forward 
ATGAAATTATTAAAAATATTGAGTTTAG 55 [32] 
blaOXA-58 
Reverse 
TTATAAATAATGAAAAACACCCAAC 55 [32] 
 190 
 191 
Purification of PCR products 192 
The PCR product were purified using 2 U Shrimp Alkaline Phosphatase (SAP) (AEC-Amersham, 193 
Little Chalfont, United Kingdom) and 10 U Exonuclease (Amersham, Little Chalfont, United 194 
Kingdom) as per manufacturer’s instructions. After the addition of 2 U of SAP and 10 U of 195 
Exonuclease I, the PCR tubes were briefly incubated at 32°C for 30 min and then at 80°C for 15 196 
min in a water bath to deactivate the enzymes. 197 
 198 
 199 
 200 
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DNA sequencing of blaOXA-23 amplicons  201 
Gene sequencing was performed with the ABI Big Dye Terminator v 3.1 Cycle Sequencing kit 202 
(ThermoFisher Scientific, Waltham, Massachusetts). The sequenced products were separated by 203 
capillary array electrophoresis using the ABI 3500 Genetic Analyser (ThermoFisher Scientific, 204 
Waltham, Massachusetts).  205 
The National Center for Biotechnology Information (NCBI) database was accessed and the 206 
sample sequences were aligned and compared to a reference sequence using the Basic Local 207 
Alignment Search Tool (BLAST) (https://www.ncbi.nlm.nih.gov/). 208 
 209 
Genotypic relatedness of clinically selective Acinetobacter spp. determined by PFGE 210 
Macro-restriction analysis of multidrug-resistant Acinetobacter spp. obtained from IALCH was 211 
performed using an adaptation of the method by Seifert et al., 33 and Sader et al.,34 Pure isolates 212 
from blood agar plates were grown in brain heart infusion (BHI) broth for 15-18 hr at 37°C  in a 213 
shaking incubator (Vacutec, South Africa) for plug preparation. A volume of broth corresponding 214 
to 1 optical density (OD) at 600 nm was used to make a 1 % PFGE agarose plug for each isolate. 215 
DNA was extracted within the agarose blocks by cell lysis over 18hr. Plug slices for each isolate 216 
were digested with 20U Apal restriction endonuclease (New England Biolabs, USA) for 4hr at 217 
37ºC. The restricted DNA was electrophoresed n a 1 % Pulsed–Field Electrophoresis Gel 218 
(BioRad) in 0.5X Tris-Borate-EDTA buffer (Merck) at 6V/cm with a 5-25 sec switch time for 24 219 
hours using the Chef-DR 3 system (BioRad). 220 
Cluster analysis was performed according to criteria outlined in Van Belkum et al.35 and a type 221 
was defined as PFGE banding patterns differing by 4 or less bands.  The results were interpreted 222 
according to the Tenover criteria.36 223 
 224 
Clinical and laboratory data collection  225 
The clinical characteristics, namely type of specimen, ward of admission, prescribed antibiotics 226 
and patient outcome, were documented from the patient records. In addition, the laboratory data 227 
were recorded from the laboratory computer system. Both the clinical and laboratory data were 228 
verified during wards rounds and analysed. 229 
 230 
Statistical analysis of clinical characteristics and patient outcomes 231 
Data was captured and analysed using the Statistical Package for Social Sciences (IBM® SPSS 232 
Statistics version 19). Results were presented using descriptive statistics such as frequency and 233 
percentage. The association between underlying patient condition and response to antibiotic 234 
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agents was determined using the Pearson chi-square test or Fisher’s exact test. Logistic regression 235 
was used to test for factors associated with patient mortality.  236 
 237 
 238 
Results  239 
Drug susceptibility tests and MICs 240 
During the study period, forty-four of the sixty stored Acinetobacter spp. isolates were confirmed 241 
MDR by the MICs. The selected isolates were resistant to carbapenems, with MIC values for 242 
imipenem and meropenem at 8 to >16 µg/mL as determined by the Vitek (BioMérieux, France) 243 
automatic system and confirmed with E-test (BioMérieux, France). The control isolate (ATCC 244 
19606) showed sensitivity to imipenem and intermediate sensitivity to meropenem, with MICs of 245 
0.25 and 1 µg/mL respectively. The blaOXA-23 positive control isolate was resistant to imipenem 246 
and meropenem with a MIC of >16 µg/mL for both. The blaOXA-58 positive control strain was 247 
resistant to imipenem and meropenem with a MIC of 8 and 4 µg/mL respectively (Table 2).  248 
 249 
Table 2:  MICs of imipenem and meropenem for Acinetobacter spp. isolates from  250 
the central Hospital in the academic Complex and the occurrence of the  251 
corresponding carbapenemase gene 252 
 253 
Number of isolates 
(n=24) 
IMP MEM blaOXA-23 
+ or - 
blaOXA-58 
+ or - 
17 >16 >16 + - 
1 8 >16 + - 
6 <0.25 <0.25 - - 
*blaOXA-23 >16 >16 + - 
**blaOXA-58 8 4 - + 
ATCC 19606 <0.25 1 - - 
 254 
Key: +, detected; -, not detected; IMP, Imipenem; MEM, Meropenem;   255 
*, positive control for blaOXA-23 known Acinetobacter spp.; **, positive control for blaOXA-256 
58 known Acinetobacter spp. 257 
 258 
 259 
 260 
128 
 
The clinical characteristics and patient outcomes were analysed in those patients whose 261 
isolates showed the presence of the blaOXA-23 gene (n=18) 262 
Among the eighteen isolates, four (22%) were XDR isolates which possessed the same 263 
antibiogram and fourteen (78%) were resistant to all agents except amikacin and colistin (Table 264 
3).  265 
Table 3: Clinical characteristics and outcomes of the patients with Acinetobacter spp.  266 
 isolates with blaOXA-23 gene   267 
 Clinical outcomes (n=18) 
   Deceased, n (%)  
7 (39%) 
Discharge n (%) 
11(61%) 
Antibiotics  Resistance n (%) Resistance n (%) 
Ceftazidime 7 (100%) 11(100%) 
Ciprofloxacin 7(100%) 11(100%) 
Piperacillin-tazobactam 7(100%) 11100%) 
Imipenem 7(100%) 11(100%) 
Meropenem 7(100%) 11(100%) 
Amikacin  3(17%) 1(6%) 
Colistin 0 0 
 p>0.05 (0.288) 
ICUs  5(28%)! 9(50%)! 
Non-ICUs 2 (11%) 2(11%) 
 p <0.05 (0.001)!  
 p >0.05 (0.515) 
Sterile specimens 5(28%) 6(33%) 
Non-sterile specimens 2(11%) 5(28%) 
 p >0.05 (0.417) 
Monotherapy 3(17%) 5(28%) 
Combination therapy 4(22%) 6(33%) 
 p >0.05 (0.648) 
*Horizontal transfer (n=14; 7 pairs )  
**Both in one pair  4(22%) 6(33%) 
***One patient in one pair 2(11%) 2(11%) 
 p >0.05 (0.643) 
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Key: *, PFGE typing showed horizontal transfer that strains were related from no more than 268 
two patients and thus no outbreak occurred during the study period. 269 
**, among the 7 pairs of patients, 2 pairs were deceased and 3 pairs were discharged;  270 
***, one patient in each pair was deceased and other one patient was discharged. 271 
! P <0.05: the outcomes in ICU was statistically significance 28% in ICU deceased 272 
whereas 50% survived.   273 
Sterile specimen (BC, blood culture; CSF, cerebrospinal fluid);  274 
Non-sterile specimen (ETA, endotracheal aspirate; pus; CT, catheter tip);  275 
ICUs (N-ICU, neonatal intensive care unit; ICUT, intensive care unit trauma);  276 
Non-ICUs (LW, labour ward; neurosurgical ward; high care unit, surgical unit, vascular 277 
unit) 278 
 279 
Amplification result of the blaOXA-23 and blaOXA-58 genes by PCR (n=24) 280 
The blaOXA-58 gene was not detected in any of the isolates tested. The blaOXA-23 gene was detected 281 
in 18 clinical isolates, but not in 6 carbapenem sensitive Acinetobacter spp. isolates (Figure 1, A-282 
D). The majority (17 out of 18) of Acinetobacter spp. isolates carrying the carbapenemase gene 283 
exhibited high MICs (>16 µg/mL) to carbapenems (Table 2).  284 
 285 
Sequencing finding of blaOXA-23 amplicon  286 
Sequencing of the blaOXA-23-like amplicon of 18 Acinetobacter spp. isolates revealed 100 % 287 
identity with that from the GenBank database. 288 
 289 
 290 
Figure 1 A, B, C and D:   Detection of the Oxacillinase genes (blaOXA-23 and blaOXA-58 genes)  291 
in Acinetobacter spp.  in a 1.5% agarose gel following amplification by PCR. 292 
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Phenotypic resistant Acinetobacter spp. (MDR Acinetobacter spp., 18 isolates) 293 
Key:  Figure 1A: blaOXA-23 amplication product of 640 bp 294 
M, molecular weight marker (mw); lane 1, positive control (PC); lane 2, negative control 295 
(NC); lanes 3 - 11, phenotypic resistant Acinetobacter spp. (9 isolates);  296 
lanes 12-15, (four isolates were phenotypic sensitive Acinetobacter spp.)  297 
lane 16, ATCC 19606 isolate was included.  298 
 299 
      Figure 1B:  blaOXA-23 amplication product of 640 bp.  300 
      Key: M, molecular weight marker (mw); lane 1, positive control (PC);  301 
  lane 2, negative control (NC); lanes 3-6, 8, 9 and 12-14, phenotypic resistant 302 
Acinetobacter spp. (9 isolates); lanes, 10, 11 (two isolates phenotypic sensitive  303 
Acinetobacter spp.); lane 7, ATCC19606. 304 
 305 
 306 
Figure 1C: blaOXA-58 amplication product of 376 bp 307 
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Key:        Lanes 1- 7, phenotypic MDR Acinetobacter spp., lane 8, ATCC19606,  308 
      Lane 9, positive control; lane 10, molecular weight markers.  309 
 310 
Figure ID:  blaOXA-58 amplication product of 376 bp. 311 
Key: Lanes 1- 11, phenotypic MDR Acinetobacter spp. (blaOXA-58 gene was not 312 
detected) lanes 13, positive controls; lane14, negative control;  313 
Lane 15, molecular weight marker (376 bp)  314 
ATCC 19606 isolate was included.  315 
 316 
Correlation between PCR results and MICs of MDR Acinetobacter spp. (n=18) 317 
Table 2 shows the MICs of the eighteen MDR Acinetobacter spp. isolates, correlated with the 318 
presence of the CHDL genes. The blaOXA-23 gene was detected in all the isolates which were 319 
phenotypically resistant to carbapenems, with MICs of 8 to >16µg/mL for imipenem and 320 
meropenem. This gene was not detected in the four carbapenem sensitive strains tested (Figure 321 
1A). 322 
 323 
Genotypic relatedness of clinically selective Acinetobacter spp. determined by PFGE (n=24) 324 
Twenty-four out of forty-four MDR Acinetobacter spp. isolates were selected according to 325 
clinical characteristics for genotyping by PFGE. 37All isolates except for four in lanes 3, 5, 19 and 326 
25 for the strains 12, 9, 16 and 14 were successfully typed (Figure 2).  The MICs of those four 327 
isolates were different although they possessed the same antibiogram. Therefore the PFGE typing 328 
was not repeated for those four isolates. The control isolates (ATCC 19606), lane 28 (OXA-23) 329 
and lane 29 (OXA-58) showed a fingerprinting pattern different to the rest of the isolates, 330 
indicating that the technique was suitably discriminatory for the investigation of their spread 331 
(Table 4).   332 
132 
 
Two clusters consisting of two isolates each (30 and 19 in lanes 13 and 15) and (24 and 25 in 333 
lanes 9 and 10) were indistinguishable and identified as horizontal transfer between each pair 334 
(Table 4; Figure 2). According to the Tenover criteria36, isolates that demonstrate no band 335 
differences are regarded as indistinguishable, and 2-3 band differences are closely related, and 336 
are therefore, most likely related to each other and interpreted as horizontally transmitted. Isolates 337 
with 4-6 band differences are possibly related. The interpretation of PFGE typing results 338 
according to the Tenover criteria are shown in Table 4. Based on this interpretation, MDR 339 
Acinetobacter spp. were most likely horizontally transferred among seven pairs of patients: six 340 
pairs in ICUs and one pair in the vascular unit (VU).  341 
 342 
Figure 2: Pulsed field gel electrophoresis results of the OXA-23 producing Acinetobacter spp.  343 
Key:     Lane 27: ATCC 19606; Lane 28: OXA-23, lane 29: OXA-58 strains controls; lanes 344 
2-15 and lanes 17-26, Acinetobacter spp. (n=24 isolates); lane 16, Salmonella 345 
Braenderup (H9812) used for the DNA ladder.  346 
 347 
 348 
 349 
 350 
 351 
 352 
 353 
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Table 4: PFGE typing interpretation (n=24) 354 
No. of 
pairs 
(patients) 
Typical no. 
of fragment 
differences 
(pulsotypes) 
Admission 
Date 
Specimens  Wards  Epidemiologic 
interpretation 
/Comments * 
1 0 Within a week BC-CSF,  ICU2A-ICU2 B Indistinguishable  
horizontal transfer 
1 0 Same date CSF-ETA ICU2A Indistinguishable  
horizontal transfer 
1 1 Within a week BC- BC ICU2B- NICU Closely related  
horizontal transfer 
2 2 Same date BC- CVPtip  
CSF-Pus  
ICU2A x 2** Closely related  
horizontal transfer 
1 2 Same date ETA-Pus ICUT Closely related  
horizontal transfer 
1 3 Within a week ETA-ETA VU Closely related  
horizontal transfer 
4 5 Within a week CVPtip-
CSF 
CVPtip-BC 
CVPtip-Pus 
CVPtip-
ETA   
ICU2A x 4** Possible related  
4 6 Within a week BC-Pus 
BC-ETA 
ICU2A-ICUT 
ICU2A-VU x 2** 
ICU2B-NICU 
Possible related  
7 ≥7 >one week ETA-ETA 
ETA-CSF 
ETA-Pus 
CSF-Pus 
ICU2A- NICU 
ICU2A-VU x 4** 
VU-VU,  
VU-ICUT 
Unrelated  
Key:  PFGE typing interpretation according to Tenover criteria36 355 
          * One pair (2 patients) (horizontal transfer between 2 patients/one pair);  356 
** pairs; 2 pairs of patients in ICU2A and horizontal transfer in each pair, possible related 357 
in each pair x 4 pairs in ICU2A, possible related in each pair x 2pairs in ICU2A and VU, 358 
unrelated in each pair x 4 pairs; VU, vascular unit; BC, Blood culture;  359 
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CSF, Cerebrospinal fluid, ETA, Endotracheal aspirate; CVP tip, Central venous pressure 360 
line tip. 361 
 362 
 363 
Correlation between clinical characteristics and laboratory results (n= 44) 364 
Of the forty-four stored MDR Acinetobacter spp. isolates, thirty-eight (86%) and forty-four 365 
(100%) were sensitive to amikacin and colistin respectively (Table 5). The MICs of both 366 
imipenem and meropenem against OXA-23 carrying Acinetobacter spp. were high (8 to 367 
>16µg/mL) (Table 2). The clinical characteristics and outcomes of patients with Acinetobacter 368 
spp. producing blaOXA-23 gene are shown in Table 3. Fourteen (78%) of the eighteen strains 369 
showed identical antibiograms sensitive to amikacin and colistin. Four (22%) showed the same 370 
phenotypic antibiogram and were only sensitive to colistin, therefore defined as XDR. The 371 
fourteen (78%) colstin and amikacin sensitive isolates were obtained from patients in ICUs and 372 
the remaining four (22%) from non-ICUs. 373 
Eleven (61%) of the eighteen OXA-23 carrying MDR Acinetobacter spp. cultured were from 374 
sterile sites, namely blood cultures and CSF, while seven (39%) were from non-sterile sites such 375 
as ETA, pus, catheterised urine and catheter tip. 376 
Eight (45%) patients were treated with monotherapy and ten (55%) with combination therapy. 377 
Eleven patients (61%) were discharged. The seven (39%) patients who demised were mostly 378 
admitted at ICUs among the patients with OXA-23-carrying Acinetobacter spp. (Table 3). Of the 379 
seven pairs of patients from whom the horizontally transferred strains were cultured from ICUs 380 
(six pairs) and the vascular unit (one pair), both in two pairs demised and three pairs were 381 
discharged. Of the remaining two pairs of patients, one of pair demised and one of other pair was 382 
discharged (Table 3). 383 
 384 
The results clearly indicate there are several pulsotypes of Acinetobacter spp. within wards 385 
studied at IALCH (Table 4). There were four distinct pulsotypes identified suggestive of 386 
horizontal transfer of organisms among the ICUs: (NICU, ICU2A and ICU2B), (ICUT and 387 
ICU2A and within ICU2A itself) and between the ICU2A and the non- ICU (Vascular unit) ward. 388 
There were several isolates which were unrelated to the four main pulsotypes. No conclusion 389 
could be made regarding how they were acquired in the patients. However, the PFGE typing 390 
showed diversity in these collection of MDR Acinetobacter spp. clones, where isolates were 391 
related from no more than two patients. Therefore it is likely that no outbreak had occurred. 392 
 393 
 394 
135 
 
Table 5: MICs of appropriate antibiotics (n=44) 395 
                            MICs   µl/mL 
No. of 
isolates  
(n=44) 
TZP AK CAZ   CIP IMP MEM CST Specimen Ward 
21 >128 16 64 >4 >16 >16 <0.5 BC ICU 2A ,2B 
3* >128 >64 64 >4 >16 >16 <0.5 ETA ICU2A 
3 >128 8 64 >4 >16 >16 <0.5 BC ICU2B 
2 >128 8 16 >4 >16 >16 <0.5 TIP ICU2B 
1 >128 4 8 >4 >16 >16 <0.5 BC ICU2B 
1 >128 8 8 2 >16 >16 <0.5 ETA ICU2A 
1 >128 16 64 >4 8 >16 <0.5 ETA ICU2A 
2 >128 <2 64 >4 >16 >16 <0.5 PDF ICUT 
1 >128 8 8 >4 >16 >16 <0.5 PUS ICUT 
1 >128 16 64 >4 8 >16 1 URINE ICUT 
1* >128 64 64 >4 8 >16 1 PUS Non-ICU 
2 >128 8 32 >4 >16 >16 <0.5 CSF Non-ICU 
2* >128 64 64 >4 >16 >16 <0.5 BC Non-ICU 
1 >128 16 2 >4 8 >16 <0.5 PF Non-ICU 
1 >128 16 8 <0.25 >16 >16 <0.5 ETA Non-ICU 
1 >128 4 64 >4 >16 >16 <0.5 FLUID Non-ICU 
 396 
Key: TZP, piperacillin-tazobactam; AK, amikacin; CAZ, ceftazidime; CIP, ciprofloxacin;  397 
IMP, imipenem; MEM, meropenem; CST, colistin 398 
*, XDR-Acinetobacter spp. (resistant to all except colistin);  399 
Non-ICUs (high care unit, vascular unit, labour ward, neurosurgery unit,  400 
Orthopedic unit) 401 
 402 
 403 
Discussion 404 
All tested Acinetobacter spp.  (n=44) were MDR, defined in the current study as resistant to three 405 
or more classes of drugs or carbapenem,27 and inclusive of XDR, defined as MDR Acinetobacter 406 
spp. resistant to all agents except colistin. Previous studies confirmed that Acinetobacter spp. are 407 
resistant to many antibiotics 2-4, 12, 13, 38 and susceptibility tests revealed that the strains displayed 408 
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the colistin-only-sensitive (COS) profile. Multidrug-resistance of Acinetobacter spp. is a major 409 
challenge and treatment options for these infections are limited.  410 
This study has demonstrated that carbapenem drugs are no longer active against selected MDR 411 
Acinetobacter spp. at local setting. The data revealed isolates with high susceptibility to amikacin 412 
(86%) and colistin (100%) among the forty-four tested MDR Acinetobacter spp. isolates. 413 
Therefore, these agents are the mainstay, last resort antibiotics for MDR Acinetobacter spp. in the 414 
local setting. In this current situation, there are no standardised guidelines for the management 415 
for MDR- and XDR- Acinetobacter spp. infection.  416 
Acinetobacter spp. isolates with the same sensitivity pattern in the antibiograms were selected for 417 
molecular investigation, namely four XDR and fourteen MDR isolates.  BlaOXA-23 encoded- 418 
OXA-23-carbapenemase was detected in MDR and XDR but not sensitive Acinetobacter spp. at 419 
intensive care units in an academic complex.  420 
The blaOXA-23 gene is believed to be responsible for the mechanism of carbapenem antibiotic 421 
resistance in Acinetobacter spp.39 The OXA-23 gene of carbapenem resistant Acinetobacter spp. 422 
was first reported in 1985 in Scotland40 and subsequent outbreaks of OXA-23-producing A. 423 
baumannii occurred in various locations around the world. 39, 40  424 
MDR Acinetobacter spp. represents a high-risk global and local infection control challenge.40 In 425 
one study, the gene encoding OXA-23 was found in plasmids, facilitating its spread among 426 
Acinetobacter species.14 In this study, the spread of blaOXA-23 carrying Acinetobacter spp. was 427 
demonstrated by PFGE typing. These findings suggest horizontal transfer between the pairs of 428 
patients in ICUs and the vascular unit (Table 4). Moreover, it should be noted that an isolate in 429 
the neurology ward adjacent to the ICU unit showed possible relatedness. Thus, it is possible that 430 
the establishment of clones in different wards does not account for clonal transmission in 431 
hospitals. 432 
The OXA-23 producing MDR Acinetobacter spp. isolates were cultured from both sterile and 433 
non-sterile clinical specimens, hence the recommendation for aseptic handling of specimen 434 
collection. In addition, hand washing practices need to be audited due to this investigation 435 
confirming the dramatic rise of multiple clones with blaOXA-23 producing MDR Acinetobacter spp. 436 
in the local setting. Awareness of the development and existence of drug resistant organisms plays 437 
a crucial role in optimising infection control practices, establishing antimicrobial stewardship 438 
programs, and establishing active regional surveillance systems. This study also showed a 439 
correlation between the MDR phenotype and genes related to carbapenem resistance. MDR 440 
Acinetobacter spp. with resistant MICs to either of the carbapenem agents may be associated with 441 
isolates producing the plasmid-mediated or chromosome-mediated gene encoding blaOXA-23.  442 
 443 
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During this study time, the antibiograms of all these isolates were phenotypically identical for 444 
more than three strains in ICUs. However, the PFGE typing demonstrated a diversity in the MDR 445 
Acinetobacter spp. clones, which suggests that isolates were related from not more than two 446 
patients per cluster, and therefore, no outbreak had occurred based on the PFGE typing 447 
interpretation. Therefore, isolates with the same antibiogram nevertheless need to be typed 448 
genotypically, and as a minimum, their MIC values should be checked.  449 
 450 
According to data analysis of clinical characteristics, patient outcomes and laboratory data, the 451 
clinical outcomes had no association with the following factors: resistance patterns of 452 
Acinetobacter spp. cultured, ICU versus non-ICU wards, sterile sites versus non-sterile sites, and 453 
monotherapy versus combination therapy. There was no statistical significance (p >0.05) in each 454 
analysis (Table 3). This may be due to the small sample size, which is the main limitation of our 455 
study. The selected small representative strains were subjected to molecular methods of analysis 456 
due to the financial limitation and lack of facilities at the molecular laboratory in the local setting. 457 
Continuous surveillance of antibiotic resistance genes in MDR Acinetobacter spp. is crucial for 458 
epidemiological purposes and to prevent further dissemination of these genes. In addition, it is 459 
necessary to monitor the clinical prevalence and spread of antibiotic resistance genes associated 460 
with Acinetobacter spp. Future research should include the detection of other resistance genes, as 461 
well as determining the genetic relatedness of Acinetobacter spp. isolates in other hospitals in 462 
KZN. 463 
In conclusion, this study discovered that the main carbapenem resistance mechanism of 464 
Acinetobacter spp. was due to OXA-23 carbapenemase activity. Although the isolates were 465 
spread in ICUs and other ICU related units, there did not seem to be an outbreak according to the 466 
demographic clinical data, MICs and PFGE typing (Table 4). 467 
This is the first report on epidemiological and molecular observations of Acinetobacter spp. with 468 
the detection of the blaOXA-23 gene in MDR Acinetobacter species. Molecular typing of the 469 
selected isolates showed that MDR Acinetobacter species carried the blaOXA-23 gene responsible 470 
for resistance to carbapenems (MICs 8 to >16 µg/mL). The outcomes provided support for a local 471 
infection prevention and control management guidelines as part of the antibiotic stewardship 472 
programme. Continued molecular surveillance of local epidemiological information and 473 
antibiotic resistance surveillance are crucial for infection prevention and control and also for an 474 
essential part of standard management at the hospital. 475 
 476 
 477 
 478 
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Abstract       36 
Introduction: Drug resistant Acinetobacter species (Acinetobacter spp.) presents a serious 37 
therapeutic and infection control policy challenge globally. This study investigated the 38 
relationship between the minimum inhibitory concentrations (MICs) of standard drugs against 39 
Acinetobacter spp. and genes associated with colistin and amikacin resistance. The association 40 
between drug resistance and clinical outcomes of patients with Acinetobacter spp. in a central 41 
academic hospital was also determined.  42 
Method: Case information from 107 patients cultured with Acinetobacter spp. was recorded 43 
during clinical wards rounds, including clinical outcomes, history of antibiotics prescribed and 44 
microbiological investigations. The 107 Acinetobacter spp. isolates were investigated for 45 
susceptibility to antimicrobial agents in use at local hospitals. Resistant genes related to colistin 46 
(IpxA) and amikacin (aphA6) were investigated by polymerase chain reaction (PCR) and 47 
sequencing. Analysis was performed on the relationship between clinical outcomes and 48 
antimicrobial resistant patterns, as well as on the MICs of amikacin (n=6) and colistin (n=6) in 49 
resistant isolates versus their PCR results. 50 
Results: Amikacin and colistin resistance were observed in six isolates each. All six amikacin 51 
resistant isolates were extensively drug resistant (XDR). The MICs were >16 µg/mL for the six 52 
colistin resistant isolates and 32 and ≥64 µg/mL for the amikacin resistant isolates. The IpxA gene 53 
was absent in colistin resistant isolates and correlated with high MICs. The aphA6 gene was 54 
detected in all amikacin resistant isolates. While the majority (63%) of cases were discharged, 55 
mortality rates were high (21.5%). No underlying clinical factors were significantly associated 56 
with clinical outcome. 57 
Conclusion:  Colistin resistance may be associated with the absence of the IpxA gene and is 58 
not a surrogate marker for MDR Acinetobacter species. The emergence of colistin resistance is 59 
of serious concern, highlighting the urgency for standardised guidelines for the treatment and 60 
management of Acinetobacter species. 61 
  62 
Key words: molecular characterisation, IpxA gene, aphA6 gene, phenotypic antibiogram,  63 
  clinical outcome 64 
 65 
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Introduction   69 
Acinetobacter species (Acinetobacter spp.) have emerged as major hospital-associated pathogen, 70 
which have developed into multidrug-resistant (MDR) and extensively drug-resistant (XDR) 71 
isolates in the past decade.1  Acinetobacter spp. have the capacity to acquire resistance to 72 
antimicrobial agents through genetic factors, such as plasmids and pathogenicity islands,2 73 
resulting in resistant strains that are difficult to treat.3 Therefore, the Infectious Diseases Society 74 
of America (IDSA) has included Acinetobacter spp. among six antimicrobial-resistant pathogens 75 
responsible for high morbidity and mortality.3,4 76 
Although Acinetobacter spp. are common coloniser that may lead to community-acquired 77 
infection, also an opportunistic pathogen often found in immunocompromised patients with 78 
prolonged hospitalisation.5 Immunosuppressive therapy places cancer patients at risk of 79 
developing Acinetobacter spp. infections which may result in sepsis, respiratory infections, 80 
wound infections and urinary tract infections. 3, 6-8   81 
Extensively drug- resistant (XDR) Acinetobacter spp. are defined as being resistant to all the 82 
tested antimicrobials, except for colistin, while pandrug-resistant (PDR) isolates are resistant to 83 
all agents.9 A rise in infections from XDR Acinetobacter spp. has been reported. 10,11. The global 84 
rise of multidrug-resistant (MDR) Acinetobacter spp. and the emergence of XDR and PDR 85 
Acinetobacter spp. therefore poses a major challenge to current treatment options and infection 86 
control.12,13 87 
Until recently, amikacin was the most active aminoglycoside in the treatment of infections caused 88 
by Acinetobacter spp., especially in our local academic complex hospitals.  They remain the drugs 89 
of choice for treatment of MDR Acinetobacter infections, yet resistance has increased in recent 90 
years.14  91 
Acinetobacter spp. have several mechanisms of aminoglycoside resistance.15,16 In general, the 92 
major mechanism in Gram-negative bacteria is enzymatic modification of the amino or hydrolol 93 
groups of the agent through aminoglycoside modifying enzymes (AMEs), most commonly 94 
acetyltransferases (AAC), nucleotidyl transferases (ANT) and phosphotransferases (APH). The 95 
enzymes alter the amino and hydroxyl groups of the agent, resulting in reduced binding to the 96 
ribosome. 15-17 AACs and APHs produce high levels of resistance. Amikacin resistance in 97 
Acinetobacter spp. is facilitated by APH (3’)-VI, corresponding with the aphA6 gene.14, 17 In 98 
addition, the aacA4 gene, which encodes AAC (6’)-Ib, confers resistance of amikacin, netilmicin, 99 
and tobramycin, 15 while aadB is associated with resistance of kanamycin, gentamicin and 100 
tobramycin.14 101 
 102 
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Therapeutic agents for XDR Acinetobacter spp. infection often include colistin methansulfonate 103 
(CMS), a bactericidal agent used as a last resort.14 However, there has been an increased use of 104 
colistin for treating MDR infections, leading to the emergence of colistin resistance.18-23 105 
Colistin interacts with the lipid A components of lipopolysaccharide (LPS), disrupting the outer 106 
membrane of Gram-negative bacteria.18 Colistin resistance in Acinetobacter spp. is mediated by 107 
a range of mutations affecting the structure and production of LPS. Colistin resistance in 108 
Acinetobacter spp. is mediated by a range of mutations affecting the structure and production of 109 
LPS. Mutations in the lpxA, lpxC and lpxD genes result in loss of LPS production. Mutations in 110 
the pmrA and pmrB genes of the two-component regulatory system, as well as in the pmrC gene 111 
coding for a lipid A phosphoethanolamine transferase, result in the modification of LPS.18-23 112 
Fortunately, the local data showed that amikacin sensitivity was high (59% to 90%), and 99% of 113 
Acinetobacter spp. were still sensitive to colistin during the period 2008 to 2014. These two drugs 114 
are commonly used in our local academic complex hospital due to the increasing prevalence of 115 
MDR and XDR Acinetobacter species.  116 
Despite the possible future risk, data in local academic complex hospital is scarce regarding the 117 
clinical, microbiological and molecular characteristics of Acinetobacter spp., including resistance 118 
mechanisms of amikacin and colistin-resistant infections. Such information will facilitate a better 119 
understanding of the pathogen, in order to formulate guidelines for a standardised approach to 120 
management.  121 
 122 
This study aims to characterise Acinetobacter spp. isolates at academic complex central hospital 123 
in Durban, South Africa: by i) evaluating their susceptibility to colistin and amikacin and 124 
determining the minimum inhibitory concentrations (MICs); and ii) comparing the clinical 125 
outcomes of infected patients with phenotypic and genotypic characteristics of XDR and colistin 126 
resistant Acinetobacter species. 127 
 128 
 129 
Methods 130 
The study received ethical approval from the Biomedical Research Ethics Committee, College  131 
of Health Sciences, University of KwaZulu-Natal (Reference No BE 283/12). 132 
 133 
Patients and bacterial isolates 134 
Non duplicate Acinetobacter spp. isolates (n=60) were selected and stored from the specimens of 135 
107 patients at Inkosi Albert Luthuli Central Hospital (IALCH) from 2013 to 2014.  136 
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107 patients were included for the analysis of clinical outcomes and antimicrobial resistant 137 
patterns: Information, including clinical outcomes, prescribed antibiotic history and 138 
microbiological results of 107 patients cultured with Acinetobacter spp. were recorded during 139 
clinical wards rounds. The 107 Acinetobacter spp. were analysed for the susceptibility to 140 
antimicrobial agents in use at local hospitals. The association of the clinical outcomes versus 141 
antimicrobial resistant patterns of the isolates from the 107 patients was analysed. These isolates 142 
were identified and tested for resistance to antimicrobial agents in use at local hospitals for routine 143 
management.  144 
Amikacin and colistin-resistant Acinetobacter spp. were stored for further phenotypic and 145 
genotypic characterisation, at the Microbiology Laboratory, National Health Laboratory Service 146 
(NHLS), Durban.  147 
Based on the antibiogram of the isolates from the 107 patients and MICs of 60 isolates, the six 148 
colistin resistant, another six amikacin resistant and seventeen susceptible isolates were identified. 149 
The presence of the genes related to colistin (IpxA), amikacin (aphA6) and (aacA4) resistance 150 
were further investigated by using polymerase chain reaction (PCR). The MICs of amikacin (n=6) 151 
and colistin (n=6) were compared to the PCR results of these resistant isolates. 152 
The IpxA gene detected isolates, as well as the aphA6 gene detected isolates were sequenced. 153 
 154 
Susceptibility Testing 155 
Susceptibility testing was performed using the Vitek 2 automated system (BioMérieux, France) 156 
with the VITEK® 2 GN ID card and the VITEK®2 AST-N255 card. The MICs of the appropriate 157 
antimicrobial agents in use were determined for sixty Acinetobacter spp. isolates using the 158 
Epsilometer test (E-test®) (BioMérieux, France). The MIC90 and MIC50 were determined for each 159 
tested antibiotic agent against the sixty isolates. The antibiotics included amikacin, cabapenems 160 
(imipenem, meropenem), ceftazidime, ciprofloxacin, colistin and piperacillin-tazobactam. 161 
Acinetobacter ATCC 19606 was used as the quality control strain. The results were interpreted 162 
according to the Clinical and Laboratory Standards Institute.24 MIC >32 μg/mL for amikacin and 163 
>0.5 μg/mL for colistin were considered to be resistant.24 164 
 165 
Molecular methods (PCR and Sequencing)  166 
Genomic DNA, from each of twenty-seven isolates, comprising six clinical colistin resistance 167 
strains, six amikacin resistance strains, three controls and twelve sensitive clinical isolates, was 168 
extracted from an overnight culture using a loopful of colonies suspended in 500 µL of 1x TE 169 
buffer (Tris EDTA) (10 mM Tris hydrochloride-1 mM EDTA (pH 8.0), (Capital Laboratory 170 
Supplies, Durban, South Africa). Cell lysis and protein digestion were performed using a 171 
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combination of 10% Sodium Dodecyl Sulfate and 10 mg/mL (1%) proteinase K (Capital 172 
Laboratory Supplies, Durban, South Africa). Proteins were precipitated with 10% Cetyltrimethyl 173 
ammonium bromide (CTAB)/4% NaCl and polysaccharides were extracted by the addition of 174 
24:1 chloroform-isoamyl alcohol (Capital Laboratory Supplies, Durban, South Africa). The DNA 175 
was precipitated with isopropanol, washed with 70% cold ethanol (Capital Laboratory Supplies, 176 
Durban, South Africa) and dissolved in an appropriate volume of 1xTE buffer. The DNA was 177 
electrophoresed in a 1% agarose gel (Capital Laboratory Supplies, Durban, South Africa) to 178 
determine quality and quantity. The extracted genomic DNA was stored at -20°C.25, 26 (Defy Ltd, 179 
Multimode, SA) until further analysis. 180 
 181 
PCR to detect the IpxA gene was performed on six colistin resistant and seventeen colistin 182 
susceptible Acinetobacter spp. isolates. The amikacin resistant genes aphA6 and aacA4 were also 183 
investigated on twelve isolates (including controls). PCR was performed using primer sets shown 184 
in Table 1 and Taq DNA polymerase (ThermoFisher Scientific, USA). The thermal cycling 185 
conditions were set for initial denaturation at 5 min at 95°C followed by 40 cycles of 20 s at 95°C, 186 
1 min at 55°C and 30s at 72°C. This was followed by a final extension step of 5min at 72°C. A 187 
negative template free control and an ATCC19606 control were included.  Amplification was 188 
repeated at least twice for strains with negative PCR results. The expected PCR product sizes  of 189 
1179 bp for IpxA, 797 bp for aphA6 and 489 bp for aacA4 were detected on a 1.5% agarose gel 190 
(Capital Laboratory Supplies, Durban, South Africa). 191 
Mutations in the amplified genes were determined by purification of amplicons with Shrimp 192 
Alkaline Phosphatase and exonuclease 1 as per manufacturer’s instructions followed by 193 
sequencing using the ABI Big Dye Terminator v 3.1 Cycle Sequencing kit (Applied Biosystems, 194 
USA) in an ABI 3500 Genetic Analyser (ThermoFisher Scientific, Waltham, Massachusetts). 195 
Sequences were analysed, aligned and compared using the Basic Local Alignment Searching Tool 196 
(BLAST). http://www.ncbi.nlm.nih.gov/blast/ 197 
 198 
Comparison colony morphology of colistin resistant and sensitive Acinetobacter spp.  199 
(n: 10) 200 
Six colistin resistant and four sensitive isolates were subcultured on MacConkey agar plates to 201 
examine colony morphology. Plates were inoculated with a bacterial suspension of optical density 202 
equivalent to the 0.5 McFarland standardand incubated aerobically at 37°C for 24 hrs and the 203 
colony morphology was examined. 204 
 205 
 206 
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Clinical and laboratory data collection  207 
The clinical and laboratory data of 107 patients were analysed. The data included demographics, 208 
underlying medical condition, type of specimen, exposure to antimicrobial agents before and after 209 
isolation of Acinetobacter spp. isolates, admission to intensive care units or other units and 210 
clinical outcomes. The type of infection was defined by the clinicians. Patients who did not 211 
receive specific treatment for Acinetobacter spp. were classified as colonised. Clinical response 212 
to treatment was classified as successful in patients whose infection-defining signs and symptoms 213 
resolved, and as failed for patients who deteriorated or whose signs and symptoms persisted. 214 
 215 
Statistical analysis of the data  216 
The data was captured, standardised and analysed using the Statistical Package for Social 217 
Sciences (SPSS version 19). The association between underlying conditions and outcome was 218 
analysed using the Pearson chi-square test. Logistic regression was used to test for factors 219 
associated with the survival status of patients. This analysis represents p values mentioned under 220 
“Demographic features, clinical characteristics and outcomes of all patients with infections due 221 
to Acinetobacter spp. (n=107). 222 
 223 
 224 
Results  225 
Susceptibility of Acinetobacter spp. strains (n=107) 226 
Six isolates (5.6%) that were resistant to amikacin were defined as extensively drug-resistant 227 
(XDR) based on their antibiograms. Another six (5.6%) were resistant to colistin. Eighty isolates 228 
(75%) were MDR. The rest were resistant to less than three different class tested agents and 229 
therefore not classified as MDR (Table2). Table 3 shows the antimicrobial MICs of sixty 230 
Acinetobacter species. The MIC50 and MIC90 of imipenem differed at 24 and >32 μg/mL 231 
respectively. Both MIC values were the same for ciprofloxacin and piperacillin-tazobactam, at 232 
>32 and >256 μg/mL respectively. The MIC50 and MIC90 of amikacin (8 and 16 μg/mL) and 233 
colistin (0.25 and 0.5 μg/mL) were within the sensitive range among the tested antibiotics.  234 
Among the six colistin resistant isolates, the MICs of colistin were >16 µg/mL, while among the 235 
other six amikacin resistant isolates, the MICs of amikacin  ranged between 32  and ≥ 64 µg/mL 236 
(Table 4). 237 
 238 
 239 
 240 
 241 
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Colony morphology of colistin resistant species on MacConkey plates  242 
No difference was observed in the appearance of the colonies of the resistant and susceptible 243 
strains cultured on McConkey agar plates. The strains looked like those that can be considered 244 
wild-type. 245 
 246 
Detection of the IpxA, aphA6 and aacA4 genes  247 
Six patients with colistin-resistant and six with amikacin-resistant Acinetobacter spp. were 248 
identified in the study period between 2013 and 2014 (Table 5).  249 
From the twenty-three (clinical isolates and the ATCC19606 control isolate), the IpxA gene was 250 
not detected by PCR in the six colistin resistant isolates. In contrast, the remaining seventeen 251 
isolates, phenotypically sensitive to colistin with MICs <0.5 µg/mL, harboured the IpxA gene. 252 
(Table 4, Figures 1A, 1B).    253 
PCR amplification allowed for detection of the aphA6 gene (797 bp) from the six amikacin 254 
resistant Acinetobacter spp. clinical isolates [Figure1C]. However, the aacA4 gene (489 bp) was 255 
not present in these isolates [Figure 1.D]. Sequencing of the IpxA in susceptible isolates and 256 
aphA6 amplicons revealed 100% identity with the genes specifically related to Acinetobacter spp. 257 
listed in the GenBank database. 258 
 259 
Phenotypic and genotypic analysis of the colistin resistant and amikacin resistant 260 
Acinetobacter spp. 261 
Twenty-three Acinetobacter spp. isolates comprising colistin resistant (n=6) and colistin sensitive 262 
(n=17), were characterised phenotypically and genotypically. The MICs of colistin and other 263 
drugs against these isolates are shown in Table 4.  264 
One of the six colistin resistant isolates was resistant to piperacillin-tazobactam (MIC >256 265 
µg/mL) and sensitive to the other agents. However, the remaining five isolates were sensitive to 266 
appropriate drugs, including amikacin, carbapenems (imipenem, meropenem), ceftazidime, 267 
ciprofloxacin and piperacillin-tazobactam.  268 
Correlation of antibiogram with IpxA gene  269 
From the selected strains, colistin-susceptible Acinetobacter spp. isolates (n=17) that were 270 
identified by MIC values (Table 4) also showed amplification of the IpxA gene. Fourteen [82% 271 
(17)] were resistant to meropenem and imipenem (MDR AB), and three [18%) (17)] were 272 
sensitive to only colistin (XDR AB) (Table 4).   273 
All seventeen colistin-susceptible Acinetobacter spp. isolates harboured the IpxA gene. All six 274 
colistin-resistant Acinetobacter spp. isolates showed an absence of the IpxA gene (Figure 1 A-B). 275 
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Seventeen strains out of the selected twenty-three [74% (23)] had colistin-susceptible 276 
Acinetobacter spp. isolates which correlated phenotypically and genotypically (Table 4, Table 5).  277 
Correlation of antibiogram with aphA6 and aacA4 genes  278 
The MICs of amikacin and other tested drugs are shown in Table 4.  The six amikacin resistant 279 
strains were sensitive to only colistin and thereby defined as XDR Acinetobacter spp. (Table 4, 280 
Table 5). These six strains were phenotypically resistant and showed the presence of the aphA6 281 
gene but not the aacA4 gene (Figure 1C, 1D).  282 
 283 
Demographic features, clinical characteristics and outcomes of all patients with infections 284 
due to Acinetobacter spp. (n=107) 285 
Clinical data was analysed by using simple descriptive data analysis. The demographic data of 286 
patients with Acinetobacter spp. (n=107) are shown in Table 6. More males than females were 287 
infected, at a ratio of 3:1 in children and 3:2 adults, with the predominant age group 25 to 60 288 
(Table 6). Acinetobacter spp. were more commonly isolated from adult patients in non-ICU wards 289 
and in neonates among pediatric patients. 290 
Underlying diseases 291 
Acinetobacter spp. were cultured more commonly in adults presenting with trauma and injury, 292 
and in pediatric patients with abnormal congenital organs. Trauma was predominant overall. 293 
Retroviral disease (RVD), oncology and other conditions showed little risk of colonisation and 294 
infection (Table 6). No statistically significant difference [P >0.05 (0.151)] were observed 295 
between children and adults with medical and surgical conditions and the presence of 296 
Acinetobacter spp. infections. 297 
Antibiotic usage  298 
Tazocin (piperacillin–tazobactam), ciprofloxacin and meropenem were used in the majority of 299 
cases. Colistin monotherapy and colistin combinations were not commonly used. This analysis 300 
revealed that Acinetobacter spp. isolates were treated mostly with a piperacillin-tazobactam and 301 
amikacin combination, while XDR strains were treated with colistin monotherapy or other 302 
combinations according to individual cases (Table 6). The usage of colistin, combinations and 303 
amikacin showed a significant statistical difference between adult and pediatric patients  304 
[P <0.05; (0.018)]. 305 
Clinical outcome  306 
The majority of cases, 67 (63%) of the 107, were discharged but mortality was high at 23 (21.5%) 307 
(Table 6). Clinical outcome was not significantly associated with age [P >0.05; (0.942)]. 308 
 309 
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Clinical characteristics and outcomes of patients with infections due to colistin resistant 310 
Acinetobacter spp. (n=6) 311 
The types of infection in patients harbouring colistin-resistant Acinetobacter spp. included 312 
bacteraemia and suspected line sepsis (Table 5). Five of the six isolates were cultured from blood, 313 
one from a catheter tip and all samples from patients with clinical sepsis. However, none of the 314 
patients with the colistin-resistant isolates were from the ICUs. Four patients were from labour 315 
ward and two patients had underlying cardiac disease. Five patients were discharged and one 316 
patient from the oncology unit demised after eight days in hospital (Table 4).   317 
 318 
Clinical characteristics and outcomes of patients with infections due to amikacin resistant 319 
Acinetobacter spp. (n=6) 320 
All six patients with amikacin resistant Acinetobacter spp. were hospitalised in different units for 321 
longer than two weeks (21 to 43 days) with chronic illness (Table 5). Two isolates were obtained 322 
from blood culture, three from pus swabs and one from an ETA. Two patients were treated with 323 
colistin while two received no antibiotics. Two out of the six demised while four recovered and 324 
were discharged (Table. 5).  325 
 326 
 327 
Discussion 328 
Despite Acinetobacter spp. being classified by the Infectious Diseases Society of America a 329 
decade ago as one of six most important MDR microorganisms in hospitals worldwide, 3, 4, 27 drug 330 
resistant Acinetobacter spp. still presents a serious therapeutic and infection control challenge. 331 
Increasing antimicrobial resistance among Acinetobacter isolates resulting in the evolution of 332 
XDR and PDR strains has been documented globally.12 333 
 334 
This study revealed amikacin and colistin resistant Acinetobacter spp. isolates, with six (5.6%) 335 
of 107 of the isolates being amikacin resistant and sensitive only to colistin, defined as XDR 336 
Acinetobacter species. Interestingly, the other six (5.6%) of 107 colistin-resistant strains were not 337 
PDR, i.e. resistant to all appropriate tested drugs,9 as they were sensitive to other appropriate 338 
antibiotics such as the carbapenems, ceftazidime, ciprofloxacin, amikacin and piperacillin-339 
tazobactam, with the exception of one isolate that was resistant to piperacillin-tazobactam. These 340 
findings suggest that colistin resistance, therefore, is not a surrogate marker for MDR 341 
Acinetobacter spp. and even for PDR Acinetobacter spp. The rates of colistin resistance in the 342 
current study (5.6%) are slightly higher than that of another surveillance study (5.3%), 27 while 343 
much lower than rates those of study in Asia  (28%). 28 344 
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In this study, colistin-resistant Acinetobacter spp. was found mostly in patients who had not 345 
received prior colistin therapy. In contrast, a previous study determined the distinguishing factor 346 
of colistin resistance in Acinetobacter spp. as prior drug exposure.29   This conclusion is similar to 347 
a report on colistin-resistant Acinetobacter spp. from the US military health system.20 348 
According to Moffatt et al., the complete loss of lipopolysaccharides (LPS) is responsible for 349 
polymyxin resistance in Acinetobacter species.30 Mutations in either IpxA, IpxC or IpxD were 350 
responsible for this complete loss of LPS production, resulting in high-level colistin resistance.31-351 
33 The current study revealed the complete loss of the IpxA gene that encodes the initial binding 352 
target, the lipid A component of LPS  in all colistin-resistant Acinetobacter spp. isolates, but in 353 
none of the colistin-susceptible isolates. Furthermore, sequencing revealed no polymorphisms 354 
were observed in the IpxA gene in all 17 of the colistin sensitive isolates tested.  These findings 355 
could possibly indicate a complete loss of the Lipid A motif due to the complete absence of IpxA 356 
gene that encodes the Lipid A domain. However, it is possible that the IpxA gene was not 357 
amplified due to the specifity of the primers for A. baumannii and not other Acinetobacter species. 358 
However, further research is necessary to confirm this, such as the inclusion of internal controls 359 
to exclude amplification inhibition, a second primer set to exclude mispriming, amplicon 360 
sequencing to detect for mutations in the pmrA and pmrB genes, whole genome sequencing and 361 
southern hybridisation. In addition, future research is essential to understand the mechanism by 362 
which the gene is lost. 363 
 364 
The findings in this study also provides motivation for implementing enhanced infection control 365 
measures in patients colonised and infected with polymyxin resistant Acinetobacter spp., with the 366 
view of preventing its continued spread.  367 
 368 
In this local setting, amikacin is commonly used with piperacillin-tazobactam as a second line 369 
treatment option in general antibiotic policy. Fortunately, 101 (94%) of 107 Acinetobacter spp. 370 
isolates were highly sensitive to amikacin. In the past, aminoglycosides have played a crucial role 371 
in the treatment of MDR Acinetobacter spp. However, recent reports indicated that Acinetobacter 372 
isolates are developing resistance to aminoglycosides around the globe.33 Modifying enzymes 373 
such as acetyl transferases, phosphotransferases, and adenylyl transferases result in inactivation 374 
of aminoglycosides, leading to resistance,14 and a range of resistance genes have emerged in 375 
recent times.33 The current study showed that amikacin resistant Acinetobacter spp. isolates carry 376 
the aphA6 gene but not the aacA4 gene in the local academic complex hospitals in KwaZulu-377 
Natal, South Africa. The prevalence at 5.6% was significantly lower in the local setting compared 378 
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to the study in Korea, according to the KONSAR Study 2009, where amikacin-resistant 379 
Acinetobacter spp. increased to 48%.33 380 
Our data analysis identified a potential emerging challenge to treatment and clinical management 381 
that was elucidated by phenotypic and genotypic characterisation of Acinetobacter species. Due 382 
to the MIC50 and MIC90 of imipenem, ciprofloxacin, ceftazidime and piperacillin-tazobactam 383 
were within the highly resistant range, while the MIC50 and MIC90 of amikacin and colistin were 384 
within the sensitive range among the tested isolates (Table 3), this study highlights the crucial 385 
role of amikacin and colistin usage standardly. 386 
 387 
Therapy for MDR Acinetobacter spp. infection usually requires the use of other appropriate drugs 388 
based on the local antibiogram or individualised microbiological results. Acinetobacter spp. 389 
isolates were mostly treated with piperacillin-tazobactam plus amikacin, while XDR 390 
Acinetobacter spp. were treated with colistin monotherapy or combinations according to the 391 
individual case. However, there was no standard criteria and guideline for colistin therapy during 392 
the study period.    393 
 394 
Previous studies have reported MDR Acinetobacter spp.-associated sepsis as more common in 395 
ICU patients.1, 34, 35 Acinetobacter spp. in our study showed that the isolates were more common 396 
in both non-ICUs wards and, among ICU patients, were associated more with trauma cases. The 397 
prevalence was significantly lower in our study than in the literature.33 All isolates were cultured 398 
from the specimens after 21 to 43 days of hospitalisation and prior to amikacin exposure.  399 
 400 
Acinetobacter spp. were most prevalent in patients aged 25 to 60 in wards commonly including 401 
non-ICU, trauma and post-op pediatric units. Trauma cases were predominant overall, since 402 
Acinetobacter spp. is part of the skin flora and an environmentally acquired organism. Moreover, 403 
in this study, retroviral disease, oncology and other clinical conditions were not prone to 404 
colonisation and infection in the local academic hospital, possibly because infection prevention 405 
control measures are enhanced in all high care units.    406 
 407 
The majority of the 107 patients were treated with antibiotics such as piperacillin-tazobactam, 408 
amikacin, ciprofloxacin and meropenem as per generalised local protocol. There was no standard 409 
criteria and guidelines for colistin therapy during study period. However, colistin monotherapy, 410 
drug combinations and amikacin with tazocin combination, were used significantly more in adult 411 
patients than pediatric patients [p <0.05; (0.018)]. XDR Acinetobacter spp. isolates were treated 412 
with colistin monotherapy or combinations according to the individual case, based on consultation 413 
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between the clinician and microbiologist. Our study highlighted that colistin is a key therapeutic 414 
option for the treatment of XDR Acinetobacter species. In addition, colistin-resistant 415 
Acinetobacter spp. is not necessarily MDR- or PDR-Acinetobacter spp. in our clinical setting. 416 
While the majority of cases, 67/107 (63%) resulted in discharge, the high mortality rates 417 
23/107(21.5%) are a serious cause for concern and interventions are urgently required to reduce 418 
this. According to the patient data, the usage of antibiotics should be standardised with appropriate 419 
guidelines that should be implemented as an antibiotic guideline policy for Acinetobacter spp. 420 
infections.  421 
 422 
Colistin-resistant Acinetobacter spp. isolates were sensitive to other appropriate antibiotics from 423 
the academic hospital, suggesting that colistin resistance is not a surrogate marker for MDR 424 
Acinetobacter species. However, the emergence of colistin resistance in Acinetobacter spp. 425 
isolates in our local setting is of great concern and highlights the urgent need for standardised 426 
antibiotic guidelines, including colistin usage and antibiotic combinations specifically for the 427 
management of patients with MDR-, XDR-, and PDR-Acinetobacter spp. at academic complex 428 
hospitals in Durban and the wider KwaZulu-Natal. In another interesting observation, colistin 429 
resistant strains were sensitive to other appropriate antibiotics and colistin-resistant Acinetobacter 430 
spp. occurred mostly among patients who had not received previous colistin therapy. It is possible 431 
as these isolates were contracted from the hospital environment as wild-type. Four out of six 432 
isolates were isolated from the blood culture specimens of sepsis patients. This finding highlights 433 
the need to enhance infection prevention and control measures.  434 
 435 
As far as we are aware, this study is the first to describe detailed clinical and molecular 436 
characteristics of colistin- and amikacin-resistant Acinetobacter spp. at local academic complex 437 
hospitals in KwaZulu-Natal. Molecular analysis suggested a potential mechanism of colistin 438 
resistance may be associated with absence of the IpxA gene (requires confirmation) and for 439 
amikacin to be the presence of the aphA6 gene. However, additional molecular methods 440 
(Southern blotting and genome sequencing) to test the veracity of our IpxA findings, will be 441 
planned for the near future, as funding is not available to perform this within the scope of the 442 
PhD. 443 
The underlying clinical diseases were not significantly associated with clinical outcome in 444 
Acinetobacter spp. infections.  445 
Molecular epidemiological studies are required when investigating transmission dynamics, which 446 
will in turn inform intervention strategies to prevent spread of drug resistant strains. Further 447 
studies should also focus on the best use of colistin to minimise the risk of developing increased 448 
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resistance. There is a need for continuous surveillance of antibiotic resistance genes and their 449 
association with antibiotic resistance profiles. Infection prevention and control should also aim to 450 
identify reservoirs and sources of infection in an attempt to recognise and prevent further spread 451 
of MDR, XDR, and PDR Acinetobacter species.  452 
 453 
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 600 
 601 
 602 
Table 1: PCR primer sequences of IpxA, aphA6 and aacA4 Genes 603 
 604 
Primers Sequence (5’ to 3’) References 
IpxA forward ACGCCAGGATCCGGTTCATTATTCCTGTTTGCT (18)  
IpxA reverse ATTCAAGGATCCCACCTCGAGCATTGTACCA (18)  
aphA6 forward ATGGAATTGCCCAATATTATTC (36)  
aphA6 reverse TCAATTCAATTCATCAAGTTTTA  (36)  
aacA4 forward ATGACTGAGCATGACCTTGCG (36)  
aacA4 reverse TTAGGCATCACTGCGTGTTCG (36)  
 605 
 606 
 607 
 608 
 609 
 610 
 611 
 612 
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Table 2: Drug resistance patterns of Acinetobacter spp. (n= 107) 613 
Antibiotic susceptibility patterns  n= 107 (%) 
 
MDR Acinetobacter spp. 80  (75) 
XDR Acinetobacter spp. *   6  (6) 
PDR Acinetobacter spp.   0 
Amikacin resistance*   6 (6) 
Colistin resistance   6 (6) 
Resistance to < 3 tested agents (Not MDR) 15 (14) 
Total ( 80+6+6+15) 107 
 614 
Key: * same Acinetobacter spp.  615 
MDR Acinetobacter spp.: multidrug resistant Acinetobacter spp.;  616 
XDR Acinetobacter spp.: extensively drug resistantly Acinetobacter spp.;  617 
PDR Acinetobacter spp.: Pandrug resistant Acinetobacter spp.  618 
 619 
 620 
Tabe 3:  MIC50 and MIC90 value of the Acinetobacter spp. (n= 60)  621 
 n=60 MICs (CLSI) 
Antibiotics  MIC50 MIC90 Sensitive  Resistant  
 µg/mL µg/mL µg/mL µg/mL 
CST 0.25 0.5 <0.5 >0.5   
IMP 24 >32 <1 >4 
MEM 24 >32 <1 >4 
TZP >256 >256 16 >32 
AK 8 16 16 >64 
CIP >32 >32 0.5 4 
CAZ >16 >16 16 >16 
 622 
Key: Antimicrobial MICs of Acinetobacter spp. isolates from clinical specimens (n= 60) 623 
CST, colistin; IMP, Imipenem; MEM, Meropenem; TZP, Piperacillin-tazobactam;  624 
AK, Amikacin; CIP, Ciprofloxacin; CAZ, Ceftazidime  625 
 626 
 627 
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Table 4:  Patients’ clinical characteristics and outcome, and MICs of other tested 628 
antibiotics against colistin and amikacin resistant and sensitive  629 
Acinetobacter spp. (n=26).  [n = no. of patients] 630 
 MIC (µg/ mL )      
Isolates IMP MEM AK TZP CAZ CIP CST Wards Specimen Days in 
hospital 
Treat with Outcome 
CST-R 0.5 0.5 <2 <4 8 <0.25 >16 LW BC 21 TZP+AK DC 
CST-R 2 4 <2 >128 16 0.5 >16 D2W BC 42 TZP+AK DC 
CST-R <0.25 <0.25 4 <4 4 <0.25 >16 LW BC 35 TZP+ AK DC 
CST-R <0.25 <0.25 <2 <4 16 <0.25 >16 Onco BC 8 MEM+VAN D 
CST-R <0.25 1 4 16 16 <0.25 >16 LW BC 22 MEM DC 
CST-R 0.5 0.5 <2 <4 8 <0.25 >16 LW CT 20 TZP+AK DC 
AK-R >16 >16 >64 >128 64 >4 <0.5 LW BC 15 TZP+AK/ 
MEM+CST 
DC 
AK-R >16 >16 >64 >128 64 >4 <0.5 ICUT PUS 23 TZP+AK D 
AK-R >16 >16 >64 >128 64 >4 <0.5 ICU2A ETA 28 CST DC 
AK-R >16 >16 32 >128 64 >4 <0.5 C4E BC 35 CST DC 
AK-R 8 >16 32 >128 64 >4 1 D1E PUS 43 None DC 
AK-R >16 >16 32 >128 64 >4 0.5 D1W PUS 29 None DC 
CST, AK-S >16 >16 16 >128 64 >4 <0.5 ICU2A CT 32 TZP+AK DC 
CST, AK-S <0.25 <0.25 <2 <4 4 <0.25 <0.5 NS ETA 32 None DC 
CST, AK-S <0.25 0.5 <2 16 8 0.5 <0.5 A4E BC 27 CST DC 
CST, AK-S <0.25 1 <2 <4 16 1 <0.5 
   
ATCC 
 
CST, AK-S >16 >16 16 >128 64 >4 <0.5 ICU2A BC 35 CST DC 
CST, AK-S >16 >16 16 >128 64 >4 <0.5 LW BC 14 None DC 
CST, AK-S >16 >16 4 >128 64 >4 <0.5 NICU FL 33 MEM DC 
CST, AK-S >16 >16 8 >128 8 >4 <0.5 ICUT PUS 25 CST +MEM DC 
CST, AK-S >16 >16 4 >128 8 >4 <0.5 BU BC 113 None DC 
CST, AK-S >16 >16 16 >128 8 <0.25 <0.5 NHC ETA 48 TZP+AK DC 
CST, AK-S >16 >16 16 >128 64 >4 <0.5 NS CSF 10 CST DC 
CST, AK-S >16 >16 8 >128 32 >4 <0.5 NS CSF 35 CST D 
CST, AK-S >16 >16 16 >128 64 >4 <0.5 ICU2B BC 37 CST D 
CST, AK-S >16 >16 16 >128 64 >4 <0.5 N-ICU BC 24 TZP+AK DC 
Key: None: No antibiotics given  631 
CST-R, colistin resistant (n= 6); AK-R, amikacin resistant (n= 6);  632 
CST, AK-S: colistin and amikacin sensitive isolate (n= 14); BC: blood culture;  633 
CT, catheter tip; WS, wound sepsis; FL, Fluid; ETA, Endotracheal aspirate;   634 
MVA, motor vehicle accident; TB, tuberculosis; RVD, retroviral disease;  635 
Non-ICU, (LW: labour ward; A4E, Rheumatology unit; C4E, high care unit;  636 
D1W, Vascular Unit (VU); D2E, Plastic unit; BMTU, bone marrow transplant unit;  637 
D2W, Surgery unit; NS, Neurosurgery);  638 
CST, colistin; AK, amikacin; MEM, meropenem; TZP, piperacillin-tazobactam;  639 
VAN, vancomycin; DC, Discharged; D, Deceased. 640 
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Table 5: Phenotypic, genotypic and clinical characteristics and outcomes of patients with 641 
colistin and amikacin resistant Acinetobacter species 642 
 643 
Key:      BC, Blood culture; CT, Catheter tip; ETA, Endotracheal aspirate;  644 
WS, wound sepsis; MVA, motor vehicle accident; TB, tuberculosis; RVD, retroviral 645 
disease; A-S, aortic stenosis; A-P, abruptio placenta; A-A, aplastic anaemia 646 
Non –ICUs [LW, labour ward; D2W, surgery unit; Onco, oncology unit; C4E, high care 647 
unit; D1E, Ortho unit ; D1W, vascular unit (VU)];  648 
R, resistannce; S, sensitive 649 
CST, colistin; AK, Amikacin; MEM, Meropenem; VAN, vancomycin;   650 
TZP, Piperacillin-tazobactam; DC, Discharged; D, Deceased   651 
 652 
 653 
 654 
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Table 6: Demographic and clinical data of patients cultured with Acinetobacter  655 
spp. (n=107) 656 
 (n=107 patients)   
 <1year (n) >1 year /paed (n) Adults (n) 
Gender/Sex-     
Male 12 6 46 
Female 5                               1 31 
NA 3 1 2 
Total  20 8 79 
Ward     
ICU pediatrics 5 1   
Pedriatric surgery 1 1   
Neonatology 14    
Pedriatric Oncology  2   
Pedriatric Medical unit  1   
Trauma  2  
NA  1 6 
ICUs adults    18 
Non-ICU   55 
Underlying disease      
RVD  5  7 
abnormal organ  10    
Respiratory Disease 2 1   
Sepsis 3    
Oncology  2 3 
Surgery   17 
Medical cases  2 20 
Injury / Trauma   3 32 
Antibiotic History     
Colistin  1  11 
Colistin + combination    1 
Amikacin (inhalation) 1 2 11 
Others ( TZP, Cip, MEM) 17 4 30 
No antibiotics given 1 2 26 
166 
 
Outcomes  <1year (n) >1 year /paed (n) Adults (n) 
Discharged [67/107 (63%)] 10 8 49 
Deceased [23/107 (21.5%)] 6  17 
NA [17/107 (16%)] 4   13 
 657 
Key: NA, Not available;  658 
TZP, piperacillin –tazobactam; Cip, ciprofloxacin; MEM, meropenem 659 
 660 
 661 
 662 
 663 
 664 
1A: PCR detection of IpxA gene  665 
Lanes 3- 17: Isolates 1-15 666 
Lanes 3, 4, 8: Colistin resistant Acinetobacter species 1, 2, and 6 (IpxA gene absence :)  667 
Lane 1: negative control (NC); Lane 18: positive control (PC) ATCC19606 668 
Lane 2: molecular weight marker (MWM);  669 
 670 
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 671 
1B: IpxA gene absence in lanes 7, 8, 9 and 10 672 
1B: PCR detection of IpxA gene  673 
Lanes 7-9: Colistin resistant Acinetobacter species isolates 46, 47 and 60 (IpxA gene absence) 674 
Lanes 1-5: Isolates 17- 21 675 
Lane 6: positive control; Lane 10: negative control; Lane 11, MWM. 676 
 677 
 678 
 679 
1C:  PCR for detection of aphA6 gene 680 
Lanes 1-4 and 7-8: Acinetobacter species resistant strains 9, 11, 15, 31, 42, 51 681 
(aphA6 gene detected);  682 
Lanes 5, 6, 9, 10: amikacin sensitive strains 8, 20, 25, and 60, 683 
(aphA6 gene bands absence);  684 
Lane 11: negative control; Lane 12: positive control; Lane 13, MWM. 685 
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 686 
1D:  aacA4 gene absence in all tested Acinetobacter species isolates  687 
Lanes 1-11, Isolates; Lane 12, positive control; Lane 13, MWM 688 
 689 
Figure 1A, 1B, IC and 1D. PCR detection of the colistin resistant IpxA, and amikacin resistant 690 
aphA6 and aacA4 genes of Acinetobacter species (n=27) (including control isolates).  691 
169 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 7:   MANAGEMENT GUIDELINE  
 
A standardised approach to the treatment and management of significant Acinetobacter 
species infection at academic complex hospitals in KwaZulu-Natal 
 
 
 
 
 
 
 
 
 
 
 
Submitted to IALCH Management and ASWP Committee  
 
170 
 
MANAGEMENT GUIDELINE  1 
 2 
A standardised approach to the treatment and management of significant Acinetobacter 3 
species infection at academic complex hospitals in KwaZulu-Natal, South Africa 4 
SUMMARY 5 
Acinetobacter species (Acinetobacter spp.) are known important nosocomial pathogen whose 6 
resistance patterns result in significant challenges for clinicians and microbiologists. Despite the 7 
prevalence of infection, there is limited scientific data to help the clinician select optimal 8 
empirical and subsequent targeted therapy. One of the problems identified in local settings was 9 
the absence of a standardised algorithm for patients with significant Acinetobacter spp. infection 10 
and a flow chart of definitions to differentiate between significant sepsis and mere colonisation. 11 
In this standard management guideline, we review the currently available antimicrobial agents 12 
and discuss local data supporting the use of various agents.  13 
According to the first one year study, multidrug resistant Acinetobacter species were found to be 14 
significant cause of sepsis at the intensive care unit of a regional hospital in Durban. Further 15 
studies determined the prevalence of Acinetobacter spp. over seven years (2008 to 2014) with 16 
analysis of clinical and microbiological criteria on isolates that assist the preauthorisation of 17 
antibiotics at the patient level for an effective antibiotic stewardship programme. The synergy 18 
effect of colistin with seven combinations against Acinetobacter spp. isolates was tested to 19 
determine the effectiveness of combination therapy. Molecular methods such as; pulsed field gel 20 
electrophoresis (PFGE) typing, polymerase chain reaction (PCR) detection, sequencing of 21 
resistant genes in Acinetobacter spp. isolates were performed. In addition, clinical data and 22 
laboratory data of 107 patients in 2013 were analysed using with clinical and microbiological 23 
criteria, as well as a review of previous antibiotic guidelines for multidrug-resistant Gram- 24 
negative bacteria (MDR GNB) and Acinetobacter species. Based on the outcomes, a flow chart 25 
of definitions for Acinetobacter spp. sepsis and colonisation was developed, as well as a 26 
standardised management algorithm for clinicians and synergy test protocol for the microbiology 27 
laboratory. This standard approach recommends individual specific antibiogram as the best 28 
approach for treatment in KZN, South Africa. 29 
A proposed standardised algorithm for treatment guideline specifically for Acinetobacter spp.   30 
Infections in academic complex hospitals in Durban, KwaZulu Natal, South Africa, is 31 
recommended and implemented.  32 
Key words:  Individual specific antibiogram approach; standardised algorithm for 33 
management; significant Acinetobacter species infections 34 
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7.1. Introduction  35 
Antibiotic resistance is a major challenge in the healthcare sector. Pathogens display changing 36 
resistance patterns while antibiotic costs are rising for management. This results in difficult 37 
decisions for clinicians selecting optimal treatment. Furthermore, if the optimal usage of 38 
antibiotics guideline are not developed and overusing and underusing of antimicrobial agents are 39 
not determined, the efficacy of antibitic usage will be compromised.  40 
  41 
In response to these challenges, the Antimicrobial Stewardship Program (ASWP) was created in 42 
2015 and firstly we need to develop a standardised algorithm for the management of patients with 43 
significant Acinetobacter species (Acinetobacter spp.) infections that is part of the urgent essential 44 
antibiotic policy in Inkosi Albert Luthuli Central Hospital (IALCH), KwaZulu-Natal, South 45 
Africa.  46 
 47 
The general guidelines were initially developed by unit specific antibiograms and have been 48 
revised and expanded annually. However, the standardised management algorithm for 49 
Acinetobacter spp. infections will be the new guideline, based on literature review, national 50 
guidelines, consensus statements and current microbiologic data from the National Health 51 
Laboratory Service (NHLS), IALCH Academic complex.  52 
 53 
Acinetobacter spp. isolate are opportunistic nosocomial pathogen and one of the six most 54 
important multidrug-resistant microorganisms in hospitals worldwide [1]. The organism leads to 55 
a range of infections, most commonly ventilator-associated pneumonia and bloodstream 56 
infections, with mortality rates reaching 35% [1]. Community-acquired infections have also been 57 
observed but few isolates have been recovered from environmental sources and infection 58 
reservoirs external to the hospital have not yet been identified [2, 3]. 59 
 60 
Acinetobacter spp., is an important pathogen whose resistance patterns result in significant 61 
treatment challenges for the clinician. Despite its increasing prevalence and improved research, 62 
there is limited scientific data to help the clinician select optimal empirical and subsequent 63 
targeted therapy for a variety of infections. We will review the available antimicrobial agents 64 
supporting the use of the various agents and discuss clinical and local data. 65 
 66 
How to use this guide 67 
Dose of antibiotics for a particular infection.  68 
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All doses in the text are for pediatric and adult patients with normal renal and hepatic 69 
function. 70 
Some important treatment notes explain why particular antibiotics were chosen and provide some 71 
important tips on diagnosis and management. 72 
Please refer to the sections on antibiotic dosing to determine the correct dose. 73 
PLEASE glance at these notes when you are treating infections, as we think the information will 74 
prove helpful. All references are on file in the office of the Antimicrobial Stewardship Program 75 
(ASWP). 76 
 77 
Contacting us 78 
Dr Khine Swe Swe-Han (draft the standard approach guideline)  79 
Approved by Prof. Koleka P Mlisana [Head of Department] 80 
 81 
Precaution: The recommendations given in this guide are meant to serve as treatment guidelines. 82 
They should NOT supplant clinical judgment or Infectious Diseases consultation when indicated. 83 
The recommendations were developed for use at the IALCH Academic complex, Durban, KZN, 84 
South Africa and thus may not be appropriate for other settings. We have attempted to verify that 85 
all information is correct. However, since research is ongoing, please contact the Microbiologists 86 
and Infectious Diseases Specialists for the latest information. 87 
Also, please note that copies of the book should not be distributed outside of the institution 88 
without permission. 89 
 90 
 91 
7.2. Inkosi Albert Luthuli Central Hospital formulary and restriction status 92 
7.2.1 Obtaining ID (Infectious diseases), approval 93 
The use of restricted and non-formulary antimicrobials requires preapproval from 94 
Microbiologists. This approval can be obtained by any of the following methods: 95 
 96 
7.2.1.1  Approval method 97 
The clinicians (consultants) sign the prescription form, providing the reason for prescription, and 98 
send the form to the specific Microbiologist in charge for signature. Then the signed prescription 99 
forms along with the microbiology result form will be sent to the pharmacy for release of the 100 
specific restricted antimicrobial agents.  101 
 102 
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7.2.2  Selected formulary antimicrobials and restriction status 103 
The following list applies and includes the appropriate antimicrobial agents for Acinetobacter 104 
species infection (Table 1). 105 
 106 
Table 1. Appropriate antimicrobial agents for Acinetobacter spp. infection 107 
 108 
Unrestricted anti- Acinetobacter spp. infection Restricted anti- Acinetobacter spp. infection 
Ceftazidime Colistin  
Piperacillin –tazobactam   
Amikacin   
Ciprofloxacin   
Imipenem   
Meropenem   
 109 
 110 
 111 
7.3 Antimicrobial agents –specific guidelines 112 
 113 
7.3.1 Appropriate for Acinetobacter spp. infections  114 
Medications to which Acinetobacter is usually sensitive include the following; 115 
Ceftazidime  116 
Piperacillin-tazobactam  117 
Amikacin  118 
Ciprofloxacin 119 
Meropenem 120 
Imipenem  121 
Colistin  122 
Minocycline  123 
Tigecycline  124 
 125 
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In general, first-, second-, and third-generation cephalosporins, macrolides, and penicillins have 126 
little or no anti-Acinetobacter activity, and their use may predispose to Acinetobacter colonisation 127 
[4]. Monotherapy for nebuliser medication and combination therapy has been used successfully 128 
[(e.g. amikacin), and minocycline, or colistin ± rifampincin)] [5] with synergy tests on individual 129 
isolates [6]. 130 
 131 
7.3.2 Antibiotics 132 
7.3.2.1. Colistin  133 
Colistin is a polymixin antibiotic. It has in vitro activity against Acinetobacter spp. and 134 
Pseudomonas spp. but does NOT have activity against Proteus, Serratia, Providercia, 135 
Burkholderia, Stenotrophomonas, Gram-negative cocci, Gram-positive organisms, or anaerobes. 136 
 137 
Acceptable uses 138 
Management of infections due to MDR Acinetobacter and Pseudomonas is on a case by case 139 
basis. 140 
Unacceptable uses 141 
Monotherapy for empirical treatment of suspected Gram negative infections. 142 
 143 
Dose 144 
 Renal function and dialysis (see Table 2.  For dose adjustment recommendation). 145 
 146 
Toxicity 147 
 Neurotoxicity & renal toxicity  148 
 149 
Colistin methanesulfonate (CMS) dosages and dosing interval terminology:  150 
1 Vial = 1 MU = 80 mg CMS= 30 mg colistin base 151 
 152 
Colistin dosing instructions: 153 
• Reconstitute each vial with 5 mL 0.9% sodium chloride (normal saline), further dilute 154 
to 100 mL for loading dosage and 50 mL for maintenance 155 
Dosage: 156 
• Infuse loading dose over 60 minutes. 157 
• Infuse maintenance dose over 15 to 30 minutes. 158 
• Must be given with a second agent (either rifampicin or a carbapenem) – never on its own. 159 
 160 
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Additional comments: 161 
• Very nephrotoxic. 162 
• Need blood results to apply for a Section 21 approval – Very important!! 163 
• Store below 25°C. 164 
• Cannot be stored once mixed – therefore discard any unused portion 165 
 166 
 167 
Table 2:  Recommended adult dosages of IV colistin methanesulfonate (CMS) in 168 
critically-ill patients [7] 169 
 170 
Normal renal function:  Loading dose: 12 million units- Then: 
3 million units every 8 hours  [or]  
4.5 million units every 12 hours 
Renal impairment:  
CrCl* 40-60 ml/min  2 million units every 12 hours 
CrCl* 10-40 ml/min  2 million units every 24 hours 
CrCl* <10 ml/min  1.5 million units every 36 hours 
Renal replacement therapy:  
Haemodialysis  As per CrCl*, with an additional 2 million units after dialysis 
CVVHD**   Dosing as for normal renal function 
*Creatinine clearance (CrCL) based on Cockcroft-Gault equation; 171 
**Continuous veno-venous hemodialysis 172 
 173 
 174 
 175 
 176 
 177 
 178 
 179 
 180 
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Table 3: Recommended paediatric dosages for colistin methanesulfonate (CMS) [7] 181 
 182 
 Dosage based on colistin methanesulfonate (CMS) 
Neonates  Neonates 50 000 - 75 000 IU/kg/day in three divided dosages  
75 000 – 120 000 IU/kg/day in three divided dosages have been used in 
this population 
 
Infants and 
children  
 75 000 - 150 000 IU/kg/day in three divided dosages. 
 
Inhalation   CMS < 40kg: 500 000 IU every 12 hours 
 
 183 
 184 
 185 
Table 4: Colistin methanesulfonate (CMS) reconstitution outline information [7] 186 
 187 
Dosage Final Volume Diluent Infusion time 
12 MU loading dose  100 mL  0.9% sodium chloride (normal saline)  60 minutes 
 
3 MU 8 hourly  50-100 mL 0.9% sodium chloride (normal saline)  15-30 minutes 
 
4.5 MU 12 hourly 50-100 mL 0.9% sodium chloride (normal saline)  15-30 minutes 
 
 188 
 189 
 190 
Inhalational use of colistin  191 
Inhalational use of colistin prevents systemic side effects, while providing high concentrations in 192 
the airways represents a significant advantage. Studies have suggested that the lung 193 
concentrations of colistin obtained following the inhalational route of administration may reach 194 
levels adequate to eradicate the susceptible Acinetobacter spp. isolates [8]. 195 
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Table 5: The dosing of aerosolised colistin [7] 196 
 197 
Body weight  Dosing recommendation 
<40 kg  500 000 IU 12-hourly 
>40 kg  1 000 000 IU 12-hourly 
Recurrent/severe pulmonary infections  2 000 000 IU 8-hourly 
NB: The use of colistin must be restricted in hospitals in South Africa. A hospital’s 198 
consumption of colistin is a surrogate marker of the efficacy of its antimicrobial 199 
stewardship and infection prevention efforts, which should be considered standard care 200 
[9]. 201 
 202 
 203 
Table 6. Colistin dosing: [7] 204 
Table 6 A. Colistin dosing in normal patients 205 
Dosing in normal patients 
Loading dose 12 MU 
Maintainance dose  3 MU tds (8-hourly) 
OR 
4-5 MU bd (12 hourly) 
 206 
 207 
Table 6 B. Colistin dosing in renal impairment patients [7] 208 
Renal impairment: Colistin dosing  
CrCl* 40-60 ml/min  2 million units, 12-hourly 
• CrCl* 10-40 ml/min  2 million units, 24-hourly 
• CrCl* <10 ml/min  1.5 million units, 36-hourly 
Renal replacement therapy:  
Haemodialysis  As per CrCl*, with an additional 2 million units after dialysis 
• CVVHD**  Dosing as for normal renal function 
 209 
 210 
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7.3.2.2 Tigecycline 211 
Tigecycline is a tetracycline derivative called a glycylcycline. It has in vitro activity against most 212 
isolates of Staphylococci and Streptococci (including MRSA and VRE), anaerobes, and many 213 
Gram-negative organisms including Acinetobacter species, with the exception of Proteus spp. 214 
and Pseudomonas aeruginosa. It is Food and Drug Administration (FDA) approved for skin and 215 
skin-structure infections and intra-abdominal infections. 216 
 NOTE: Peak serum concentrations of tigecycline do not exceed 1 mcg/mL which limits 217 
its use for treatment of bacteraemia. 218 
 219 
Acceptable uses 220 
Management of intra-abdominal infections in patients with contraindications to both β-lactams 221 
and fluoroquinolones. 222 
 223 
Management of infections due to organisms including Acinetobacter species and 224 
Stenotrophomonas maltophilia on a case by case basis. 225 
Salvage therapy for MRSA, VRE infections on a case by case basis.  226 
Dose 227 
 100 mg IV once & 50 mg IV 12Hrly  228 
 100 mg IV once & 25 mg IV 12 hrly  229 
Toxicity: Nausea & vomiting  230 
 231 
 232 
7.4 Organism-specific guidelines 233 
Background and Literature review of Acinetobacter spp.  234 
The following people served as section/topic reviewers 235 
Dr K Baba  236 
Prof. K P Mlisana  237 
 238 
Headed by ASWP Committee, an Infectious Disease physician and an Infectious Disease 239 
clinician, the mission of the program is to ensure that every patient on antibiotics at IALCH 240 
Academic complex KZN, SA receives optimal therapy. These guidelines are a step in that 241 
direction. 242 
Academics from various departments have reviewed and approved these guidelines. As you will 243 
see, in addition to antibiotic recommendations, the guidelines also contain information about how 244 
to interpret the microbiology results and clinical data and other useful management tips. 245 
179 
 
We want to learn about new approaches and new data as they become available so that we may 246 
update the guidelines as needed. 247 
You should also document the reasons for departure in the patient’s chart. 248 
 249 
The study was conducted in the Department of Microbiology, National Health Laboratory Service 250 
(NHLS), IALCH, Durban, KwaZulu- Natal, South Africa, between January 2013 and December 251 
2013. Four-hundred-and-four isolates of Acinetobacter spp. from different sources (both sterile 252 
and non-sterile specimens), from unique patients, were subjected to antimicrobial sensitivity 253 
testing by (Kirby–Bauer method as recommended by Clinical and Laboratory Standards 254 
Institute,(CLSI, USA) [10] and the Vitek 2 (bioMérieux, France) automated method for the 255 
following antimicrobial agents: ceftazidime (30 μg), cefepime  (30 μg), ciprofloxacin (5 μg),  256 
amikacin (30 μg), piperacillin (100 μg), piperacillin-tazobactam (100/10 μg), and imipenem (10 257 
μg) .  258 
These isolates were subsequently divided into three groups based on their resistance patterns to 259 
different classes of antimicrobials—i.e., aminoglycosides (amikacin), β-lactams with inhibitors 260 
(piperacillin–tazobactam), fluoroquinolones (ciprofloxacin), carbapenem (imipenem) and 261 
colistin; as follows: 262 
Group 1 consisted of those isolates that were resistant to carbapenem or any three groups of 263 
antimicrobials and defined as multidrugs- resistant isolates (MDR). Multidrug- resistant isolates 264 
were defined according to the (European Centre of Disease Control and Prevention/ Centers of 265 
Diseases Control and Prevention (ECDC/CDC). Multidrug-resistant isolates are resistant to at 266 
least one agent in three or more antimicrobial categories [11].In this study, MDR Acinetobacter 267 
spp. are those isolates that showed resistance to carbapenems or any three groups of 268 
antimicrobials. [11]. 269 
Group 2 consisted of those isolates that were resistant to four groups of antimicrobials except 270 
colistin and defined as extensively drug- resistant isolate (XDR). 271 
Group 3 consisted of those isolates that were resistant to all five groups of antimicrobials and 272 
defined as pandrug-resistant isolate (PDR). 273 
Group 4 Sensitive Acinetobacter spp. (Community acquired Acinetobacter spp.) 274 
Group 5 Polymicrobial infection Acinetobacter spp. with Gram- positive bacteria  275 
Group 6 Polymicrobial infection Acinetobacter spp. with Gram –negative bacteria 276 
 277 
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7.4.1 Resistant patterns of Acinetobacter species  278 
7.4.1.1 MDR Acinetobacter species (Carbapenem-resistant Acinetobacter spp.) 279 
Acinetobacter species have emerged as important nosocomial pathogens worldwide, capable of 280 
accumulating multiple antibiotic resistance genes, including β-lactamases, alterations in 281 
membrane permeability, and efflux pumps, leading to the emergence of isolates resistant to all 282 
commercially available antibiotics [12]. As with other carbapenem-resistant organisms, 283 
prolonged infusion carbapenem therapy in combination with a second agent is a reasonable 284 
therapeutic approach [13]. Polymyxins have been used with variable success for the treatment of 285 
Acinetobacter spp. pneumonia, bacteraemia, and meningitis [14-15]. 286 
 Prolonged infusion meropenem PLUS aminoglycoside OR fluoroquinolone OR 287 
colistin (dosed as above)  288 
The sulbactam component of ampicillin-sulbactam may retain activity against highly drug-289 
resistant Acinetobacter spp. [16] and remains a treatment option for carbapenem-resistant 290 
Acinetobacter species when susceptible in vitro [17-19].  291 
 292 
7.4.1.2 XDR Acinetobacter species 293 
Despite the limitations of existing data, we believe intravenous polymyxins remain an option for 294 
patients infected with Acinetobacter spp. resistant to β-lactam agents. 295 
 When no other options are available, tigecycline should be considered [17]. 296 
 Tigecycline (dosed as above) [not available in local hospital] 297 
 298 
7.4.1.3 PDR Acinetobacter species (Acinetobacter spp.)  299 
Consisted of those isolates that were resistant to all five groups of antimicrobials and defined 300 
pan drug-resistant isolate (PDR). 301 
Colistin with carbapenem or piperacillin-tazobactam or ciprofloxacin;  302 
However, the synergy test will be done for confirmation of synergy effect [6]. 303 
 304 
 305 
7.4.2 Sensitive Acinetobacter species (Community acquired Acinetobacter spp.) 306 
Although the sensitive strain can be treated with appropriate antimicrobial agents, the clinical 307 
and microbiological indicators of sepsis need to be confirmed to avoid over- and under-308 
treatment for Acinetobacter spp. infections.  The treatment chosen will depend on the site of 309 
infection, underlying risk of patients, and type of unit (ICU or other high risk areas). 310 
 Ceftazidime  311 
 Piperacillin –tazobactam with amikacin or  312 
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 Ciprofloxacin or 313 
 Carbapenem 314 
 315 
7.4.3 Polymicrobial infection Acinetobacter species with Gram- positive bacteria  316 
 Piperacillin –tazobactam with amikacin or carbapenem or ciprofloxacin with cloxacillin 317 
for sensitive Gram-positive polymicrobial infections. 318 
 Colistin with vancomycin or rifampicin for resistant Gram-positive polymicrobial 319 
infection (synergy test should be done) [6]. 320 
 321 
7.4.4 Polymicrobial infection Acinetobacter species with Gram-negative bacteria 322 
 Carbapenem (imipenem or meropenem) 323 
 Carbapenem (imipenem or meropenem) with amikacin  324 
 Colistin with Carbapenem (imipenem or meropenem) or ciprofloxacin or  325 
Piperacillin –tazobactam  326 
 Colistin with rifampicin  327 
If PDR with polymicrobial infections  328 
 Colistin with carbapenem with rifampicin or  329 
 Colistin with fosfomycin  330 
 331 
NOTE:  synergy test should be done. 332 
Patients with infection or colonisation with the resistant Acinetobacter 333 
species (MDR-, XDR-, and PDR- Acinetobacter species) sould be placed on 334 
CONTACT precautions. 335 
 336 
 337 
7.5. Microbiology report information 338 
7.5.1  Interpreting the microbiology report 339 
Acinetobacter spp. isolates were identified using standard laboratory techniques [API], 340 
antimicrobial susceptibility testing (Kirby–Bauer method as recommended by CLSI, USA [10] 341 
and the Vitek 2 automated system. Their antibiograms were studied to categorise isolates as 342 
MDR-, XDR- and PDR. 343 
The clinical findings were correlated with laboratory data to assess their pathogenic status, and 344 
pure and mixed growth of Acinetobacter spp. were compared in patients with clinically defined 345 
sepsis and colonised groups [supplementary Figure 1 flow chart].    346 
 347 
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7.5.2 Classification and Treatment  348 
The isolation of Acinetobacter spp. from each site was considered one episode of infection.  349 
If it was isolated on more than one occasion from the same site (at least 7 days apart), or from a 350 
different site, these events were considered separate infection episodes. 351 
Infections for which the first isolation of Acinetobacter spp. was sent for analysis at least 48 h 352 
after admission to the ICU were considered hospital-acquired infections. It was reported as 353 
community-acquired if the patient was admitted directly from the emergency room or an 354 
outpatient department.  355 
All initial antibiotic prescriptions and any changes to existing medication were made practically. 356 
The appropriateness of changes to the antibiotic regimen was determined by analysing the 357 
microbiological sensitivity patterns and this local policy guideline will be used.  358 
The Microbiology laboratory utilises standard reference methods for determining susceptibility. 359 
The majority of isolates are tested by the automated system. 360 
The minimum inhibitory concentration (MIC) value represents the concentration of the 361 
antimicrobial agent required at the site of infection for inhibition of the organism. The MIC of 362 
each antibiotic tested against the local organism was reported (Table 10) 363 
 364 
NOTE:  MIC values vary from one drug to another and from one bacterium to 365 
another, and thus MIC values are NOT comparable between antibiotics or 366 
between organisms. 367 
 368 
7.5.3  Spectrum of antibiotic activity  369 
The spectrum of activity table is an approximate guide of the activity of commonly used 370 
antibiotics against frequently isolated bacteria. It takes into consideration IALCH Academic 371 
complex specific resistance rates, in vitro susceptibilities and expert opinion on clinically 372 
appropriate use of agents. For antibiotic recommendations for specific infections refer to relevant 373 
specific unit of the IALCH antibiotic guidelines. 374 
 375 
7.5.4  IALCH Antibiogram of Acinetobacter spp.  376 
In our local hospital, the prevalence (proportion) of MDR Acinetobacter spp. was 53 to 60% 377 
during a seven year period (2008 to 2014). Among these MDR isolates, the prevalence of 378 
Acinetobacter spp. in patients diagnosed with sepsis ranged from 37% and 51% during the study 379 
period [20]. Therefore, clinical and microbiological indicators of sepsis need to be confirmed to 380 
avoid over- and under-treatment for MDR Acinetobacter spp. infections.   381 
183 
 
In 2013, the local antibiogram showed that 45 (75%) of the 60 Acinetobacter spp. were MDR and 382 
54 (90%) were still sensitive to amikacin [6, 20]. This local data highlighted that direct therapy is 383 
a good approach rather than empirical therapy for Acinetobacter spp. infections.  384 
In addition, MIC was estimated for 60 representative isolates of differing levels of drug resistance 385 
for the mentioned drugs, proving that drug-resistant Acinetobacter spp. presents an increasing 386 
challenge to health care.  Although previous surveillance studies reported that resistance is 387 
increasing among carbapenems, they are still considered as the primary treatment against these 388 
bacteria [21]. 389 
Similarly, although this study also showed that Acinetobacter spp. display lower sensitivity to 390 
carbapenems 15 (25%), the carbapenems are still be considered to be the primary treatment if the 391 
organism is sensitive according to susceptibility results [20].  392 
Other studies showed that β-lactams, aminoglycosides, ceftazidime, fluoroquinolones and colistin 393 
have been the mainstay for the treatment of Acinetobacter spp. infections. However, the intensive 394 
use of antimicrobials inevitably leads to the appearance of isolates resistant to these drugs [21].   395 
Although the study indicated that Acinetobacter spp. showed a low prevalence of sensitivity to 396 
imipenem and ciprofloxacin (25%), penicillins with inhibitors (piperacillin-tazobactam) (20%), 397 
these drugs are still be used as appropriate direct therapy. Individual specific antibiogram 398 
approach is the best way of treatment in KZN, South Africa [20]. 399 
 400 
 401 
7.6 Guidelines for the treatment of various infections (Table.7) 402 
Table 7. Antimicrobial Agents for the Treatment of Acinetobacter Infections [22] 403 
Medication Dosage Route Toxicity Comments 
Imipenem-
cilastatin 
500 mg every 6 h 
up to  
1 g every 6–8 h  
IV Phlebitis, GI, anaphylaxis, 
seizures, nephritis 
Extended infusions 
have been used,  
Meropenem    500 mg to 1 g  
every 8 h 
IV GI, headache, dermatologic, 
hematologic, angioedema, seizure 
Extended infusions 
have been used, 
limited data 
Amikacin 
Regimen 1  15 mg/kg daily   IV Nephrotoxicity, ototoxicity, 
neuromuscular blockade 
 
Regimen 2  30 mg  IVent   
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Continue; 
Medication  Dosage Route   Toxicity  Comments 
Colistin (colistimethate) 
Regimen 1   5 mg/kg/day, 2–4 
divided doses 
IV Nephrotoxicity and neurotoxicity   
Regimen 2   1–3 million IU 
every  
8 h  
IH Must be used immediately after 
reconstitution to prevent 
accumulation of colistin–lung 
toxicity 
1 million IU is 80 mg 
of colistimethate. A 
variety of doses used 
in studies(see in 
colistin ) 
Polymyxin B  50,000 units daily 
 (5 mg) 
 
IT Meningeal irritation  
 
Has been used as 
intraventricular 
injection but not 
FDA labeled as 
approved by this 
route 
Polymyxin E 
(colistin)    
10 mg daily  IT/ 
IVent 
Meningeal irritation Has not been FDA 
approved for either 
route of 
administration 
Tigecycline  100 mg once then 
50 mg every 12 h 
 
IV GI, shock, pancreatitis, 
anaphylaxis  
Avoid use in blood 
stream infections due 
to large volume of 
distribution and low 
mean maximum. 
steady-state levels 
Minocycline  100 mg every 12 h  IV  GI, hepatic, dermatologic  MIC90 lower than that 
of doxycycline; 
limited data on use in 
severe infections; 
most active of all the 
tetracyclines  
Key: FDA, US Food and Drug Administration;  404 
GI, gastrointestinal (eg, nausea, vomiting, and diarrhea); H, inhalational; hepatic, 405 
jaundice and hepatitis; IT, intrathecal; IV, intravenous; IVent, intraventricular 406 
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7.6.1  Community-acquired infections 407 
Pure growth of Acinetobacter spp. from sterile specimens with clinical significance infection. 408 
Sensitive to all appropriate antibiotics Acinetobacter spp. isolates are mostly from community 409 
(Table 8). 410 
 411 
Table 8.  Appropriate antibiotics for community-acquired Acinetobacter spp. infection. 412 
Prescribe antibiotics  Indication for infections  
Ceftazidime  CNS infection , CVS infection  
Ciprofloxacin  Skin & soft tissue infection , local infection ,UTI 
Piperacillin-tazobactam  Intra-abdominal infections, systemic sepsis  
Amikacin  PD Peritonitis , nebulizer for respiratory tract infection  
Imipenem  Intra-abdominal infections, systemic sepsis  
Meropenem  Intra-abdominal infections, systemic sepsis , CNS infection  
 413 
 414 
7.6.2  Hospital-acquired infections  415 
Direct therapy with individual specific antibiogram approach for medication of Acinetobacter 416 
spp. infections, is the best way of treatment in IALCH, KZN, South Africa. 417 
Appropriate antibiotics for Acinetobacter spp. 418 
 Imipenem 1 g IV q6h or 419 
 Meropenem 1 g IV q8h or 420 
 Doripenem 500 mg IV q8h or 421 
 Ampicillin-sulbactam 3 g IV q6h or (not use in IALCH) 422 
 Tigecycline 100 mg IV in a single dose, then 50 mg IV q12h or (NOT available at IALCH) 423 
 Colistin 5 mg/kg/day IV divided q12h – combination therapy  424 
 Duration of therapy: 14-21d 425 
 426 
7.6.2.1  Ventilator-associated pneumonia  427 
Indication for Empirical therapy: Patients with a history of risk factors for Acinetobacter and 428 
other resistant Gram-negative organisms, example: bronchiectasis, broad-spectrum antibiotics for 429 
>7 days in the past month; prolonged hospitalisation>7 days; immunocompromised due to organ 430 
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transplant, debilitated nursing home resident; recent mechanical ventilation >48 hours; 431 
haematologic malignancy, bone marrow transplantation, active chemotherapy; prednisolone 432 
treatment >20 mg daily for >3 weeks; treat as severe illness with tailoring of antibiotics based on 433 
past culture data [23]. 434 
 435 
7.6.2.2  Line sepsis/Catheter-related blood stream infections. [24] 436 
Diagnosis: if the catheter is infected (> minimum erythema or any purulence at the exit site) - it 437 
should be removed and replaced at a different site. 438 
If catheter related blood stream infection (CR-BSI) is suspected, two sets of blood cultures (>1 439 
from peripheral sites) should be sent. 440 
If the blood culture is negative and tip has Acinetobacter spp., should not be treated. If 441 
meet with the criteria for line sepsis, (CR-BSI), should be treated with direct therapy. 442 
 443 
7.6.2.3 Catheter-related urinary tract infection 444 
 Remove the catheter whenever possible 445 
 Replace catheters that have been in ≥2 weeks if still indicated  446 
 Prophylactic antibiotics at the time of catheter removal or replacement are NOT 447 
recommended due to low incidence of complications and concern for development of 448 
resistance. 449 
 Catheter irrigation should not be used routinely [25]. 450 
   451 
7.6.2.4 Wound sepsis / surgical related post operative wound sepsis.  452 
 Exposure to soaking, whirlpool, hot tub: usually polymicrobial, may involve Acinetobacter 453 
and Pseudomonas  454 
 Chronic wound with prolonged exposure to antibiotics  455 
 Necrosis or gangrene (Treat according to IDSA guideline) [26]  456 
 457 
7.6.3 Other anatomical sites-infections  458 
 (Examples: Eye infection, ear infection, joint infection etc.) 459 
Direct therapy with individual specific antibiogram approach for Acinetobacter spp. infections, is 460 
the best way of treatment in IALCH, KZN, South Africa. 461 
NB:  The flow chart (Figure 1) and algorithm for the management: (Figure 2) have to be 462 
applied.  463 
 464 
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7.7 Prognosis of Acinetobacter spp. infections 465 
The prognosis of Acinetobacter infection depends on the underlying health of the host and the 466 
extent of organ involvement; it is the same as for other aerobic Gram-negative bacillary infections.  467 
 468 
7.8 Infection control                                                             469 
7.8.1 Hospital Epidemiology and infection Control  470 
The presence of OXA-23 in MDR Acinetobacter spp. correlated with resistant MICs. Molecular 471 
analysis suggested horizontal transmission in ICUs and vascular unit. Six percent of isolates 472 
showed amikacin and colistin resistance. Resistance to colistin in Acinetobacter spp. may be 473 
associated with absence of IpxA gene (this will be confirmed using further molecular sequencing 474 
method in future) at academic complex Hospital, KwaZulu-Natal, South Africa. The presence of 475 
the aphA6 gene in amikacin resistant Acinetobacter spp. isolates was detected. Continuous 476 
surveillance for the prevalence of resistance genes in MDR-, XDR- Acinetobacter spp. is crucial 477 
for epidemiological and infection control purposes (local data-submitted). 478 
 479 
7.8.2 Infection control precautions (Table. 9) 480 
Drug-resistant Acinetobacter spp. presents a serious global infection control challenge. The 481 
increasing rates of resistance of Acinetobacter spp. to the available antimicrobial drugs means 482 
that outbreaks should be identified and controlled early. The high prevelence of MDR 483 
Acinetobacter spp. hightlighted to enhence the infection prevention and control (IPC) measures 484 
as below;  485 
Table 9. Methods for control and prevention of multidrug-resistant Acinetobacter infection  486 
[19]. 487 
Method  Comments 
Point source control Effective in the outbreak setting when a point source is identified 
Standard precautions Includes hand hygiene, correct and consistent glove use, and 
appropriate use of gowns and eye protection; reported compliance 
among healthcare personnel is often poor 
Contact barrier 
precautions 
Includes dedicated patient care equipment and gowns and gloves 
for health care personnel on entry to an isolation room 
188 
 
Environmental 
cleaning and 
disinfection  
Widespread environmental contamination is often reported in the 
epidemic setting, and environmental reservoirs likely play a role in 
the endemic setting as well 
Cohorting of patients  Grouping colonised and infected patients into a designated unit or 
part of a unit 
Cohorting of health 
care personnel 
Designating staff to care for only patients colonised or infected 
with the organism 
Clinical unit closure  Required in some outbreak settings to interrupt transmission and 
allow for thorough environmental disinfection 
Antimicrobial 
stewardship 
Programs to promote judicious antimicrobial use and prevent 
emergence of resistance 
Surveillance  Passive or active surveillance can identify infected or colonised 
patients so that interventions can be implemented 
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7.9 Flow charts, supplementary table and definitions 488 
 489 
7.9.1  Figure 1. Flow chart of clinical and microbiological criteria of sepsis and 490 
colonisation 491 
 492 
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7.9.2 Definitions  493 
*Colonisation criteria  494 
Microbiological criteria for Colonisation  495 
 Acinetobacter spp. isolated from positive blood culture once; repeated blood culture with 496 
other bacteria or no growth. 497 
 Acinetobacter spp. isolated from ETA once and other organisms without Acinetobacter spp. 498 
or no bacterial growth from repeated ETA.  499 
 Mixed growth in any one site of specimens of septic screen.  500 
Isolation of Acinetobacter spp. with other bacteria even from the sterile specimens with 501 
clinical sepsis caused by bacteria others than Acinetobacter spp.  502 
 503 
Clinical criteria for colonisation  504 
 Patients responded to the empirical or current broad spectrum antibiotics that are resistant to 505 
Acinetobacter spp. isolate. 506 
 Clinically stable (no signs and symptoms of infections) 507 
 508 
Criteria for microbiological significance:   509 
Acinetobacter spp. cultured in pure growth from blood culture bottle and/or other appropriate 510 
specimens, sterile specimens or repeated specimens from the same or multiple sites, with patients 511 
not responsive to empirical or current broad-spectrum antibiotics; Acinetobacter spp. cultured in 512 
mixed growth cultures from repeated specimens from the same site with clinical symptoms. 513 
 514 
 515 
 516 
 517 
 518 
 519 
 520 
 521 
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 522 
7.9.3 Figure 2. A standardised algorithm for the management of patients with significant  523 
Acinetobacter species infections; Individual specific antibiogram approach antibiotics 524 
guideline in KwaZulu- Natal, South Africa. 525 
 526 
 527 
 528 
 529 
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7.9.4 Table 10: MIC50 and MIC90 value of the Acinetobacter spp. (n=60)  530 
     531 
n=60 
Antibiotics  MIC50 MIC90 
CST 0.25 0.5 
IMP 24 >32 
IMP+CST 6 32 
TZP >256 >256 
TZP+CST 96 >256 
AK 8 16 
AK+CST 6 16 
CIP >32 >32 
CIP+CST >32 >32 
VAN >256 >256 
VAN+CST 16 >256 
LIZ >256 >256 
LIZ+ CST 96 >256 
RIF 4 >32 
RIF+CST 0.32 8 
 532 
Table 10: Antimicrobial MICs of Acinetobacter spp. isolates from clinical specimens 533 
(n=60) 534 
Key:  The MIC50 of amikacin was 8 μg/mL and MIC90 was 16 μg/mL Both the MIC50 535 
and MIC90 of imipenem was 32 μg/mL, and both MIC values were 32 μg/mL for 536 
ciprofloxacin and >25 μg/mL for pipercillin-tazobactam. MIC50 was 0.25 μg/mL 537 
and MIC90 was 0.5 μg/mLfor colistin. 538 
The MIC50 of vancomycin, linezolid and rifampicin was: >256 μg/mL, 539 
>256μg/mL and 4 μg/mL respectively, while the MIC90 was >256 μg/mL, >256 540 
μg/mL and >32 μg/mL respectively.  541 
The MIC50 and MIC90 of amikacin and colistin were within the sensitive range 542 
among the tested appropriate antibiotics.  543 
 544 
 545 
 546 
 547 
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SYNERGY TEST  548 
Future Plan: NHLS SOP 549 
 550 
DRUG SUSCEPTIBILITY TESTING 551 
 552 
Media preparation  553 
Iso-Sensitest agar plate (without colistin/drug free agar media) and with a fixed concentration of 554 
colistin 0.5 µg/mL were prepared [27].   555 
 556 
Minimum inhibitory concentration (MIC)  557 
Acinetobacter spp. susceptibility results were identified using a Vitek®2 (bioMerieux, France) 558 
with the VITEK® 2 GN card and the VITEK® 2 AST-N255 card (bioMerieux, France) according 559 
to the manufacturer’s instructions.  560 
 561 
The Epsilometer test (E-test®) (bioMerieux, France) was used to test the minimum inhibitory 562 
concentration (MIC) for each of the isolates that exhibited differing levels of drug resistance for 563 
the colistin in combination with different drugs. MIC results were interpreted according to the 564 
Clinical and Laboratory Standards Institute (CLSI) breakpoint criteria for Acinetobacter spp. [28]. 565 
Since there are no criteria relevant to Acinetobacter spp. for some agents such as vancomycin, 566 
linezolid and rifampicin, the susceptibility breakpoints for these antibiotics were based on the 567 
MIC interpretive standards of CLSI for Gram-positive bacteria [27]. An Acinetobacter spp. 568 
control strain (ATCC 19606) was included. 569 
 570 
Synergy testing by the Epsilometer test (E-Test®) method 571 
The synergy test was performed using by the ‘E-test®’ method [27, 29].  572 
Colistin was incorporated into Iso-Sensitest agar at a fixed concentration of 0.5 µg/mL. Plates 573 
were inoculated with a bacterial suspension of optical density equivalent to 0.5 McFarland 574 
standard. Thereafter, the drug Etest® strip (bioMerieux) was applied on the colistin containing 575 
plate and the colistin free plate. 576 
Plates were incubated aerobically in incubator (Jouan aerobic incubator) at 37°C for 18-24 h. The 577 
MIC of each drug in the presence of colistin was compared to the MIC of each drug on colistin-578 
free agar and all MIC values were recorded. 579 
 580 
 581 
 582 
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Interpretation I [30]        583 
DEFINITIONS 584 
MICA:   MIC of drug A alone 585 
MICB:  MIC of drug B alone 586 
MICAB: MIC of A in the presence of drug B 587 
Synergy  588 
MIC of combination is ≥ 2 dilutions LOWER than MIC of the most active drug alone. 589 
e.g. MICA = 8, MICB = 16 (i.e. A= most active);  590 
MICAB = 2. MIC of A is reduced from 8 to 2 in combination with B i.e. by 2 dilutions.  591 
Antagonism  592 
MIC of combination is ≥ 2 dilutions HIGHER than MIC of the most active drug alone.  593 
e.g. MICA = 4, MICB = 16 (i.e. A= most active);  594 
MICAB = 16. MIC of A is increased from 4 to 16 in combination with B i.e. by 2 dilutions. 595 
Indifference/Additive       596 
MIC of combination is within +/- 1 dilution compared to the most active drug alone.  597 
E.g. MICA= 1, MICB = 2 (i.e. A= most active);  598 
MIC of A or B in combination = 1. 599 
Combination of A with B shows no change in MIC of A, the most active drug (Indifference) 600 
 601 
 602 
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8. SYNTHESIS 
This thesis comprises a study with various components, all aimed at developing a standardised 
approach to the management of patients with Acinetobacter species (Acinetobacter spp.) infection 
at academic complex hospitals in Durban, KwaZulu-Natal.  The problem identified in local 
settings was the absence of a standardised algorithm for patients with significant Acinetobacter 
spp. infections and the lack of definitions to differentiate between significant sepsis and mere 
colonisation. At the time of this study, which includes intensive care units (ICUs) in the regional 
hospital and ICUs and non-ICUs in academic complex hospitals in Durban, there was institutional 
knowledge of management strategies for categories of infection, appropriate antimicrobial agents, 
prevention of multidrug- resistant (MDR) Acinetobacter spp. and characterisation of MDR 
Acinetobacter spp. isolates. However, it was observed that Acinetobacter spp. were more 
commonly managed as a coloniser, while targeted treatment was reserved for MDR  
Acinetobacter spp. 
The study demonstrated the use of clinical, microbiological, molecular and epidemiological data 
to develop a standard laboratory and clinical approach to the management of MDR Acinetobacter 
spp. infection. Included in this approach is synergy testing on individual isolates and definitions 
of the criteria for clinical and microbiologically significant sepsis. Based on this work, steps for 
developing a standard guideline are recommended, which may be adapted to suit administrative 
structures in the KwaZulu-Natal (KZN) areas of implementation. For academic complex 
hospitals, a specific guideline for standard approach of Acinetobacter spp. infections needs to be 
implemented urgently in order to assist the antibiotic stewardship program (ASWP). The study 
outcomes revealed that local Acinetobacter spp. was a significant cause of sepsis, with the 
emergence of horizontal transfer of carbapenem resistant genes, XDR- and colistin resistant 
Acinetobacter species in ICUs and non-ICUs, and that the results of synergy testing are species 
dependent. Therefore, the integration of a standard approach to treatment and prevention is 
valuable and applicable. Moreover, this study discovered that Acinetobacter spp. resistance to 
colistin was potentially mediated by the absence of the IpxA gene which encodes the lipid A 
component of lipopolysaccharide (LPS). This could possibly indicate a complete loss of the Lipid 
A motif. This is contradictary with other reports and therefore, it is essential to perform further 
molecular techniques to confirm the absence of the IpxA gene in colistin resistant Acinetobacter 
species. 
Due to budget constraints, the study did not include the molecular identification of Acinetobacter 
baumannii using multiplex PCR, screening of the other resistant genes and whole genome 
sequencing/southern hybridisation/new primer sequences for confirmation of absence IpxA gene. 
Further research at the post-doctoral level is recommended to determine the mechanisms 
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associated with drug resistance and for continuous molecular surveillance. More immediate 
research should focus on the extent to which the proposed standardised guideline is utilised in 
academic complex hospitals, province of KZN. Similar studies on MDR Acinetobacter spp. are 
recommended for other locations in KZN. Moreover, in local academic hospitals, research on 
clinical outcomes, including toxicity of colistin combination therapy and mechanisms of 
resistance during therapy, is recommended.  
The key findings of this study and the conclusions are outlined below. 
 
8.1  Multidrug-resistant Acinetobacter species: A significant cause of sepsis in an  
 intensive care unit in a regional hospital, Durban 
In order to address the overall study objectives, the prevalence of multidrug-resistant 
Acinetobacter species (MDR- Acinetobacter spp.) causing significant sepsis in an ICU was first 
established, along with differentiation criteria and clinical outcomes. According to the results of 
this study, MDR Acinetobacter spp. causing significant sepsis was generally high, with a high 
mortality rate compared to mere colonisation in the one year study period (SweSwe-Han and 
Pillay, 2015). This is the first study of its kind in a local hospital and consistent with those 
conducted elsewhere (Peleg et al., 2008; Morrow et al., 2009; Ahmed et al., 2012; Leao et al., 
2016). The data revealed a picture of MDR Acinetobacter spp. leading to sepsis and high mortality 
rates among patients in surgical ICU in a local academic complex hospital. These results support 
the view that nosocomial sepsis due to A. baumannii is associated with increased mortality in 
other areas (Weinstein et al., 2005; Robenshtok et al., 2006; Peleg et al., 2008; Turkoglu et al., 
2011; Punpanich et al., 2012; Özgür et al., 2014; Basri et al., 2015; Uwingabiye et al., 2016).  
The findings highlighted the importance of antibiotic stewardship and the urgent need for the 
development of standardised guidelines for the treatment of Acinetobacter species. Patients with 
MDR Acinetobacter spp. sepsis presented with advanced disease and suffered a great deal of 
morbidity and mortality in ICUs and non-ICUs. This is a continuing problem. 
It is still difficult to differentiate between colonisation and sepsis caused by Acinetobacter spp. 
for treatment decisions at the hospital level (Almasaudi, 2016.). This is an important part of the 
ASWP, since Acinetobacter spp. are recognised as common hospital and community acquired 
pathogens and colonisers, while a significant number of nosocomial isolates, including MDR 
isolates, are present in the academic complex hospitals of KZN. However, the prevalence of 
resistant patterns, the significance of differentiation between sepsis and colonisation, and the 
criteria of clinical and microbiological sepsis versus colonisation, are lacking. In addition, it was 
necessary to explore the prevalence of significant sepsis in order to establish the study aim of 
developing a recommended standard management guideline. 
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8.2   Analysis of clinical and microbiological data on Acinetobacter species   
       assist the preauthorisation of antibiotics at the patient level for an effective  
       antibiotic stewardship programme (Seven years study from 2008- 2014) 
The integration of antibiotic preauthorisation at the patient level into the antibiotic stewardship 
programme (ASWP) requires standard criteria for the analysis of clinical and microbiological data 
(Barlam et al., 2016). This study developed definitions of the criteria for clinical and 
microbiological sepsis and colonisation based on laboratory and clinical data of a large sample of 
patients during the seven-year study period. 
 
Previous literature mentions the high polymicrobial bacteraemic rate of Acinetobacter spp., which 
may reflect potential polymicrobial sources of infection (Siau et al., 1996; Begum et al., 2013; 
Dash et al., 2013). This study revealed a high percentage of polymicrobial infection in the sepsis 
group. Pure growth of Acinetobacter spp. was not always interpreted as a significant pathogen for 
sepsis, while correlation of the clinical and microbiological data showed a statistically significant 
difference between the presence of the pathogen and colonisation. Therefore, interpretation of 
both clinical and microbiology data is essential before prescribing appropriate medication for 
Acinetobacter spp., in order to reduce over and under medication. 
 
Management of MDR-, XDR- and PDR- Acinetobacter spp. infection poses a great challenge for 
physicians and clinical microbiologists (MacDougall and Polk, 2005; Manchanda et al., 2010). 
This study highlighted the impact of infection prevention control in reducing MDR Acinetobacter 
spp. infection. The high prevalence of MDR Acinetobacter spp. and the rates of resistance to 
polymyxins are concerning, since polymyxins are generally considered the last option due to the 
lack of new antimicrobial agents (Mathaia et al., 2012).   
 
This study uncovered XDR and PDR Acinetobacter spp., highlighting the need to use broad-
spectrum antibiotics with caution. The study also revealed a high prevalence of Acinetobacter 
spp., specifically MDR strains, in both ICU and non-ICU settings. The specific concern was XDR 
and PDR Acinetobacter spp., which emerged in both the significant sepsis and colonised patient 
groups. Findings from this research may aid clinicians in using early and appropriate antibiotic 
regimens, particularly in patients at risk of more virulent MDR infection.  
Clinical and microbiological indicators of sepsis in patients should be analysed by clinical 
microbiologists, clinicians and infectious diseases specialists by using the flow chart in chapter 3 
(Swe-Han SK et al., 2017) and management guideline (Chapter 7). The urgent development of 
standardised management for patients with significant Acinetobacter spp. infection is 
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recommended. Further recommendations include research on the effectiveness of synergy tests 
on colistin therapy and clinical outcomes, continuous surveillance for modification of local, unit 
specific antibiograms, as well as phenotypical and genotypical investigation of MDR 
Acinetobacter spp. and its spread.  
 
8.3  Colistin exhibits diverse and species dependent synergy in combination with 
different antibiotics against Acinetobacter spp. isolates 
Several studies have investigated synergistic combinations for treating multidrug resistant 
pathogens (Bonapace et al., 2000; Tatman-Otkun et al., 2004; Wareham and Bean, 2006; Pankey 
and Ashcraft, 2009; Falagus et al., 2010; Cai et al.,2012; Vidaillac et al.,2012; Daoud  
et al.,2013; Durante et al., 2013; lee et al., 2013; Temocin et al., 2015; Zafar et al., 2015). 
However, there were no studies involving colistin with seven different combinations on the same 
Acinetobacter spp. isolates during the same time.  
This study therefore investigated the effectiveness of colistin combination therapy with different 
commonly used appropriate agents, observing the effects of the combinations used on each isolate 
at the same time. The results of synergy testing were highly diverse and there is no evidence to 
use these combinations for empirical treatment of Acinetobacter spp. infections in the academic 
complex hospitals in Durban.  
Our findings suggest that synergy testing should be performed for individualised direct therapy 
and a synergy protocol is recommended for the laboratory.  
Due to the emergence of extensively drug resistant (XDR)-Acinetobacter spp. and the discovery 
of colistin resistant Acinetobacter spp., synergistic drug combinations were a suitable alternative 
to carbapenems. Moreover, colistin combinations provide effective, first-line drug treatment 
options, and may be used for XDR-, PDR-Acinetobacter spp. and mixed polymicrobial infection. 
Optimal treatment and the role of combination therapy should be explored in a future prospective 
clinical trial. This study provided a recommendation for the standard operation procedure (SOP); 
namely that synergy testing should be part of a standard management guideline for XDR-, PDR-
Acinetobacter spp. and polymicrobial infections.  
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8.4  Horizontal transfer of OXA-23-carbapenemase- producing Acinetobacter species in 
intensive care units at an academic complex hospital, Durban, KwaZulu-Natal, 
South Africa  
The production of carbapenemase is one of the mechanisms of carbapenem resistance in MDR 
Acinetobacter species. The gene encoding the enzyme OXA-23 of carbapenem resistant  
Acinetobacter spp.  has been identified in both chromosomally and on plasmids, which allows it 
to spread among various Acinetobacter spp., and outbreaks have been observed globally (Dalla-
Costa et al., 2003; Carvalho et al., 2009; Chang et al., 2015). Genetic elements may be responsible 
for the spread of Acinetobacter spp., particularly in ICUs and high risk areas.  
This study reported on epidemiological and molecular observations of Acinetobacter spp. in the 
academic complex central hospitals in KwaZulu- Natal. The existence of MDR Acinetobacter 
spp. with the blaOXA-23 gene was discovered by polymerase chain reaction (PCR) and confirmed 
in an academic complex hospital in Durban. The presence of OXA-23 in MDR Acinetobacter 
spp. strains correlated with their phenotypical antibiograms. 
The results showed that amikacin and colistin are the mainstay antibiotics for MDR Acinetobacter 
spp.  in the local setting. There was a correlation between the MDR phenotype and genes related 
to carbapenem resistance, as well as with blaOXA-23. Molecular analysis suggested horizontal 
transmission of MDR Acinetobacter species. Molecular typing of the selected MDR 
Acinetobacter species carried the blaOXA-23 gene responsible for resistance MICs to carbapenems 
(8 to >16µg/mL). In addition, the PFGE typing of a diverse collection of MDR Acinetobacter spp. 
clones showed that strains were related from no more than two patients. This suggests, therefore, 
no outbreak had occurred during the study period.  
 
The outcomes provided support for a local infection prevention and control management 
guidelines as part of the antibiotic stewardship programme. Continued molecular surveillance of 
local epidemiological information and antibiotic resistance surveillance are crucial for infection 
prevention and control purposes and an essential part of standard management at the hospital. 
 
Strict infection prevention control measures must be urgently implemented to prevent the spread 
of infection. Continuous surveillance of antibiotic resistance genes in MDR Acinetobacter spp. is 
crucial for epidemiological purposes and to prevent further dissemination of these resistance 
genes. In addition, it is also necessary to monitor the prevalence and spread of resistance genes 
linked to other antibiotics associated with Acinetobacter spp. (namely amikacin and colistin) in 
clinical settings, other units at hospitals and community health clinics in KZN.  
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8.5.  Colistin resistant clinical Acinetobacter species may be mediated by absence of 
IpxA gene at academic complex hospitals in Durban, KwaZulu-Natal, South Africa  
Acinetobacter spp. are recognised as community, hospital acquired pathogen and classified by the 
Infectious Diseases Society of America as one of six important MDR microorganisms in hospitals 
worldwide (Talbot et al., 2006; Gonzalez-Villoria and Valverde-Garduno, 2016) while XDR and 
PDR- Acinetobacter spp have emerged globally (Manchanda et al., 2010; Gonzalez-Villoria  and 
Valverde-Garduno, 2016). This study was set in a central academic hospital and investigated the 
relationship between the minimum inhibitory concentrations (MICs) of standard drugs against 
Acinetobacter spp. and resistant genes for colistin and amikacin. In addition, the association 
between drug resistance and clinical outcomes of patients with Acinetobacter spp. was examined. 
The results revealed amikacin and colistin resistant Acinetobacter spp. strains with high MICs 
correlated with the presence of the aphA6 gene and an absence of the IpxA gene.   
According to Moffatt et al., high level polymyxin resistance is the result of the complete loss of 
all lipopolysaccharides (LPS) (Moffatt et al 2010), caused by mutations in either lpxA, lpxC or 
lpxD (Li et al., 2006; Moffatt et al., 2011; Pogue et al., 2015).  
In this study, Acinetobacter spp. resistance to colistin was potentially mediated by the absence of 
the IpxA gene which encodes the lipid A component of lipopolysaccharide (LPS). This 
modification was observed in all colistin-resistant Acinetobacter spp. isolates, and in none of the 
colistin-susceptible isolates.  Sequencing revealed no polymorphism, confirming that colistin 
sensitive isolates with the IpxA gene harbor no mutations. In this study, IpxA primer detection by 
polymerase chain reaction (PCR) was optimised and performed three times with susceptable 
isolates and resistant isolates at the same run. Therefore, in order to determine the type of 
modification associated with the loss of lipid A, further lipid analysis should be conducted. The 
cell wall may have a different appearance and should be investigated by electron-microscope. 
This can be achieved through mass spectrometry or alternatively primers associated with Ipx 
modifications (mutants), while the entire genome sequencing may be used to determine point 
mutations associated with colistin resistance.  
 
The discovery of colistin resistant Acinetobacter spp. lacking the IpxA gene is new in KZN, and 
described for the first time at an academic complex hospital in Durban, KwaZulu-Natal, South 
Africa. However, before any conclusions can be drawn, further investigation is needed to confirm 
our findings. 
In another interesting observation, colistin-resistant strains were sensitive to other appropriate 
antibiotics. In addition, colistin-resistant Acinetobacter spp. occurred mostly among patients who 
had not received previous colistin therapy. It is likely that these isolates originated from the 
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hospital environment as a wild-type. Four out of six isolates were isolated from the blood culture 
specimens of sepsis patients. This finding highlighted the need to enhance infection prevention 
and control measures.  
Although colistin resistance is not a surrogate marker for MDR Acinetobacter spp., the frequent 
occurrence of colistin resistance in Acinetobacter spp. isolates at a local academic hospital is 
worrying. The researcher found no standard guidelines for colistin therapy in IALCH academic 
complex hospitals that highlighted a standard management antibiotics approach, including the 
recommended colistin therapy standard guideline.  
Future studies should focus on how to best utilise colistin to minimize resistance. There is a need 
for continuous surveillance of antibiotic resistance genes, as well as need to recognise and trace 
pathogenic drug resistant Acinetobacter spp. isolates. 
 
8.6  A standardised approach to the treatment and management of significant 
Acinetobacter species infection at academic complex hospitals in KwaZulu-Natal  
(Including a standardised algorithm: Individual specific antibiogram approach) 
The treatment, prevention and prediction of MDR Gram-negative bacteria is included in the 
current local protocol, but without specific data on Acinetobacter species. Moreover, medication 
was mainly focused on general cultured microorganisms other than MDR Acinetobacter spp.  
Based on this study, a standardised algorithm for a treatment guideline specifically for 
Acinetobacter spp. infections in academic hospitals was developed. 
 
8.7 Limitation of this study  
The study limitations relate primarily to financial and facility restrictions. We were not able to 
perform a number of additional requirements currently, although we expect to implement them in 
future. 
The identification of individual Acinetobacter species by their phenotypic traits is difficult and 
the use of current automated or manual commercial systems will require further confirmatory 
testing. Although it may be facilitated by molecular methods such as 16S rDNA sequencing, 
DNA-DNA hybridisation, gyrB multiplex PCR and the rpoB gene sequencing, the local routine 
diagnostic laboratory is unable to perform these molecular methods. Therefore, the study is based 
on Acinetobacter spp. as a whole. 
Further research is needed in the form of comprehensive studies with clinical evidence. Synergy 
mechanisms should be explored in order to facilitate understanding of our results and predict the 
effects of other antibiotic combinations. In addition, the validation and comparison of the new 
rapid synergy tests might be done in future (Van-Belkum et al., 2015).  
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As far as we are aware, this study is the first to describe detailed clinical and molecular 
characteristics of colistin- and amikacin-resistant Acinetobacter spp. at a local academic complex 
hospital in KwaZulu- Natal.  
A further limitation of this study is the lack of confirmation of  the absence of the IpxA gene using 
additional molecular techniques such as including internal amplification controls, new primer 
design to exclude mis-priming, southern hybridisation and genome  sequencing. These have been 
planned for the near future, as funding is not available to perform this within the scope of the 
PhD. However, while the published primers that were used possess a BamHI restriction site, and 
the annealing temperature was high, the IpxA gene was successfully amplified in the positive 
control, ATCC19606 and susceptible clinical strains. This success confirms that conditions were 
optimal for the amplification of the IpxA gene. Amplification of the resistant strains was 
performed at the same time as the susceptible and ATCC strain. The PCR was repeated more than 
once. Future research should include the detection of the exact mechanism if complete loss of the 
IpxA gene in colistin resistant Acinetobacter species is confirmed. Should the confirmatory tests 
prove the complete absence of the IpxA gene as a novel resistance mechanism, further lipid 
analysis through mass spectrometry should be conducted in order to determine the type of 
modification associated with the loss of lipid A. Cell walls may appear differently and should be 
investigated by electron microscope. 
The final limitation of the study is that we were not able to perform PFGE at the local setting.  
PFGE analysis software is currently not used by at the Johannesburg (JHB) molecular laboratory 
because of financial limitations and lack of access to this software program. We hope to be able 
to access this valuable tool in the near future. The PFGE typing interpretation was correlated with 
the clinical demographic data and phenotypical MICs results of the Acinetobacter species in order 
to accurately facilitate user interpretation. 
 
8.8 General conclusions  
Significant findings in the one year study at ICU (Chapter 2) include a high mortality rate (60%) 
in sepsis patients with multi-drug resistant Acinetobacter species. 
XDR-and MDR- Acinetobacter spp. infections were significantly associated with severe sepsis in 
ICU and non-ICU patients in an expanded study during a seven year period. Based on the analysis 
of clinical and microbiological information of the patients with Acinetobacter spp., strategies and 
criteria for differentiation of significant sepsis from colonisation were developed as a standard 
algorithm.  
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The results of specific effective combination drugs with colistin were diverse and species 
dependent. The synergy test protocol will be implemented at the local microbiology laboratory to 
make synergy testing a part of the standard guideline. 
The presence of resistant genes blaOXA-23, and aphA6 were correlated with high level MICs of 
carbapemem and amikacin resistant Acinetobacter spp. isolates respectively. 
Therefore, isolates with the same antibiogram nevertheless need to be typed genotypically. At the 
minimum, their MIC values should be checked. The selected MDR Acinetobacter species carried 
the blaOXA-23 gene responsible for resistance to carbapenems (MICs 8 to >16 mg/L), while 
molecular and clinical data analysis suggested horizontal transmission in ICUs. In addition, the 
PFGE typing of a diverse collection of MDR Acinetobacter species clones showed that isolates 
from no more than two patients were related, suggesting that no outbreak had occurred.  
The absence of the IpxA gene was detected in colistin resistant (high MICs) Acinetobacter spp. 
isolates, while the gene was detected in colistin-susceptible Acinetobacter spp. isolates. 
In addition, colistin resistance was not a surrogate marker of MDR- and PDR- Acinetobacter 
species. The frequent occurrence of colistin resistance in Acinetobacter spp. isolates at local 
academic hospital is worrying. Continued molecular surveillance of local epidemiological 
information and antibiotic resistance surveillance are crucial for infection prevention and control 
purposes and an essential part of standard management at the hospital. 
 
The results of the study may help the clinician to select optimal therapy by providing a flow chart 
of definitions for Acinetobacter spp. sepsis and colonisation, a standardised management 
algorithm and a synergy test protocol. 
 
8.9  Future Research 
In order to further ideas explored in this thesis, a standard management antibiotic guideline is 
recommended and should be implemented urgently. Future studies should focus on how best to 
utilise colistin to minimise the risk of developing resistance.  
Moreover, the synergy testing should be done with a new method, a novel two-dimensional 
antibiotic gradient technique named XactTM, and thereafter compared with the E-test method. This 
method may be applicable in routine microbiology in future and the new test has been shown to 
be diagnostically useful, easy to implement and less labour intensive than the classical method 
(Van Belkum et al., 2015).  Currently, the synergy testing cannot be done using the new method 
and subsequently compared to the E-test due to funding limitations.  
The absence of the IpxA gene was detected in colistin resistant (high MICs) Acinetobacter spp. 
isolates, while the gene was detected in colistin-susceptible Acinetobacter spp. isolates. 
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Therefore, these results will be confirmed by other techniques such as the inclusion of an internal 
control to exclude amplification inhibition, PCR with a second primer set to exclude mispriming, 
sequencing and southern hybridisation. Furthermore, it is possible that the primers are specific 
for A. baumannii and not the other Acinetobacter species which may not have been identified 
through the current identification system. Moreover, future research should include the detection 
of the exact mechanism associated with the IpxA gene in colistin resistant Acinetobacter spp. In 
order to determine the type of modification associated with the loss of lipid A, further lipid 
analysis should be conducted. Cell walls may appear differently and should be investigated by 
electron microscope. This can be achieved through mass spectrometry or alternatively primers 
associated with Ipx modifications (mutants) and the entire genome sequencing can be used to 
determine point mutations associated with colistin resistance. 
An audit of pre-authorisation and prospective review of antibiotics as a measure to improve the 
efficacy of ASWP will be conducted based on the standard approach of management, in order to 
achieve a successful ASWP in a local academic complex hospital.  
There is a need for continuous surveillance of antibiotic resistance genes compared to resistance 
profiles and the source of infection, with the aim of preventing further spread. The prevalence and 
spread of other resistance genes in clinical settings in KZN should be monitored. 
A prospective study for the effect of the proposed interventions on morbidity and mortality will 
be planned. The results will be shared as recommendations to other tertiary referable hospitals. A 
Standard Operating Procedure (SOP) Synergy test using the National Health Laboratory Service 
(NHLS) Format will be planned for departmental use.  
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